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Abstract 
6-Methylsalicylic acid (6-MSA) is one of the oldest known polyketides. It is synthesised in 
vivo by the polyketide synthase 6-methylsalicylic acid synthase (6-MSAS), a multifunctional 
enzyme which uses its active sites iteratively. The stereochemistry of the hydroxyl produced 
from the single ketoreduction, as well as the order of dehydration, cyclisation and 
aromatisation steps, remain cryptic, despite extensive study. 
 
Holo 6-MSAS was heterologously expressed in E. coli and purified in two steps. A non-
hydrolysable carba(dethia)malonyl-N-acetylcysteamine analogue was synthesised and used 
to off-load enzyme-bound intermediates from 6-MSAS. In assays with acetyl-CoA and 
acetoacetyl-CoA alone, diketide and triketide intermediates were off-loaded and detected 
by HPLC-HR-ESI-MS. In the presence of NADPH, the off-loaded triketide was reduced by the 
ketoreductase domain of 6-MSAS. A potential dehydrated intermediate was also observed. 
 
The dehydratase domain of 6-MSAS has recently been reassigned as a thioester hydrolase. 
To test this theory, the catalytic histidine residue in 6-MSAS was mutated to an alanine and 
the abolition of production of 6-MSA in vivo was observed. Mutated 6-MSAS was still able to 
produce the shunt product triacetic acid lactone. Incubation of mutated 6-MSAS with acetyl-
CoA, malonyl-CoA, NADPH and carba(dethia)malonyl-N-acetylcysteamine saw only the off-
loading of diketide and triketide analogues. 
 
To investigate the stereochemistry of ketoreduction in 6-MSA biosynthesis, steps were made 
to synthesise the resolved diastereomeric reduced-triketide CoAs which would be the 
substrates for the ketoreductase domain. Attempts to phosphopantetheinylate apo 6-MSAS 
in vitro with three different phosphopantetheinyltransferases were unsuccessful. Limited 
proteolysis of both holo and apo 6-MSAS found that the apo synthase rapidly lost a C-
terminal fragment while holo 6-MSAS was much more stable under the same conditions. 
Attempts were made to express the acyl carrier protein domain from 6-MSAS to overcome 
these problems. 
 
These experiments represent the first use of the non-hydrolysable analogue methodology in 
a Type I iterative polyketide synthase and provide a framework for future experiments 
investigating intermediates in the biosynthesis of 6-MSA. 
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1.1 Natural products  
Natural products can be defined as compounds which are derived from a natural 
source such as animals, plants and micro-organisms and which often have biological 
activities.1 They have been used in crude form by human beings for medicinal 
purposes for centuries. 
 
The interest in purified natural products in a pharmaceutical context began after the 
mass production of penicillin during World War II.2 The antibiotics streptomycin3, 
gentamicin4, tetracycline5 and erythromycin6 were discovered within a few years and 
shifted the focus of the pharmaceutical industry to compounds which could be 
obtained by fermentation.  
 
The emergence of antibiotic resistance in a clinical environment has led to a 
biological arms race. The development of new antibiotics to treat infections that 
have become resistant to older antibiotics is in direct competition with the ability of 
micro-organisms to mutate and gain resistance to these new drugs. The emergence 
of so-called ‘superbugs’ such as methicillin-resistant Staphylococcus aureus (MRSA)7, 
CHAPTER 1 
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vancomycin-resistant enterococci (VRE)8 and extensively drug-resistant tuberculosis 
(XDR-TB)9 has revealed how finely balanced the contest is. 
 
Advances in natural product chemistry did not just yield antibiotics. Anti-fungals such 
as amphotericin10, immunosuppressants like rapamycin11 and the cholesterol-
lowering statins12, such as compactin and mevinolin have all entered clinical use.  
 
Natural products are biosynthesised as part of secondary metabolism in organisms. 
Primary metabolism encompasses all processes in a living organism which are 
necessary for the maintenance of life. Secondary metabolism is concerned with the 
production of molecules which are not absolutely necessary for life such as 
antibiotics, pigments, pheromones and signalling molecules in quorum sensing. 
 
Natural product structures make excellent lead compounds in the search for 
improved pharmaceuticals as they have a wide variety of targets within cells.13 Both 
gene expression and DNA transcription can be altered using compounds which 
alkylate DNA, inhibit DNA polymerases or inhibit DNA topisomerases.14 Protein 
biosynthesis can be disrupted by compounds such as the aminoglycosides which bind 
to one of the ribosomal subunits. This has been exploited to yield novel 
aminoglycoside analogues which can cause readthrough of unnatural stop codons.15 
Mammalian fatty acid synthase (mFAS) is a useful target as cancer cells express a 
much higher level of this enzyme than normal cells. An analogue of the natural 
product methylenolactocin which inhibits mFAS was shown to be active against 
human breast cancer cells.16  Plant-derived natural products, such as the 
benzophenanthridine alkaloid chelerythine and other structurally related 
compounds, have been shown to trigger cell death by the intrinsic apoptotic 
pathway.  For the majority of significant targets within a cell,  it has been postulated 
that there exists at least one cognate natural product ligand.14  
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1.2 Polyketides 
Polyketides are an extremely successful class of pharmaceutically useful natural 
products. The most successful cardiovascular drugs of all time, the statins, are of 
polyketide origin. Of natural product and natural product-derived compounds which 
were approved for clinical trials in 2005-2007, more than a third were based on 
polyketides.17 
 
Clinically important polyketides include the antibiotic erythromycin (4) and its semi-
synthetic derivative azithromycin, the enediyne class of anticancer agents18, the 
immunosuppressant rapamycin and the anti-hypercholesterolemic lovastatin. The 
success of polyketides against a wide range of cellular targets is due to their great 
structural diversity. The class ranges from 6-methylsalicylic acid (6-MSA, 1) and 
orsellinic acid (2), which contain only eight carbons, up to maitotoxin (3), a marine 
polyketide which is the largest and most toxic non-biopolymer natural product 
known with 168 carbons in its backbone.19 
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Figure 1.1: A great diversity in polyketide-derived skeletons exists, from small 
aromatic polyketides (6-MSA, 1 and orsellinic acid, 2) , macrolides such as 
erythromycin A (4) and amphotericin B (6) and polyaromatic compounds like 
actinorhodin (5) to very large polyethers (maitotoxin, 3). 
 
The variation in size is not the only reason for the efficacy of polyketides. The 
polyketide class encompasses a vast spectrum of functionality, from the macrocycles 
such as erythromycin (4), aromatic compounds such as actinorhodin (5), polyenes 
such as amphotericin B (6) and polyethers such as monensin and maitotoxin (3) 
(Figure 1.1). 
 
Despite the great array of structures, all polyketides are biosynthesised by a 
common mechanism from a common pool of building blocks. 
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1.2.1 The acetate hypothesis 
The earliest forays into investigating polyketide biosynthesis were undertaken by 
James Collie in 1893. After boiling dehydroacetic acid (7) with barium hydroxide he 
discovered that one of the products was the aromatic compound orcinol (8) (Figure 
1.2).20 He proposed that this could be formed via a polyketone intermediate. Further 
investigations such as the formation of a naphthalene derivative from 
diacetylacetone and the formation of orcinol from ethyl acetoacetate21  led Collie to 
the hypothesis that all of these natural products could be formed by repeated 
condensation of acetate units. He also extended his theory to include the 
biosynthesis of sugars by hydrolysis of pyrones and from there to starches and 
celluloses.22  With no available methods to test the theory the acetate hypothesis 
failed to gain ground in the natural product field for the next 45 years.23 
 
 
Figure 1.2: Collie’s synthesis of orcinol (8) from dehydroacetic acid (7). 
 
The revival of the acetate hypothesis and interest in the field of polyketide 
biosynthesis was due to experiments carried out by Birch in the 1950s. To confirm 
his acetate hypothesis Birch administered 14C-labelled acetate to a culture of 
Penicillium griseofulvum which produced the polyketide 6-MSA (1).24 The 
biosynthesis was proposed to feature the head-to-tail condensation of four acetate 
units, a reduction at one of the keto-groups to form a hydroxyl, an aldol 
condensation to form the 6-membered ring followed by dehydration and enolisation 
to yield the aromatic product. This putative pathway would lead to the incorporation 
of radioactivity at four sites in the product 6-MSA. The pattern of distribution of 
radioactivity was determined by a series of degradation reactions to produce 
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identifiable fragments and confirmed that 6-MSA was assembled from an acetate 
precursor. 
 
Figure 1.3: The incorporation of labelled acetate into 6-MSA (1) by feeding the 
labelled compound to Penicillium griseovfulvum. 
 
1.3 Fatty acid biosynthesis 
Much work of the early understanding in the field of polyketide biosynthesis came 
from insights gained in the related field of fatty acid biosynthesis. 
 
Fatty acids are synthesised de novo in all living organisms for use in membrane 
biosynthesis, although other uses such as post-translational modification of proteins 
and bacterial quorum sensing are also known.25 Their biosynthesis proceeds by 
repeated condensation of C2 units until a chain of the correct length is formed. The 
two-carbon unit is from malonyl-CoA (9), which reacts by decarboxylative Claisen 
condensation with an initial acyl unit. Throughout this process both the malonate 
and acyl compounds are bound to the enzyme catalysing the reaction, fatty acid 
synthase (FAS), as thioesters. 
 
The fatty acid synthase is divided up into distinct functionalities, known as domains, 
each of which catalyses a separate reaction in the biosynthetic pathway. In animals 
and fungi the FAS is a single large protein, with the active sites distributed along the 
polypeptide, also known as a type I synthase. In bacteria the FAS active sites are all 
on separate proteins which associate in solution to perform reactions This is termed 
a type II synthase. 
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A malonate unit is attached to the acyl carrier protein (ACP) domain as a thioester. 
Rather than directly attaching the malonate to a cysteine residue, a serine residue on 
the ACP is modified post-translationally to attach a 4’-phosphopantetheine arm.26 
This is added by the enzyme holo-ACP synthase which transfers the 4’-
phosphopantetheine moiety from coenzyme A (CoA). The phosphopantetheine arm 
has a terminal thiol to which the malonate group becomes attached as a thioester 
(Figure 1.4). The addition of a flexible 18 Å arm to the ACP allows the growing fatty 
acid chain to be delivered to the active sites of other domains while still remaining 
bound to the enzyme. The ACP in type II systems has been shown to be able to load 
malonyl units onto itself without need for a transferase domain.27 In Type I systems a 
malonyl-CoA:ACP transacylase domain (MAT) is used to transfer the malonyl group 
from malonyl-CoA to ACP.  
 
 
Figure 1.4: The addition of a 4’-phosphopanthetheine arm to the active site serine on 
the ACP is required for activity. 
 
The ketosynthase (KS) domain catalyses the decarboxylative condensation of a 
malonyl unit, which is bound to the ACP, with an initial acetyl unit (transferred by 
MAT), which is bound to a cysteine residue in its active site as a thioester (Figure 
1.5). This leads to a chain which has been extended by two carbons and is attached 
to the ACP. The -ketothioester formed is then further reacted to form the saturated 
acyl thioester. Firstly, the ketone is reduced to a hydroxyl group by the 
ketoreductase (KR) domain, followed by elimination to form a double bond which is 
catalysed by the dehydratase (DH) domain. The double bond is further reduced to 
the final saturated product by the enoyl reductase (ER) domain. Following this round 
of reductive processing, the extended chain is transferred back to the active cysteine 
in the KS domain. A malonate unit is transferred on to the ACP by the MAT and the 
process repeats. This cycle repeats until a chain of the correct length is formed 
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(usually C14, C16 or C18), when the chain is hydrolysed from the ACP by the action of 
the thioesterase (TE) domain to form the free acid (Figure 1.5). In fungal FAS the 
chain is released as a CoA-ester after transfer from the ACP by a bi-functional 
malonyl/palmitoyl transferase (MPT).25 
 
 
Figure 1.5: Fatty acid biosynthesis proceeds via the decarboxylative Claisen 
condensation of malonyl-ACP with the acyl chaing on the KS. The -ketoester is then 
reduced by the KR, the hydroxyl is dehydrated by the DH and the double bond is 
reduced by the ER. The chain can then be transferred to the KS for another round of 
elongation. 
 
While the mechanism of fatty acid biosynthesis has long been known, the 
architecture of the synthase has remained elusive until recently. High-resolution 
crystal structures of all the components in type II fatty acid biosynthesis have been 
obtained, including a number of enzyme/inhibitor and enzyme/substrate 
complexes.28 These provide the basis for much of the work done on type I systems.  
 
The fungal FAS was crystallised and revealed to be an 6 6 heterododecamer with a 
mass of 2.6 MDa. The two chains have the domains required for fatty acid 
biosynthesis shared between them. The 210 kDa  chain encodes for the ACP, KR, 
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KS, a phosphopantetheinyltransferase (PPT)and part of the MPT domain, while the 
230 kDa  chain carries the AT, ER, DH and the majority of the MPT. The structure is 
barrel-like, with a central wheel of six  chains capped by two domes of three  
chains. The fungal FAS has a highly rigid structure with reaction chambers in each 
dome (Figure 1.6).29, 30 
 
 
Figure 1.6: The domain organisation and structure of fungal FAS. The central wheel is 
made up of -chains while the domes are formed from -chains. The MAT domain is 
represented as AT. (Reprinted from Current Opinion in Structural Biology, 
Leibundgut, M.; Maier, T.; Jenni, S.; Ban, N., The multienzyme architecture of 
eukaryotic fatty acid synthases, 714-725, Copyright (2008), with permission from 
Elsevier.)31 
 
The mammalian FAS (mFAS), despite carrying out an identical series of reactions to 
the fungal FAS, has a very different structure. mFAS exists as an X-shaped dimer split 
into two sections. The lower section consists of a ‘condensing block’ and contains the 
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KS and MAT domains, while the upper section is a ‘modifying block’ which houses 
the KR, DH and ER domains. There are also pseudo-KR ( KR) and pseudo-
methyltransferase ( MT) domains which have no known function but appear to play 
an important structural role. The ACP and TE domains were not visualised in the 
structure, probably due to a high degree of conformational flexibility, but the anchor 
point for the ACP is in the centre of the upper portion of the lateral clefts of mFAS 
(Figure 1.7).29, 32 
 
 
Figure 1.7: The domain organisation and structure of mammalian FAS. mFAS is a 
head to head dimer of two identical chains and is divided into condensing and 
modifiying blocks. The ACP and TE domains were not visible in the crystal structure 
(Reprinted from Current Opinion in Structural Biology, Leibundgut, M.; Maier, T.; 
Jenni, S.; Ban, N., The multienzyme architecture of eukaryotic fatty acid synthases, 
714-725, Copyright (2008), with permission from Elsevier.)31 
 
1.4 Polyketide synthases 
The enzymes which assemble polyketides in vivo, polyketide synthases (PKSs) are 
analogous to fatty acid synthases. The greater structural diversity of polyketide 
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products comes from the fact that PKSs can vary the degree of reduction after each 
step. This can lead to formation of a ketone, hydroxyl, alkene or methylene 
functionality at C-3 in the chain after each condensation. Additional diversity comes 
from the fact that PKSs do not only use malonyl-CoA as an extender unit. Systems 
which employ methylmalonyl-CoA and methoxymalonyl-CoA are also known.33 PKSs 
can employ a wide variety of starter units and also feature C-methylation domains 
for the introduction of branching. 
 
1.4.1 Type I modular PKSs 
Type I modular PKSs are analogous to Type I FASs in that all the domains are present 
on a single polypeptide. Unlike FAS, however, each domain is only used once. The 
domains are formed into modules which collectively perform one condensation step 
and associated modification of the polyketide chain before transfer to the following 
module. 
 
The first known modular PKS was 6-deoxyerythronolide B synthase (DEBS) from 
Saccharopolyspora erythraea. Sequence analysis of the S. erythraea genome found 
three large open reading frames (ORFs) which coded for three giant polypeptides 
(approximately 350 kDa each). By sequence comparison to FAS domains, regions of 
the polypeptides were assigned biosynthetic functions.34 The DEBS megasynthases 
function as a ‘molecular assembly line’, passing the growing polyketide chain from 
one module to the next (Figure 1.8). 
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Figure 1.8: Biosynthesis of 6-deoxyerythronolide B (10) by the DEBS type I modular 
polyketide synthases. 
 
The sequence of domains corresponds exactly to the functionality observed in the 
product 6-deoxerythronolide B (6-dEB, 10). This is the principle of co-linearity, where 
the domains present on the synthase dictate the final structure of the product. Not 
all Type I modular PKSs conform to this rule. The rapamycin PKS contains modules 
which have KR, DH and ER domains that are not required to act to form the final 
product. These could be inactive and only remain to be edited out of the sequence, 
or they could be required for the structural integrity of the synthase. Alternatively, it 
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is possible that the domains are active and further oxidation happens once product is 
off-loaded from the PKS. 
 
A recently discovered sub-class of the modular PKSs is the ‘trans-AT’ group. These 
synthases have an AT domain which is supplied as a discrete protein rather than one 
per extension module. 
 
Modular Type I PKSs are dimeric and are proposed to adopt the same structure as 
mFAS, a head-to-head, tail-to-tail dimer. This structure is considerably more 
complicated than the iterative mFAS since a modular PKS can contain more than one 
covalently linked set of modules and must also be able to interact with modules on 
other polypeptide chains. 
 
1.4.2 Type I iterative PKSs 
Type I iterative PKSs are mostly found in fungi and consist of a single large 
polypeptide with multiple domains distributed along it. Fungal PKSs use a single set 
of active sites iteratively, which leads to questions of how the molecular 
programming of these enzymes occurs which enables them to produce a single 
product. 
 
Fungal PKSs can be subdivided into three classes based on their product: highly-
reducing, partially reducing and non-reducing.17 
 
Highly-reducing fungals PKSs, such as the lovastatin synthases LovB and LovF, yield 
products with a high degree of saturation. The production of lovastatin also requires 
a discrete ER domain, LovC. Interestingly LovB does possess a putative ER domain, 
but the need for LovC suggests that it is inactive.35 It is also proposed that LovB 
catalyses the intramolecular Diels-Alder reaction needed to form lovastatin (Figure 
1.9). Evidence suggests that this cyclisation occurs on an enzyme-bound hexaketide 
which is subsequently extended to the nonaketide.36 
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Figure 1.9: Biosynthesis of dihydromonacolin L (11), a precursor to lovastatin, by a 
highly reducing type I iterative PKS.37 
 
Partially-reducing PKSs are typified by 6-methylsalcylic acid synthase (6-MSAS). This 
performs only one ketoreduction in three condensation cycles to form the aromatic 
compound 6-MSA. 6-MSAS will be further discussed in section 1.6.1. 
 
The non-reducing PKSs form aromatic compounds such as orsellinic acid (2), 1,3,6,8-
tetrahydroxynaphthalene and norsolorinic acid (12), the first intermediate on the 
pathway to aflatoxin B1.
38 Norsolorinic acid synthase has been extensively studied by 
Townsend and co-workers (Figure 1.10). Analysis of the amino acid sequence of the 
synthase using the Udwary-Merski algorithm, which predicts inter-domain linker 
regions, found two new domains within the PKS. 39 The first was called a product 
template (PT) domain and is proposed to control the chain-length and folding of the 
growing polyketide. The PT domain has been crystallised and shown to be able to 
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bind both linear and bicyclic substrate mimics.40 The second new domain was 
discovered at the N-terminus of the PKS and was found to be a starter unit acyl 
transferase (SAT). This transfers a hexanoate starter unit synthesised by a dedicated 
FAS onto the PKS.41 Dissection of the norsolorinic acid synthase into individual 
domains and their reconstitution in vitro has enabled the function of each domain to 
be assigned.42 
 
 
Figure 1.10: Biosynthesis of norsolorinic acid (12) by the non-reducing type I iterative 
PKS, PksA.42 
 
Although all three classes of type I iterative PKSs carry out similar reactions, the 
makeup of their synthases are very different. HR-PKSs feature KS, AT, KR, DH, ER and 
ACP domains, along with a C-methyltransferase domain. NR-PKSs lack any domains 
from the reductive loop, but instead contain SAT and PT domains, alongside Claisen 
cyclase domains or thioesterase domains for off-loading. PR-PKSs have the most 
simple domain structure of all, containing only KS, AT, DH, KR and ACP domains 
along with a core domain of unknown function (Figure 1.11).43 
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Figure 1.11: The domain architecture of the three classes of type I iterative PKS.43 
 
A type I iterative PKS has also been found to synthesise polyunsaturated fatty acids 
(PUFAs) in marine microbes which inhabit cold environments.44 
 
1.4.3 Type II PKSs 
Type II PKSs, like bacterial type II FASs, are associated complexes of discrete proteins. 
The “minimal PKS” consists of two KS-like enzymes (KS  and KS ) and an ACP. KS  has 
been shown to be important in controlling chain length of products and is also 
known as the ‘chain length factor’ (CLF). It is unclear whether an MCAT domain is 
recruited from fatty acid biosynthesis since the ACP has been demonstrated to be 
capable of self-malonylation in vitro.45 Other proteins encoding ketoreductases, 
aromatases and cyclases can also act on the polyketide chain.46 
 
1.4.4 Type III PKSs 
Type III PKSs, like type II PKSs act in an iterative manner. Instead of the multi-enzyme 
complex, a single KS-like domain is used to carry out all decarboxylation, 
condensation, cyclisation and aromatisation reactions. Rather than utilising 
substrates bound to an ACP, type III PKSs act on CoA thioesters directly. Type III PKSs 
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such as chalcone synthase and stilbene synthase use a wide variety of acyl-CoA 
starter units to generate diversity and typically give mono- and bi-cyclic aromatic 
products.17 
 
1.5 Engineering of polyketide synthases 
Traditionally, the discovery of new polyketide drugs has been from one of two 
routes: the isolation of a new compound from its natural source or synthetic 
modification of a known polyketide. The improved understanding of the genetics 
behind polyketide biosynthesis has opened up a new avenue of investigation: the 
engineering of polyketide synthases to produce novel polyketides with new or 
improved activities.47 There have been two complementary approaches: 
combinatorial biosynthesis and mutasynthesis. 
 
1.5.1 Combinatorial biosynthesis 
The modular organisation of type I PKSs has made them an attractive target for 
engineering. Initially it was hoped that simple module-swapping and domain-
swapping experiments would provide a way to form libraries of novel polyketides. 
While experiments in this line were successful to some extent, the engineered PKSs 
had very low efficiency which made them unsuitable for high-throughput 
screening.47 
 
Subsequent investigations have found that although domain-swapping is 
theoretically possible, all domains exhibit a degree of substrate specificity and have 
preferred partner domains with which they interact. Nevertheless, it has been 
possible to reduce and increase chain length, alter the degree of ketoreduction and 
alter the starter unit and extender unit specificity through genetic engineering.48 
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An emerging area of study is the linker regions between catalytic domains. It is 
proposed that these mediate the interaction of the domains and thus careful 
selection of the linker would be necessary to increase the efficiency of the 
engineered synthase. To date over 200 novel polyketides have been synthesised 
using the combinatorial approach. 47 
 
1.5.2 Mutasynthesis 
Mutasynthesis is an improvement on precursor-directed biosynthesis, which added 
alternative starter units to cultures that produced polyketides to generate novel 
analogues. The mutasynthetic approach to forming novel polyketides relies on the 
inactivation of the PKS pathway at an early stage which removes production of the 
natural polyketide, usually by disrupting the biosynthesis of the starter unit. A 
synthetic precursor is then fed to the culture which can be taken up by the cells and 
attached to the PKS after the inactivated module. This precursor will then be 
extended as the normal substrate would have been to form an altered polyketide 
scaffold.49 
 
This approach has been used successfully to generate novel rapamycin analogues 
which were formed by a strain unable to synthesise the natural 4,5-
dihydoxycyclohex-1-enecarboxylic acid starter unit.50 Mutasynthesis is also used 
commercially to synthesise the veterinary antiparasitic drug doramectin by addition 
of cyclohexanecarboxylic acid to a culture of Streptomyces avermitilis. The strain is 
engineered to be unable to synthesise the branched fatty acid starter unit normally 
used in the biosynthesis of avermectin.51  
 
1.6 Biosynthesis of 6-methylsalicylic acid (6-MSA) 
6-MSA (1) is a polyketide produced by a wide variety of fungi and bacteria. It is the 
first identifiable intermediate in the biosynthesis of patulin (13), which is used as an 
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antibiotic in veterinary medicine and is also a cause of apple spoilage in cider 
manufacture (Figure 1.12). 
 
 
 
Figure 1.12: The biosynthesis of patulin (13) from 6-MSA (1).52 
 
6-MSA was found to be made up of four acetate units through the feeding studies of 
Birch.24 Later studies found that the rate of incorporation of 14C-acetate into 6-MSA 
in P. patulum was decreased when 6-MSA or structurally related aromatic acids were 
added to the culture medium, suggesting a degree of product inhibition in 6-MSA 
biosynthesis.53 
 
1.6.1 6-Methylsalicylic acid synthase 
6-MSA is assembled from one unit of acetyl-CoA (14) and three units of malonyl-CoA 
(9) by 6-methylsalicylic acid synthase (6-MSAS). 
 
Initial purification of 6-MSAS from P. patulum was attempted using ammonium 
sulphate fractionation, followed by sedimentation in an ultracentrifuge and sucrose 
density-gradient centrifugation. This gave enzyme extract of 100 times the purity of 
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cell free extract and an approximate molecular weight of 1.1 – 1.5 MDa.54 Later 
purification followed much the same model, but found that the inclusion of glycerol 
improved activity.55 6-MSAS was finally purified to homogeneity by ammonium 
sulphate fractionation, followed by poly(ethylene glycol) precipitation, DEAE-
Sepharose ion-exchange chromatography, hydroxyapatite chromatography before a 
final ion-exchange chromatography step. 6-MSAS was found to consist of a single 
type of subunit of molecular weight 180 kDa. Gel filtration analysis confirmed that 
the enzyme existed as a tetramer with a total molecular weight of approximately 750 
kDa, which was significantly lower than had previously been determined.56 
 
The 6-MSAS gene from P. patulum was identified by immunological screening of a 
genomic DNA expression library. The gene was found to be contained in a single 
reading frame which was 5322 base pairs long with a single 69 base pair intron in the 
N-terminal part of the synthase. 6-MSAS was calculated to be a protein made up of 
1774 amino acid with a predicted molecular mass of 190 731 Da (Figure 1.13). 
Comparison of the amino acid sequence with known FASs and PKSs found little 
similarity between 6-MSAS and the yeast and Penicillium FASs but 6-MSAS did show 
much higher similarity to the rat FAS. Homology to previously sequenced PKSs and 
FASs allowed the identification of KS, AT, DH, KR and ACP domains within the 
synthase. Interestingly no thioesterase domain for product release was detected 
within the synthase.57 
 
 
Figure 1.13: The domain organisation of 6-MSAS. The single polypeptide contains KS, 
AT, DH, KR and ACP domains. 
  
Investigations into the substrate specificity of 6-MSAS found that while acetyl-CoA 
was the preferred starter unit,  propionyl-CoA was also accepted at 1/13th of the rate 
of acetyl-CoA to form 6-ethylsalicylic acid.58 6-MSAS also accepts acetoacetyl-CoA as 
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a starter unit at 80% of the rate of acetyl-CoA, to form 6-MSA.56 A variety of starter 
units were subsequently found to be incorporated into the corresponding 
alkylsalicylic acid, including butyryl-CoA and crotonyl-CoA, but branched alkyl chains 
were not accepted by the synthase.52  
 
The 6-MSAS has been successfully heterologously expressed in Eschericia coli, 
Saccharomyces cerevisiae59 and Streptomyces coelicolor.60 In each of these systems 
production of 6-MSA was observed, revealing that no other genes were required for 
the biosynthesis. In particular, no discrete thioesterase from P. patulum was 
required to release 6-MSA from the synthase. Other type I iterative PKSs with no 
thioesterase domain release their products using cyclisation or reductive domains. 
 
Heterologously expressed 6-MSAS has been used in metabolic engineering studies in 
yeast in which the aim was to maximise polyketide production by modification of the 
phosphopantetheinyltransferase61 and acetyl-CoA carboxylase genes.62 6-MSAS has 
also been transformed into the tobacco plant where it provided some resistance 
against tobacco mosaic virus, although not as effectively as salicylic acid.63 
 
Before crystal structures of any PKS or FAS were available for comparison, the 
structure of 6-MSAS was investigated by cross-linking and limited proteolysis studies. 
The thiol-modifying cross-linking agent 1,3-dibromopropanone was found to 
inactivate 6-MSAS by selectively modifying the reactive cysteine in the KS domain 
and the thiol on the end of the phosphopantetheine arm attached to the ACP. Cross-
linked 6-MSAS dimers were observed. Incubation of 6-MSAS with acetyl-CoA 
prevented both inactivation and cross-linking, by protecting the thiol in the KS 
domain, while incubation with malonyl-CoA prevented cross-linking but not 
inactivation. These results suggest that the KS of one subunit is linked to the ACP of 
another.56, 64 Studies with the thiol-binding reagent cerulenin found that this bound 
specifically to the reactive cysteine in the KS.65 These investigations gave results 
which were analogous with those achieved in investigations of mammalian FAS, and 
so it is implied that there are great structural similarities between 6-MSAS and mFAS.  
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1.6.2 Mechanism of 6-MSA biosynthesis 
Experiments with partially purified 6-MSAS found that triacetic acid lactone (TAL) 
was produced in the absence of nicotinamide adenine dinucleotide phosphate 
(NADPH).54 When the purified synthase was incubated with acetyl-CoA and malonyl-
CoA with no NADPH it was found that TAL was formed as the exclusive product at 
10% of the rate of 6-MSA biosynthesis.56 TAL is also seen as a shunt product in fatty 
acid biosynthesis in the absence of NADPH.66  
 
Incubation of 6-MSAS with 3-pentynoyl-N-acetylcysteamine, an inhibitor which 
reacts with any dehydratase activity, completely stopped 6-MSA production. 
Oxidation of NADPH only fell to 60% of the rate seen without inhibitor, confirming 
that the reduction step was unaffected.55 These results suggest that the 
ketoreductase domain acts on a six-carbon intermediate and the resulting alcohol is 
then dehydrated to from a double bond (Figure 1.14). For the formation of 6-MSA, a 
cis double bond is required to allow cyclisation of the tetraketide intermediate, but 
polyketide dehydratases generally from trans double bonds. It is possible that a trans 
bond is formed which is then isomerised to the cis or dehydration could happen on a 
cyclised reduced tetraketide intermediate. The mechanistic considerations 
underlying the dehydration step are discussed in section 3.1.2. 
Chapter 1: Introduction 
 
35 
 
 
Figure 1.14: The proposed biosynthetic pathway to 6-MSA from acetyl-CoA (14) and 
malonyl-CoA (9), as catalysed by 6-MSAS. 
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Initial experiments using tri-deuteriated acetate found that there was high degree of 
retention of deuterium at chain building sites, but that the incorporation was not 
uniform for all sites in 6-MSA.67 Further experiments with both tri-deuteriated 
acetate and mono-deuteriated acetate found that deuterium retention at C-3 and C-
5 was consistent with the removal of hydrogen at these postions being 
stereospecific. As the hydrogens at C-3 and C-5 will be removed during the 
aromatisation sequence, this suggests that the formation of the aromatic ring 
happens under enzymatic control.68 
 
A series of elegant experiments involving chiral malonates was performed by 
Spencer and Jordan to determine which hydrogen atoms were removed in the 
formation of the aromatic ring. (R)- and (S)-[1-13C, 2-2H] malonate were converted to 
malonyl-CoA using succinyl-CoA transferase. As the transferase was unable to 
distinguish between the two acid groups in malonate, each chiral malonate reaction 
gave rise to two chiral malonyl-CoAs. Incorporation of these malonyl-CoA mixtures 
would give eight possible labelling patterns in the final 6-MSA. Four possible 
mechanisms were suggested and the appropriate labelling patterns for 6-MSA 
produced from each malonyl-CoA mixture were calculated. The mass spectra of 6-
MSA obtained after incubation with both the (R)- and (S)-[1-13C, 2-2H] malonate-
derived malonyl-CoAs with acetyl-CoA as a starter unit was compared with the 
predicted spectra. It was determined that the hydrogen atoms at C-3 and C-5 in 6-
MSA arose from hydrogen atoms with opposite stereochemistries in the polyketide 
chain.69 To determine the absolute stereochemistry of the hydrogen retained at each 
position, unlabelled acetoacetyl-CoA was used as a starter unit. This gave an 
unlabelled C-3 in 6-MSA and allowed the labelling at C-5 to be probed directly. 
Comparison of the predicted and obtained spectra of 6-MSA after incubations with 
(R)- and (S)-[1-13C, 2-2H] malonate-derived malonyl-CoAs showed that the hydrogen 
retained at C-5 came from the pro-(R) hydrogen of malonyl-CoA. This meant that the 
hydrogen retained at C-3 came from the pro-(S) hydrogen of malonyl-CoA (Figure 
1.15). 70 
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Figure 1.15: One possible mechanism to explain the stereochemistry of hydrogen 
atom removal: Removal of hydrogens from the same face of the C6 intermediate to 
form a cis double bond.52 
 
As the 6-MSAS gene contains no thioesterase domain, the mechanism of product 
release is unclear. It is possible that 6-MSA is hydrolysed by an activated water 
molecule which can be deprotonated by a base situated on the enzyme. 
Alternatively, a mechanism involving the formation of a ketene has been proposed. 
The ketene could then be hydrated to form 6-MSA (Figure 1.16).56 
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Figure 1.16: Product release from 6-MSAS could occur via a deprotonated water 
molecule or a ketene intermediate. 
 
Although investigations into 6-MSA biosynthesis have spanned over 50 years, there 
are still many unanswered questions about the formation of this deceptively simple 
polyketide. The timing of the dehydration, cyclisation and aromatisation steps 
remains unclear, as does the mechanism of product offloading. The stereochemistry 
of the hydroxyl formed by the ketoreductase has also not been determined. This 
thesis is concerned with applying new methods to this well-studied and archetypal 
system, in order to shed some light on these questions.  
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2.1 Introduction 
During polyketide biosynthesis, intermediates remain covalently bound to the 
polyketide synthase. This presents a problem in establishing the exact biosynthetic 
pathway, since the identity of enzyme-bound intermediates is difficult to establish. 
While biosynthetic intermediates are often proposed based on the domain structure 
of the polyketide synthase and the observed structure of the product, the timing of 
events such as cyclisation or epoxidation can remain cryptic. In order to examine 
these enzyme-bound intermediates, a variety of techniques have been employed. 
 
2.1.1 Methods of identifying intermediates in polyketide biosynthesis  
2.1.1.1 Labelled precursors 
 
Initial insights into polyketide biosynthesis were gained through the use of 
radiolabelled 14C-acetate. Incorporation of the radioactive precursor was assayed 
through a complex series of degradation reactions to known products. Birch was the 
first to employ this method in his investigation of 6-methylsalicylic acid production. 
CHAPTER 2 
Off-loading of intermediates 
from 6-MSAS 
Chapter 2: Off-loading of intermediates from 6-MSAS 
 
40 
The radiolabelled 6-methylsalicylic acid (6-MSA, 1) formed was degraded and the 
fragments analysed to determine the relative amounts of radiation each contained 
(Figure 2.1). It was found that 14C was uniformly incorporated at four sites. These 
corresponded to the sites predicted by Birch in his hypothesis that the biosynthesis 
proceeded via the formation of a polyketone precursor which underwent a single 
reduction event before cyclising through an aldol reaction and formation of an 
aromatic ring.24 
 
Figure 2.1: Labelling pattern of 6-MSA (1) from 14C acetate feeding experiments by 
Birch and subsequent degradation reactions. 
 
The development of NMR shifted focus from 14C-labelled precursors to 13C-labelling. 
Singly labelled 13C acetate allowed the pattern of labelling in a polyketide to be 
quickly established without the need for labour-intensive degradation studies. 
Doubly labelled 13C acetate greatly added to the depth of knowledge of the field, as 
for the first time it was possible to observe the incorporation of intact acetate units 
was able to be measured. This allowed some of the complex structural 
rearrangements that often occur after the formation of the polyketide backbone to 
be investigated, for example in the biosynthesis of aflatoxin.23 
 
The putative diketide intermediate (15) was synthesised by Cane et al. The precursor 
was incorporated into both erythromycin (4) and nargenicin A1 (16) retaining both 
the deuterium and 13C labels, showing that reduction and elimination steps took 
place after each condensation reaction in a modular PKS, rather than on the 
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assembled polyketone chain (Figure 2.2).71 This is referred to as a processive 
mechanism. 
 
 
Figure 2.2: Incorporation of the doubly labelled diketide-SNAC (15) into erythromycin 
(4) and nargenicin A1 (16) through feeding experiments. 
 
2.1.1.2 Movement of thioesterase domains 
In Type I modular polyketide synthases, intermediates can be observed by moving 
the thioesterase domain to generate a truncated product. In the 6-
deoxyerythronolide B synthases (DEBS), the thioesterase (TE) domain (which is 
normally at the end of the third megasynthase protein, DEBS3) was attached to the 
end of the first megasynthase, DEBS1 to give DEBS1-TE.72 This formed a triketide 
lactone, presumably due to off-loading of the intermediate by TE-catalysed 
cyclisation. The off-loaded intermediate could then be easily characterised by GC-MS 
and NMR experiments. 
 
Movement of the TE domain has also enabled the substrate channelling of DEBS 
modules to be probed using synthetic diketide N-acetylcysteamine (NAC) thioesters 
to form triketide lactones which can then be analysed.73 Heterologously expressed 
recombinant domains were used to establish the stereospecificity of each 
ketoreductase (KR) domain in DEBS. Incubation of a diketide-NAC ester with 
methylmalonyl-CoA, an acyl transferase-ketosynthase (AT-KS) didomain, a KR 
domain and an acyl carrier protein (ACP) led to the production of ACP-bound 
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triketide intermediates, which were then off-loaded using base hydrolysis or a TE to 
form triketide lactones.74  
 
2.1.1.3 Mass spectrometry 
Recently, the development of highly-sensitive mass spectrometers has led to the 
direct sampling of enzyme-bound intermediates. Using Fourier-transform mass 
spectrometry (FTMS) Hicks et al. were able to detect thioester intermediates bound 
to EpoC, a polyketide synthase (PKS) involved in epothilone biosynthesis. The starter 
unit was presented as a NAC-thioester which was loaded on to the synthase and 
condensed with one unit of methylmalonyl-CoA leaving the product bound to the 
ACP. EpoC was then digested using a limited proteolysis strategy and fractionated by 
liquid chromatography before being analysed using FTMS. This was compared to the 
limited proteolysis chromatograph of the holo enzyme and the change in mass of the 
fragment containing the ACP and phosphopantetheine arm was used to assign the 
identity of the reaction product.75 
 
An alternative strategy has been to utilise the facile ejection of the 
phosphopantetheine arm under MS2 conditions to directly assay intermediates. The 
advantage of this strategy is that it does not require digestion of the intact PKS or 
NRPS. Instead, the protein is subjected to tandem mass spectrometry (MS/MS) using 
methods such as collision activated dissociation and infrared multiphoton 
dissociation to induce ejection of the phosphopantetheine arm as one of two 
fragments (17 and 18, Figure 2.3). These fragments can then be detected directly 
and the intermediates attached to the thioester characterised.76 This ‘top down’ 
approach has recently been adapted for low-resolution instruments using the 
characteristic fragmentation patterns of the ejected ion under MS3 conditions.77  
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Figure 2.3: The phosphopantetheine arm attached to the carrier protein (CP) is 
ejected under MS2 conditions to give both the phosphopantetheine (17) and 
pantetheine (18) fragments. R is an intermediate bound as a thioester. 
 
Mass spectrometry has also been used to investigate starter unit specificity in non-
ribosomal peptide synthetase (NRPS) systems. The NRPS is incubated with a pool of 
potential starter amino acids and the correct one is loaded by the adenylation 
domain. Tandem mass spectrometry on the intact synthase leads to ejection of the 
phosphopantetheine ion attached to the cognate amino acid.78 
 
In the biosynthesis of aflatoxin, a toxin produced by the fungus Aspergillus 
parasiticus, the first discrete precursor is norsolorinic acid, which is synthesised by 
an iterative PKS, PksA. Norsolorinic acid is formed from a hexanoyl starter unit and 
seven units of malonyl CoA and the resulting unreduced polyketone chain is cyclised 
to give three aromatic rings. Crawford et al. used the Udwary-Merski algorithm39 to 
predict domain boundaries and dissect PksA into its discrete domains. The domains 
were expressed as separate proteins and recombined in vitro and FTMS used to 
observe intermediates attached to the ACP. Omission of domains, and analysis of the 
different intermediates produced, allowed the function of each domain to be 
assigned.42 The mass spectrometry data also showed that the unreduced polyketone 
chain was not cyclised during the rounds of chain extension. This was also shown by 
Ma et al. in their study of the interaction between a non-reducing PKS from 
Gibberella fujikuroi and the discrete ketoreductase domain from the actinorhodin 
Type II PKS. It was shown that the KR performed a reduction exclusively at the C-9 
position and so must have access to the complete ACP-bound polyketone.79 
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2.1.2 Non-hydrolysable analogues for off-loading intermediates 
The techniques, while successful in their respective systems, either lack a general 
applicability for all types of polyketide synthase or require access to expensive 
equipment. It was proposed in our research group that a common feature of all 
polyketide systems could be exploited to probe enzyme-bound intermediates; 
namely, the use of malonyl-CoA or its derivatives as an extender unit. It was 
hypothesised that a malonyl-CoA unit which could decarboxylate and form a carbon-
carbon bond with the enzyme-bound intermediate, but which was not itself enzyme 
bound, could provide a way to off-load intermediates from a megasynthase. To 
ensure that intermediates were not simply reloaded by reaction with another 
enzyme-bound malonyl unit, the off-loading agent would have to feature a non-
hydrolysable bond in place of the thioester (Figure 2.4). 
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Figure 2.4: A: Polyketide biosynthesis. Decarboxylation of the ACP-bound malonate 
unit is followed by condensation with the acyl unit on the KS, leading to an extended 
ACP-bound polyketide chain. The chain is then transferred back to the KS and the 
ACP is loaded with another unit of malonate. B: Offloading of intermediates. 
Decarboxylation of the malonyl-unit on the non-hydrolysable analogue is followed by 
condensation with the acyl unit on the KS leads to off-loading of the KS-bound 
intermediate. The non-hydrolysable linker does not allow the extended chain to be 
reloaded onto the enzyme. 
 
Initial studies were performed by Dr Dieter Spiteller and Claire Waterman using a 
non-hydrolysable analogue (19).80 This features a malonyl unit for reaction with 
intermediates, but the thioester has been replaced by a thioether. This had the 
disadvantage of introducing an additional methylene group, which might have 
interfered with molecular recognition, but this was outweighed by the facile 
synthesis of 19 in two steps. This analogue was tested with stilbene synthase (STS), a 
Type III PKS from Pinus sylvestris. Both diketide (23) and triketide (22) intermediates 
were observed by LC-MS when 4-hydroxyphenylacetyl-CoA (20) was used as a starter 
unit, but no intermediates were detected when cinnamoyl-CoA (21) was used (Figure 
2.5). This was unexpected as cinnamoyl-CoA is usually elaborated to the tetraketide 
product pinosylvin. It was proposed that this lack of reactivity was due to the 
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misalignment of the cinnamoyl-CoA and malonyl-CoA in the KS active site. The 4-
hydroxyphenylacetyl unit is a methylene unit shorter, and so may accommodate the 
longer malonyl analogue more easily. 
 
 
Figure 2.5: Non-hydrolysable malonyl CoA analogue 19 was used to off-load diketide 
(23) and triketide (22) intermediates with 4-hydroxyphenylacetyl-CoA (20) as a 
starter unit.80 
 
In order to have a better mimic of malonyl-CoA, alternative non-hydrolysable 
analogues (24) were synthesised by Dr Manuela Tosin81. These replaced the sulphur 
of the thioester group with an O or CH2 to produce a bond that was either less prone 
or inert to hydrolysis and would be almost isosteric with malonyl-CoA (Figure 2.6). In 
trials with STS, the oxa(dethia)malonyl-CoA was able to off-load only the starter unit 
to form a diketide attached to CoA. In contrast, the carba(dethia) analogue was able 
to off-load diketide, triketide and tetraketide intermediates, including some cyclised 
and/or dehydrated tetraketides for a variety of starter units. The increased activity of 
the carba(dethia) analogue over the oxa(dethia) is proposed to be due to its more 
rapid decarboxylation and because hydrolysis of off-loaded intermediates is not 
possible. 
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Figure 2.6: Non-hydrolysable malonyl CoA analogue (24) synthesised by Tosin et al.  
used to off-load intermediates from stilbene synthase. 
 
Shorter analogues of the non-hydrolysable malonyl-CoA were then investigated.82  
Pantetheine analogues (27) were synthesised with either NH, CH2 or O in place of the 
thioester sulphur atom, while a carba(dethia)methylmalonyl-NAC analogue (28) was 
also synthesised. The system used was DEBS3, the final polyketide megasynthase 
used in the biosynthesis of erythromycin. This system normally processes a 
pentaketide to a heptaketide, but in the absence of the other DEBS proteins it 
produces triketide lactones (25 and 26) from propionyl-CoA as a starter unit followed 
by two condensations with methylmalonyl-CoA as an extender unit.83 For both the 
pantetheine and N-acetylcysteamine analogues, inhibition of triketide lactone 
production was observed, however no off-loaded intermediates were detected with 
the pantetheine analogues. By contrast, both malonyl- and methylmalonyl-analogues 
(30 and 28) based on carba(dethia)-N-acetylcysteamine off-loaded intermediates 
that could be detected successfully. The advantage of the NAC analogues over the 
coenzyme A analogue is twofold: firstly, the synthesis is greatly simplified; secondly, 
the off-loaded intermediates are hydrophobic enough to be extracted into organic 
solvent, allowing the sample to be concentrated before analysis. Using the NAC 
analogues, off-loaded diketide (29 and 31) and triketide (32) intermediates were 
observed for DEBS3 when the synthase was incubated with propionyl-CoA and 
methylmalonyl-CoA (Figure 2.7). 
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Figure 2.7: Non-hydrolysable pantetheine (27) and N-acetylcysteamine (28 and 30) 
analogues were used to off-load intermediates in the biosynthesis of triketide 
lactones by the megasynthase DEBS 3. 
 
Recent in vivo work has been performed on the lasalocid-producing PKS which has 
had the last two ACPs inactivated by mutation of the phosphopantetheine arm 
attachment site. Off-loading of late stage intermediates could be observed when 
non-hydrolysable analogues were fed (Dr M Tosin, personal communication). 
 
2.1.3 Probing intermediates in an iterative synthase 
Iterative synthases present a greater challenge to the traditional methods for 
studying intermediates as they contain only a single set of active sites, so any 
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mutation in the KS or ACP active sites would destroy the synthase’s biosynthetic 
capacity altogether. 
 
6-methylsalicylic acid biosynthesis has already been extensively studied using 
labelled acetate68 and labelled malonate,69 but these have not helped in the 
deduction of later stage intermediates, particularly in the timing of the dehydration 
and cyclisation steps.   
 
2.1.4 Aims 
The aim of this section is to use a non-hydrolysable malonyl-NAC analogue to off-
load intermediates in the biosynthesis of 6-MSA. This would represent the first use 
of this methodology on a Type I iterative synthase and could also provide insights 
into the biosynthesis of this deceptively simple polyketide. 
 
2.2 Results and discussion 
2.2.1 Expression of holo 6-MSAS 
The expression of 6-methylsalicylic acid synthase (6-MSAS) proved very challenging. 
Initial attempts to express the synthase under standard expression conditions (LB 
media, 37 °C until OD600  1, then induction with 0.4 mM IPTG overnight at 16 °C) did 
not lead to any high molecular weight bands on SDS-PAGE being seen after 
ammonium sulphate purification. The method of Kealey et al.59 was used (ATCC 765 
minimal media plus 10% glycerol, 37 °C until OD600  1, then induction with 0.5 mM 
IPTG at 30 °C for 24 hours) , followed by ammonium sulphate precipitation, as used 
by Spencer and Jordan,56 gave high molecular weight bands. The cell pellet could not 
be frozen before ammonium sulphate precipitation, as this resulted  in the loss of 
the high molecular weight bands by SDS-PAGE. After a year of unsuccessful 
attempts, the following method was used to obtain active holo 6-MSAS. 
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Plasmids containing the gene coding for 6-methylsalicylic acid synthase (6-MSAS) 
(pKOS12-65a) and its expression vector (pKOS007-95) were donated by Kosan 
Biosciences Ltd. These were digested and the fragments ligated to form the 
expression plasmid pKOS007-109. This plasmid was transformed into Escherichia coli 
BL21 (DE3) alongside pET28a(+)-MtaA, a plasmid expressing the 
phosphopantetheinyltransferase (PPTase) MtaA from Stigmatella aurantiaca84 with 
an N-terminal His6-tag donated by Dr Fanglu Huang. The co-expression of a PPTase 
should ensure that the phosphopantetheine arm that is essential for activity is 
attached in vivo. 
 
Previous experiments had found that 6-MSAS did not bind to a nickel affinity column 
when expressed with N-terminal, C-terminal or both N- and C-terminal His6-tags (Dr 
Fanglu Huang, personal communication). In order to avoid any interference with 
activity from non-natural tags, it was decided to express 6-MSAS in an untagged 
form and use an alternative method of purification. 
 
The E. coli was cultured under the same conditions as previously used for 
heterologous expression of 6-MSAS by Kealey et al.59 They had found that although 
expression of the synthase in Saccharomyces cerevisiae gave a greater yield of 6-
MSA, expression in E. coli gave a higher percentage of 6-MSAS in the total cell 
proteins.  
 
Holo 6-MSAS was purified by ammonium sulphate precipitation, as by Spencer et al. 
for the enzyme from its native producer, P. patulum.56 It was found that 5 mM EDTA 
and the presence of the protease inhibitors benzamidine and phenylmethylsulphonyl 
fluoride (PMSF) in the cell resuspension buffer were vital for obtaining active 
synthase. The 22-40% ammonium sulphate pellet was then either used directly for 
assays or further purified by FPLC using a Sephadex 200 column and the buffer 
system used by Richardson et al. (Figure 2.8).85 
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Figure 2.8: SDS-PAGE analysis of ammonium sulphate fractions in the purification of 
6-MSAS and gel filtration trace of 6-MSAS. 
 
FPLC purification yielded protein which showed a strong single band of the correct 
approximate molecular weight (190 kDa calculated) by SDS-PAGE, with faint bands of 
lower molecular weight. These are probably due to degradation of the protein during 
purification. This method gave approximately 10 mg of holo 6-MSAS per litre of 
culture. 
 
2.2.2 Activity of holo 6-MSAS 
The activity of both holo and apo-6-MSAS was assayed using the fluorimetry method 
of Spencer and Jordan56, which monitors the production of 6-MSA directly. The 
ammonium sulphate pellet was redissolved in assay buffer with 10 mM DTT and 
incubated in the fluorimeter at 25 °C with acetyl CoA, NADPH and bovine serum 
albumin (BSA). The reaction was started by addition of malonyl-CoA and the 
production of 6-MSA was monitored ( ex = 310 nm, em = 390 nm). The specific 
activity was calculated by comparison with a standard curve of 6-MSA fluorescence. 
Protein concentration was determined by Bradford assay.  
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Ammonium sulphate-precipitated holo 6-MSAS without EDTA in the resuspension 
buffer gave a specific activity of 15 m-units/mg protein, while holo 6-MSAS 
resuspended in the presence of EDTA had a specific activity of 65 m-units/mg protein 
(1 unit is 1 mole of 6-MSA per minute).  This compares extremely favourably with 
the values obtained by Spencer and Jordan for the native enzyme in P. patulum, 
which had a specific activity of 5.8 m-units/mg protein at the same stage of 
purification. The low specific activity of the native enzyme was due to a co-purifying 
FAS.   
 
FPLC purified fractions gave a specific activity of 108 m-units/mg protein under the 
same assay conditions. This is less than half the specific activity recorded for the 
purified native synthase of 245 m-units/mg protein. However, this purification 
method benefits greatly from a simple two-step procedure rather than the more 
intensive five steps that were previously used. It is, however, comparable to the 
specific activity observed after four purification steps (135 m-units/mg). 
 
2.2.3 Production of 6-MSA 
The production of 6-MSA in vivo was assayed using LC-MS. 50 ml of culture 
supernatant from a 1 litre culture of holo 6-MSAS was acidified to pH 1 using 
hydrochloric acid, then extracted three times using ethyl acetate. The extracts were 
dried over magnesium sulphate and the solvent removed in vacuo. The remaining 
solid was redissolved in 1 ml of methanol and analysed by LC-MS. The UV traces at 
280 nm and 254 nm were monitored and the retention time of 6-MSA was compared 
to a synthetic standard (Figure 2.9). A peak with a mass of 153 units which 
corresponded to [M+H+] was observed. 
 
The UV peak area was used to compute the amount of 6-MSA produced by 
comparison to the standard peak area.  
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Figure 2.9: LC-MS traces of holo 6-MSAS culture extract compared to authentic 6-
MSA. 
 
Holo 6-MSAS was calculated to produce 17-25 mg of 6-MSA per litre of culture.  
 
2.2.4 Synthesis of non-hydrolysable analogue 
In order to off-load intermediates from 6-MSAS, carba(dethia) malonyl-N-
acetylcysteamine (30) was used since this had been successfully employed in off-
loading from DEBS3. The non-hydrolysable analogue (30) was synthesised by a 
procedure designed by Emily Valentine and Dr Manuela Tosin.86 GABA (31) was 
reacted with acetyl chloride in the presence of triethylamine to form 32. This was 
then coupled to Meldrum’s acid using EDC and DMAP in THF to give the cyclic adduct 
33. 33 was opened using dry methanol in toluene under reflux conditions to give the 
methyl ester 34 which was purified by preparative HPLC. The methyl ester was 
cleaved using pig liver esterase in 6-MSAS assay buffer (Tris-sulphate, pH 7.6) at 37 
°C for two hours to yield the active trapping agent 30 (Figure 2.10). As 30 could 
readily decarboxylate, the protein was precipitated from the reaction mixture using 
chloroform and the crude aqueous layer was used directly in all off-loading assays. 
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Figure 2.10: The synthesis of non-hydrolysable analogue (30) from GABA (31). 
 
2.2.5 Starter unit assay: acetyl-CoA 
To test the ability of the non-hydrolysable analogue to off-load intermediates from 
an iterative synthase, it was decided to remove the need for the malonyl analogue to 
compete with the natural extender unit, malonyl-CoA. By incubating the analogue 
with acetyl-CoA (the natural starter unit) and 6-MSAS, the acetyl unit should be 
loaded onto the KS domain by the AT, before being off-loaded by the analogue. This 
would result in only a single diketide product (35) to detect (Figure 2.11). 
 
FPLC-purified holo 6-MSAS was incubated overnight at room temperature with 
acetyl-CoA and carba(dethia)malonyl-NAC (30). Concentrations of analogue from 5 
mM to 30 mM were used, while concentrations of the other reagents were take 
from the DEBS3 experiments of Tosin et al. (acetyl-CoA 3 mM, 200 g protein in 100 
l reaction).82  
 
 
Figure 2.11: Off-loading of acetyl starter unit with non-hydrolysable analogue 30 to 
form diketide 35. 
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Assay mixtures were extracted three times with an equal volume of ethyl acetate 
which was then evaporated under nitrogen. The residue was then dissolved in a 
minimal volume of methanol before being analysed on an LTQ-Orbitrap mass 
spectrometer by Dr Manuela Tosin. 
 
The expected diketide product (35) was seen at a retention time of 11.83 mins, with 
an exact m/z of 186.1126 for all three concentrations of analogue tested (Figure 
2.12). This peak did not appear in enzyme-free, analogue-free or acetyl-CoA free 
controls. MS/MS analysis of this peak gave fragments at m/z = 168.1016 units (loss of 
water) and m/z = 126.0913 (loss of acetic acid).  
 
Incubation with NADPH did not alter the amount of diketide detected, so it was 
excluded from further assays. Extraction of the assay mixture after acidification to 
pH1 with hydrochloric acid also had no effect on the amount of diketide seen. As an 
additional control, the assay was performed with [13C2]acetyl-CoA. This gave a peak 
at a retention time of 12.0 minutes but with an increase of two mass units to 188.12, 
confirming the identity of the diketide (36).  
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Figure 2.12: HRMS traces of extracts from reactions where 6-MSAS was incubated 
with acetyl and [13C2]acetyl-CoA and non-hydrolysable analogue 30 to form 
offloaded diketides (35 and 36). 
 
2.2.6 Starter unit assay: acetoacetyl-CoA 
6-MSAS can also accept acetoacetyl-CoA as a starter unit in place of acetyl-CoA. 
Incubating the enzyme with acetoacetyl-CoA and non-hydrolysable analogue should 
lead to the formation of an off-loaded triketide intermediate (37). 
 
This triketide is a potential substrate for the KR domain, which is postulated to act on 
the enzyme-bound C6 intermediate in vivo. If the assay mixture contains NADPH and 
the KR is able to act on the off-loaded triketide (37), then the reduced triketide (38) 
would be formed (Figure 2.13). It has already been reported that 6-MSAS can reduce 
the model intermediate ethyl 3,5-diketohexanoate in the presence of NADPH.55 
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Figure 2.13: Off-loading of acetoacetyl starter unit leads to triketide 38 which can 
then be further reduced by 6-MSAS to reduced triketide 40 in the presence of 
NADPH. 
 
FPLC-purified holo 6-MSAS was incubated with acetoacetyl-CoA and 
carba(dethia)malonyl-NAC (30) overnight at room temperature. The assay mixture 
was extracted as before and analysed on an LTQ Orbitrap. 
 
Triketide (38) could be detected in the assay mixture with a retention time of 13.67 
minutes and an exact mass of 228.1227 units. Repeating the assay using 
carba(dethia)malonyl-NAC which contained a deuterated methyl group (37, donated 
by Dr Manuela Tosin) gave a peak at the same retention time (13.67 minutes) but 
with an increase in mass of three units to 231.1417 units (Figure 2.14). MS/MS 
analysis of the 228.1227 ion gave a peak at 210.1118 units, corresponding to a loss of 
water from the parent ion, and a peak at 168.1016, corresponding to a loss of acetic 
acid. MS/MS analysis of the 231.1417 ion, corresponding to the deuterated product, 
gave a peak at 213.1310 units, which shows the same loss of water observed for the 
unlabelled molecule.  
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Figure 2.14: HRMS data for extracts of reactions where 6-MSAS and acetoacetyl-CoA 
were incubated with non-hydrolysable analogue 30 or 37 showed off-loading of 
triketides 38 or 39, respectively.   
 
When NADPH was included in the assay mixture, a peak of mass 230.1578 units and 
retention time 12.38 minutes was observed which did not appear in any of the 
controls. This mass corresponded to the reduced triketide 40. A small amount of 
unreduced triketide was also visible. Incubation with the deuterated non-
hydrolysable analogue 37 gave rise to a peak at retention time 12.41 minutes with a 
corresponding increase in mass to 233.1574 units (Figure 2.15). MS/MS of the peak 
at 230.1578 units gave rise to a peak at 170.1173 units, which corresponds to loss of 
acetic acid from the parent molecule. 
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Figure 2.15: HRMS traces of extracts of reactions when 6-MSAS was incubated with 
acetoacetyl-CoA, NADPH and non-hydrolsable analogue 30 or 37 for detection of the 
reduced triketides 40 or 41, respectively. 
 
A mass search for the reduced triketide mass minus water yielded two peaks with 
mass of 212.1392 units, one at 12.4 minutes and one at 14.5 minutes. These peaks 
were not present in either the acetoacetyl off-loading assay with no NADPH or in 
control assays (Figure 2.16). For the acetoacetyl assay with no NADPH, a peak 
corresponding to the mass of triketide with loss of water is visible at the same 
retention time as the intact triketide, but there are no additional peaks. This 
suggests that the peak at 12.4 minutes is an artefact of mass spectrometry on the 
intact reduced triketide, but that the peak at 14.5 minutes may be a genuine 
dehydrated intermediate. This could be formed by the action of the 6-MSAS 
ketoreductase on the off-loaded triketide, followed by the 6-MSAS dehydratase 
domain to form a carbon-carbon double bond. The position of the double bond in 
the intermediate would be unclear as there are two ketones with which it could be 
conjugated leading to two possible products (42 and 43, Figure 2.16). 
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Figure 2.16: HRMS data showing a mass search for reduced triketide with loss of 
water for non-hydrolysable analogues without label (42) and with deuterium label 
(43). 
 
The assay off-loading acetoacetyl using the deuterated analogue (37) in the presence 
of NADPH shows the same pair of peaks when the reduced triketide minus water 
mass is searched for. Both of these peaks have a mass of 215.1580, corresponding to 
a 3 mass unit increase due to the deuterated methyl group. This confirms that both 
peaks are products of a reaction involving the off-loading agent. 
 
MS/MS analysis of the two peaks at 212.1392 units gave rise to an identical 
fragmentation pattern, with peaks at 194.1173 (loss of water) and 170.1174 (loss of 
acetic acid). Although this does not confirm the identity of the peaks or any 
differences between them, it does provide further evidence that they are both 
compounds which behave in a way consistent with being off-loaded intermediates. 
 
2.2.7 Competitive assays 
Theoretically, the non-hydrolysable malonyl-NAC analogue should be able to 
compete with malonyl-CoA as an extender unit, and so off-load intermediates from 
every stage in the biosynthesis of 6-MSA (Figure 2.17). 
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Figure 2.17: Potential off-loaded intermediates in 6-MSA biosynthesis using non-
hydrolysable analogue 30. Theoretically, the isolation of diketide, triketide and 
tetraketide intermediates could be possible. 
 
Fluorimetry assays with non-hydrolysable analogue, acetyl-CoA, malonyl-CoA and 
NADPH showed no significant decrease in rate, but the final amount of 6-MSA 
produced is decreased (Figure 2.18), which is consistent with the off-loading of 
intermediates. The observation that the rate is not changed suggests that the off-
loading occurs before the rate-determining step for 6-MSA formation. 
Quantitatively, the amount of 6-MSA produced in all cases exceeds the theoretical 
maximum value, which could be due to interfering fluorescence in the assay mixture. 
This does, however, make it difficult to determine the reason for the reaction 
stopping. The reaction could stop when the supply of malonyl-CoA is exhausted, 
however it is also possible that the reaction stops due to inactivation of the enzyme 
by the non-hydrolysable analogue. This could be tested by the addition of fresh 
enzyme or fresh reactants to the assay mixture and observing the fluorimetry traces. 
If the addition of fresh reactants causes production of 6-MSA to start again, then the 
amount of malonyl-CoA could be the limiting reagent, but if fresh enzyme is needed, 
then the enzyme is becoming inactivated by the non-hydrolysable analogue. 
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 Effect of carba(dethia)-NAC analogue on 6-MSA production
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Figure 2.18: Zero-corrected fluorimetry traces of 6-MSAS activity assays (containing 
6-MSAS (20 g ammonium sulphate pellet), acetyl-CoA (0.013 mol), malonyl-CoA 
(0.04 mol) and NADPH (0.013 mol), BSA (50 g) in 0.5 ml 6- MSAS assay buffer, pH 
7.6, 25 °C) incubated with 0, 1 and 1.5 mol non-hydrolysable analogue. 
 
2.2.7.1 Acetyl starter unit 
Non-hydrolysable analogue 30 was incubated overnight with holo 6-MSAS, NADPH, 
acetyl-CoA and malonyl-CoA. The concentration of malonyl-CoA was varied from 4.9 
mM to 12.7 mM for the acetyl assay, while other concentrations were held constant 
(3 mM starter unit, 10 mM NADPH, 15 mM analogue). The assays were worked up as 
described previously and analysed on the LTQ Orbitrap for the presence of off-
loaded intermediates. 
 
For the acetyl starter unit, both off-loaded diketide (35) and triketide (38) 
intermediates were observed (Figure 2.19) but no reduced triketide (39) was 
detected. As the concentration of malonyl-CoA in the assay was increased, the 
amount of off-loaded intermediates detected fell, suggesting that the analogue did 
not compete effectively with malonyl-CoA. 
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Figure 2.19: HRMS traces of extracts from competitive assays with 6-MSAS using 
acetyl-CoA as a starter plus malonyl-CoA as an extender unit and 30 as the offloading 
agent, showing diketide (11.8-12.5 mins) and triketide (13.6-13.8 mins) products for 
different concentrations of malonyl-CoA. The peak at 16.3-16.5 minutes appears in 
control samples (FPLC-purified 6-MSAS (100 g, treated with DTT), 30 (15 mM), 
acetyl-CoA (3 mM) and malonyl-CoA (1-13 mM) made up to a final volume of 100 l 
with 6-MSAS assay buffer, pH 7.6, room temperature, overnight). 
 
In one single assay using 8.9 mM malonyl-CoA, a potential tetraketide peak was seen 
at 16.40 minutes with a mass of 276.1207 units. This corresponds to the sodium 
adduct of reduced tetraketide with loss of water. MS/MS analysis of this peak 
yielded a fragment at 192.0988 units which corresponds to a molecular formula of 
C9H15NaNO2
+. Repeat of this experiment with and without a deuterium-labelled 
analogue did not show this peak again. 
 
From the results of the competitive assays using acetyl-CoA as a starter unit, it was 
clear that lower concentrations of malonyl-CoA led to better off-loading of 
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intermediates. Thus, for the acetoacetyl starter unit, malonyl-CoA concentrations of 
1-8.9 mM were used. 
 
2.2.7.2 Acetoacetyl starter unit 
Acetoacetyl-CoA was incubated with 6-MSAS, malonyl-CoA (1-8.9 mM), NADPH and 
non-hydrolysable analogue 30. Millimolar concentrations of malonyl-CoA were used 
to try to obtain large amounts of offloaded intermediates and to encourage the 
formation of longer chain intermediates. For 1 mM malonyl-CoA, the unreduced 
triketide (38) was observed at 13.7 minutes. For higher concentrations, very little of 
this could be seen. A small amount of reduced triketide (39) could be seen with 1 
mM malonyl-CoA at 12.7 minutes. At higher concentrations of malonyl-CoA, no 
reduced triketide could be seen (Figure 2.20).  
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Figure 2.20: HRMS traces of competitive assays with 6-MSAS using acetoacetyl-CoA 
as a starter unit, malonyl-CoA as an extender unit, NADPH as cofactor and 30 as the 
offloading agent, showing diketide (12-12.3 mins), triketide (13.7 mins) and reduced 
triketide (12.6 mins) off-loaded at varying malonyl-CoA concentrations (FPLC-purified 
6-MSAS (100 g, treated with DTT), 30 (15 mM), acetyl-CoA (3 mM), NADPH (10 mM) 
and malonyl-CoA (1-8.9 mM) made up to a final volume of 100 l with 6-MSAS assay 
buffer, pH 7.6, room temperature, overnight). 
 
In all assays a roughly equivalent amount of off-loaded diketide could be seen. This 
would be from decarboxylation of malonyl-CoA to acetyl-CoA which could then 
prime 6-MSAS and be off-loaded by the non-hydrolysable analogue. At 1 mM 
malonyl-CoA, the signal intensity of the diketide peak and unreduced triketide peak 
are approximately the same. For any higher malonyl-CoA concentrations, the 
triketide peak is an order of magnitude smaller than the diketide. This implies that 
the contaminating acetyl-CoA is preferentially loaded on to the enzyme, as the off-
loading reaction should proceed at a similar rate. This is not unexpected as 6-MSAS 
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has a Km of 10 M for acetyl-CoA and a Vmax of 0.25 mol/min per milligram of 
protein, while acetoacetyl-CoA has a much higher Km (65 M) and a much lower Vmax 
(0.012 mol/min per milligram protein).56 
 
2.3 Future work 
To obtain tetraketide intermediates, the reduced triketide-CoA (80, synthesised in 
section 4.2.2) could be supplied to the enzyme as a starter unit. Although previous 
work by Cheung et al. implies that the reduced triketide-NAC thioester is not a 
substrate for the AT domain,87 if a small amount is loaded on to 6-MSAS then it 
should be possible to detect off-loaded intermediates. This could provide further 
information as to the timing of the dehydration, cyclisation and aromatisation steps.  
 
The identity of the tetraketide seen in the single competitive assay could be 
established by synthesis or the use of a labelled starter unit or off-loading agent.  
 
If the off-loading assays could be scaled up, there is the potential for NMR 
characterisation of the purified off-loaded intermediates. By using a chiral HPLC 
column and comparing the results with synthetic standards of known 
stereochemistry, it could be possible to identify the stereochemistry of the off-
loaded reduced triketide. This would rely on the KR exhibiting the same 
stereospecificity for a small molecule substrate in vitro as for the 
phosphopantetheine-tethered thioester in vivo. This method would also allow the 
stereochemistry and position of the double bond to be established in a dehydrated 
intermediate. 
 
6-MSAS is an unusual PKS in that it is tetrameric and features a large core domain 
between the DH and KR domains which is proposed to be necessary for subunit 
interaction. A structure would enable this unusual organisation to be elucidated. 
Holo 6-MSAS is a good candidate for crystallisation as the enzyme is available in large 
quantities and is of reasonable purity. The FPLC-purified 6-MSAS could be further 
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purified by ion exchange chromatography or gel filtration using a different column to 
achieve better separation of the intact synthase from contaminating fragments. 
 
Previous attempts to crystallise an intact PKS have been unsuccessful due to the 
conformational flexibility of the megasynthase, particularly in the ACP region. This 
could be overcome by use of a non-hydrolysable analogue such as 34 or 50 (Figure 
2.21) which could bind to the PKS and introduce a degree of rigidity.  
 
 
Figure 2.21: Non-hydrolysable analogues which could be used to aid crystallisation of 
6-MSAS. 
 
Alternatively, a cross-linking agent, such as one designed by Meier et al., which links 
ACPs and dehydratases by use of a suicide substrate attached to a 
phosphopantetheine arm, could be employed.88 This would require successful 
expression of the apo synthase rather than the holo to enable loading of the ACP 
domain with the substrate using a phosphopantetheinyltransferase. 
 
2.4 Chapter summary 
Holo 6-MSAS was successfully expressed in E. coli. 6-MSAS was purified in two steps 
and showed good specific activity when assayed by fluorimetry. 
 
A non-hydrolysable carba(dethia)malonyl-N-acetylcysteamine analogue was 
synthesised and used to off-load enzyme-bound intermediates. Acetyl and 
acetoacetyl starter units were successfully off-loaded. These represent the first 
directly off-loaded intermediates from a type I iterative synthase using the non-
hydrolysable analogue methodology. The triketide off-loaded from the acetoacetyl 
starter unit was found to be a substrate for the ketoreductase domain and possibly 
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also the dehydratase domain. The latter is particularly interesting in light of the 
reassignment of the dehydratase domain as a thioester hydrolase.89 The reduction of 
the off-loaded triketide strengthens the case for the ketoreductase domain acting on 
a C6 intermediate rather than a C8 chain.  
 
Competitive assays between malonyl-CoA and the non-hydrolysable analogue were 
carried out using both acetyl- and acetoacety-CoAl starter units. It was found that 
increasing the malonyl-CoA concentration decreased the amount of off-loaded 
intermediates. For the acetyl starter unit, diketide and triketide intermediates were 
seen. For acetoacetyl, there was a small amount of triketide seen, however, a large 
amount of contaminating diketide was observed due to decarboxylation of malonyl-
CoA. In order to see tetraketide intermediates, a careful balance of analogue and 
malonyl-CoA concentrations may be required to reduce off-loading of the starter 
unit but to intercept later stage intermediates of the biosynthetic pathway. 
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3.1 Introduction 
3.1.1 The dehydratase domain 
Dehydratase (DH) domains in fatty acid synthases (FASs) and polyketide synthases 
(PKSs) catalyse the formation of an carbon-carbon double bond by elimination 
of a -hydroxyl group. While the DH domain in polyketide biosynthesis has not been 
as extensively studied as the ketoreductase domain, much has been inferred by 
comparison of the PKS DH with the DH found in FASs. 
 
In mammalian FAS the dehydratase domain forms a pseudodimer from two adjacent 
regions of the same polypeptide. A single active site is formed at the interface 
between the two subdomains, comprising a histidine residue from the N-terminal 
and an aspartate from the C-terminal subdomain.90 This is in contrast to Type II FAS 
dehydratases such as FabA and FabZ which are homodimers and contain two 
equivalent active sites.91 The DH domain is structurally a ‘double hot dog fold’, two 
-helices with a -sheet curved around them. Further homodimerisation of the DH 
pseudodimer domains is not essential for activity as DH domains from FAS monomer 
have been found to be active.92 
CHAPTER 3 
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The mammalian FAS DH dimer (consisting of two double hot dog pseudodimers) has 
an overall V-shape and an angle of approximately 90° between the two monomers 
(Figure 3.1).93 
 
 
Figure 3.1: Mammalian FAS dehydratase dimer. The substrate tunnel entrance is 
marked in orange and the substrate tunnel is marked in grey. The N terminus is 
represented by a blue sphere and the red sphere represents the C terminus 
(Reprinted from Structure, 18, Akey, D. L.; Razelun, J. R.; Tehranisa, J.; Sherman, D. 
H.; Gerwick, W. H.; Smith, J. L., Crystal Structures of Dehydratase Domains from the 
Curacin Polyketide Biosynthetic Pathway, 94-105, Copyright (2010), with permission 
from Elsevier.) 93 
 
 
Crystal structures of the EryDH4 domain94 (from the 6-deoxyerythronolide B 
synthase DEBS) and all four DH domains in the curacin biosynthetic pathway93 
confirm that DH domains in PKSs have a high degree of similarity with those in 
mammalian FAS. The polyketide DHs also consist of a double hot dog fold with the 
same histidine/aspartate catalytic dyad and form dimers in the crystal lattice. 
Interestingly all five DH dimers from PKSs are in an extended conformation with 
approximately 180° between the monomers (Figure 3.2). Although the dimeric 
structure differs between FAS and PKS DHs, superposition of the two shows that the 
active site tunnel entrance, N-termini, C-termini and symmetry axes can be 
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superimposed without altering the angle between monomers.93 This suggests that 
despite their structural differences, the DH domains can fulfil similar roles in an 
mFAS-like assembly line. An alternative is that the observed dimer can hinge 
between the subunits to form the mFAS configuration in the full PKS.94 This is less 
likely in the light of the curacin structures, since identical non-physiological 
configurations would not be expected for five different DH domains. 
 
 
 
Figure 3.2: A: Dehydratase dimer from the curacin PKS. The substrate tunnel 
entrance is marked in yellow and the substrate tunnel is marked in grey. The N 
terminus is represented by a blue sphere and the red sphere represents the C 
terminus. B: CurK DH dimer showing the Asp and His catalytic dyad (PDB accession 
number 3KG9). (Reprinted from Structure, 18, Akey, D. L.; Razelun, J. R.; Tehranisa, J.; 
Sherman, D. H.; Gerwick, W. H.; Smith, J. L., Crystal Structures of Dehydratase 
Domains from the Curacin Polyketide Biosynthetic Pathway, 94-105, Copyright 
(2010), with permission from Elsevier.) 93 
 
A 
B 
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Mutation of a nearly conserved arginine to an aspartate in the proposed ACP binding 
site of EryDH4 caused production of 6-dEB to drop to 15% of the wild type level but 
no hydrated 6-dEB was observed.94 
 
The reaction catalysed by the DH domain proceeds by proton abstraction from the 
-position and formation of an enolate intermediate, which is stabilised by hydrogen 
bonding to a backbone amide. The enolate then reforms the carbon-oxygen double 
bond before moving the double bond along the molecule to eliminate the hydroxyl 
group with proton abstraction from the catalytic aspartate (Figure 3.3). The 
abstracted proton and hydroxyl are proposed to be on the same face of the 
substrate; i.e. a syn elimination, as demonstrated for FabA, a bacterial -
hydroxydecanoyl thioester dehydrase.95 
 
 
Figure 3.3: The proposed mechanism of double bond formation by the DH domain.93 
 
The precise mechanism of dehydratases in polyketide biosynthesis is complicated by 
the formation of both cis and (mainly) trans double bonds, while fatty acids only 
form trans 2,3 double bonds, which could then be isomerised to form a cis bond if 
required (as in the isomerisation to a cis-3,4 double bond required for formation of 
cis-vaccenic acid by E. coli FAS). In some cases, such as the phoslactomycins96, the 
formation of a cis double bond has been shown to be the work of a post-PKS 
tailoring enzyme. This, however, does not account for all the cis bonds found in PKS 
products. It was proposed after sequence analysis of ketoreductase domains that 
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trans double bonds could be formed by syn elimination from a (3R)-alcohol and cis 
double bonds from syn elimination from a (3S)-alcohol.97 
 
The recently obtained crystal structures of all four dehydratase domains involved in 
the formation of curacin by a Type I modular PKS appear to support this hypothesis. 
Modelling of substrates under the condition that the catalytic aspartate should form 
a hydrogen bond with the eliminated hydroxyl led to the prediction that the product 
of an A-type KR would bind in a conformation that led to a cis bond, while the 
product a B-type KR should lead to a trans bond. This also suggested that the 
catalytic histidine would abstract different protons depending on whether the 
resulting double bond is cis (pro-S abstracted) or trans (pro-R abstracted).93 
 
However, recent work on the borrelidin (51, Figure 3.4) biosynthetic pathway 
suggests that the relationship between KR specificity and dehydration product may 
not be as simple as it first appeared. Heterologous expression of DH2 and DH3 from 
the borrelidin megasynthase and analysis of substrate specificity in vitro found that 
both DH2 and DH3 as isolated domains acted on the (3R)-alcohol, despite DH2 in the 
context of the borrelidin PKS forming a trans bond and DH3 forming a cis bond (Dr 
Jennifer Andexer, personal communication).  
 
 
 
Figure 3.4: Borrelidin (51) and epothilone A (52). 
 
In addition, in myxobacterial PKSs it has been found that some extension modules 
give rise to a double bond without containing a dehydratase domain. In the case of 
epothilone (52, Figure 3.4) biosynthesis, this is because the product of module 4 is 
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actually dehydrated by the DH domain present in the adjacent module 5. It is 
proposed that the hydroxyl-bearing chain is passed from ACP4 to ACP5, where 
dehydration occurs. The chain is then passed backwards to KS5 for the standard 
extension carried out by module 5.98 
 
3.1.2 The dehydratase domain in 6-MSAS 
The DH domain in 6-MSAS is generally proposed to act on the C6 intermediate, after 
the action of the ketoreductase. Reaction of 6-MSAS with 3-pentynoyl-N-acetyl 
cysteamine, an inhibitor which irreversibly modifies the catalytic histidine in DH 
domains, abolished 6-MSA production but did not affect the rate of NADPH 
oxidation.55 
 
The cyclisation of the tetraketide chain to form 6-MSA (1) requires the formation of a 
cis double bond to enable condensation to take place. It is, however, unclear 
whether this bond is formed directly via dehydration or is the product of a 
dehydration followed by an allylic isomerisation reaction, such as that catalysed by 
-hydroxydecanoyl thioester dehydrase (Figure 3.5).99 It is also possible that 
dehydration does not occur until after cyclisation of the tetraketide takes place, 
which circumvents the problem of cis bond formation, but would be unusual in 
polyketide biosynthesis since tailoring domains generally act before subsequent 
condensations take place.52 
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Figure 3.5: Possible routes to the formation of a cis double bond in 6-MSA 
biosynthesis, a) allylic rearrangement of a trans double bond formed by the DH, b) 
direct formation of cis double bond by the DH, c) cyclisation of the tetraketide 
followed by dehydration to form a double bond. 
 
Attempts to synthesise the potential double bond intermediate(s) in the 6-MSA 
biosynthetic pathway have been unsuccessful. Harris and Harris found that the 
double bond did not remain localised in conjugation with the thioester, instead 
forming an equilibrium with the conjugated ketone form.100 
 
Within our research group, attempts to synthesise the cis- and trans 2-enoyl from 
alkyne 53 were also unsuccessful, instead resulting in the formation of allene 54 
upon oxidation of the hydroxyl group (Figure 3.6).101 
 
 
Figure 3.6: Formation of allene 54 after oxidation of alcohol 53. 
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3.1.3 The thioester hydrolase domain 
Recently, DH domain studies have been performed with the 6-MSAS homologue ATX, 
a 6-MSA synthase from Aspergillus terreus. Mutating the catalytic histidine in the DH 
domain to an alanine abolished 6-MSA production. As dehydration is proposed to 
occur on a C6 intermediate, it was suggested that a triketide intermediate might be 
off-loaded by the enzyme, in the manner of TAL production, but this was not 
observed. Coexpression of the dehydratase mutant with ATX mutated in another 
domain restored 6-MSA production, showing that the DH mutation did not cause a 
structural change which rendered the enzyme inactive.102  
 
A double mutant inactivating the ketoreductase and dehydratase would be expected 
to produce TAL in the same manner as a previously constructed ketoreductase 
mutant.85 Instead neither 6-MSA or TAL was observed in the culture medium.102 
 
It was noted that the DH motif HxxxGxxxP was found in bacterial orsellinic acid 
synthases, despite there being no dehydration involved in this biosynthetic 
mechanism. It was proposed that the dehydratase acts instead as an isomerase to 
convert the 2-trans-enoyl intermediate to the 3-cis-enoyl form or that, in fact, this 
domain is responsible for release of 6-MSA from the enzyme, since there is no 
thioesterase domain in the 6-MSAS or ATX genes.57, 89 
 
Moriguchi et al. expressed ATX containing the His972A mutation (ATX-DHm) which 
showed no 6-MSA production.89 After incubation with acetyl-CoA, [2-14C]-malonyl-
CoA and NADPH, followed by alkaline hydrolysis it was found that radiolabelled 6-
MSA was released. When mutated ATX was incubated with labelled malonyl-CoA and 
NADPH, then digested with thrombin it was found that the radiolabel was localised 
on the ACP. These experiments suggest that ATX is able to form the tetraketide 
intermediate without need for dehydration, but is unable to off-load 6-MSA from the 
enzyme. Intact ATX was able to interact with labelled ATX-DHm to release labelled 6-
MSA. 
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In light of this evidence, Moriguchi et al. proposed that the dehydratase domain in 
ATX and related enzymes is in fact a thioester hydrolase (TH) domain (Figure 3.7). 
This is related to the standard PKS thioesterase by virtue of also being part of the hot 
dog fold superfamily, but is unusual in that it is in the middle of the synthase rather 
than at the end. Also, since ATX and 6-MSAS are not affected by the serine protease 
inhibitor PMSF, product release cannot occur via an active site serine susceptible to 
this inhibitor.56 
 
 
KS AT TH KR ACP
1774 aa
ID
 
Figure 3.7: Proposed new domain organisation in 6-MSAS replacing the DH with a 
TH. The interdomain (ID) region is proposed to be critical for subunit interaction.103 
 
Despite experiments which showed that ATX-DHm could be complemented with an 
ATX-KSmATmKRmACPm mutant, expression of the TH domain alone could not 
complement it. Instead the TH had to be expressed with a region that follows its C-
terminus which is reported to contain the interdomain region (ID). This is proposed 
to be important for subunit binding to form a tetramer.103  The TH-ID construct was 
able to complement ATX-DHm. 
 
It was also shown that both intact ATX and TH-ID could hydrolyse 6-MSA-N-
acetylcysteamine thioester. The proposed mechanism for the release of enzyme-
bound 6-MSA proceeds with deprotonation of water, by the catalytic histidine, which 
attacks the thioester. The oxyanion is protonated by the catalytic aspartate to form 
an acetal which can collapse to reform the carbon-oxygen double bond and 
eliminate the thiol group (Figure 3.8).89  
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Figure 3.8: A: Revised biosynthetic pathway to 6-MSA with the DH reassigned as a 
TH. The cyclisation and aromatisation steps are proposed to be non-enzyme 
catalysed. B: Proposed mechanism of the thioester hydrolase domain.89 
 
3.1.4 Aim of chapter 
The aim of this chapter is to install the same mutation used in the ATX work into the 
dehydratase domain of 6-MSAS to first verify that the same results are seen. The 6-
MSAS-DHm mutant will be incubated with acetyl-CoA, malonyl-CoA and NADPH and 
used for off-loading experiments with a non-hydrolysable malonyl-SNAC analogue 
(30). This provides a much milder method for investigating intermediates attached to 
the mutated synthase, since the alkaline hydrolysis conditions used for ATX would 
also promote cyclisation and aromatisation of the tetraketide intermediate. 
 
It is worth noting that while the thioester hydrolase activity of the DH/TH domain 
was confirmed, no experiments were carried out to show that the domain was not 
able to catalyse a dehydration reaction. By comparison of off-loaded intermediates 
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from the 6-MSAS-DHm and 6-MSAS, it might be possible to observe a difference 
which could provide a clue as to whether this domain performs both functions. 
3.2 Results and discussion 
3.2.1 Expression of 6-MSAS-DHm 
3.2.1.1 Construction of plasmid 
 
Primers were designed by Dr Fanglu Huang to amplify the DH domain from the 6-
MSAS-containing plasmid pKOS007-109 in two sections. The left-hand section 
introduced a mutation into the active site of the DH, converting histidine-958 to an 
alanine residue between a Bsu36I site and a KpnI site. The right-hand section 
extended the DH domain from a KpnI site to a BamHI site (Figure 3.9).  
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Figure 3.9: PCR scheme for the introduction of the H958A mutation.  The intact 6-
MSAS plasmid was used as a template for two PCR reactions. The first, using primers 
1A/1B introduced the H958A mutation and formed a 2.55 kb fragment containing 
Bsu36I and KpnI restriction sites. The second, using primers 2A/2B formed a 0.57 kb 
fragment containing KpnI and BamHI restriction sites. The gel shows PCR products 
for primer pairs 1A/1B and 2A/2B with varying MgCl2 concentration in the reaction.  
 
PCR was carried out with both sets of primers to obtain the left and right fragments 
respectively. These were digested with KpnI/Bsu36I (left) and KpnI/BamHI (right) and 
purified via gel extraction. 
 
pKOS007-109 was digested with Bsu36I and BamHI. Initially a sequential digest was 
attempted, the DNA being digested by BamHI, purified using a PCR purification kit 
(Qiagen) and then being digested by Bsu36I. This approach yielded no product, 
despite both enzymes being able to digest the plasmid separately. It was then 
decided to avoid the PCR purification step and perform a double digest followed by 
gel extraction. The three fragments were ligated using T4 ligase overnight at 16°C 
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using the concentration ratio 1:5:5 (vector:right:left) and the ligation mixture was 
transformed into competent NovaBlue cells. Colonies were picked and screened by 
comparison of plasmid size with authentic pKOS007-109, followed by sequencing. Of 
six plasmids sequenced, one (named DHm1) had the required histidine to alanine 
mutation. The other five contained a wild-type DH domain, presumably from a small 
contamination of singly cut plasmid in the doubly-digested sample. 
 
3.2.1.2 Expression 
Plasmid DHm1 was transformed into E. coli BL21 (DE3) alongside pET28a(+)-MtaA in 
order to yield mutated holo synthase. 6-MSAS-DHm/MtaA was grown under the 
same conditions as the unmutated holo synthase (section 2.2.1) and 6-MSAS-DHm 
was purified by ammonium sulphate precipitation. 
 
Analysis of the purifed protein by SDS-PAGE showed a band of the correct size in the 
ammonium sulphate 22-40% fraction. This fraction could be further purified by FPLC 
under the same conditions as used previously, which gave a peak at the same elution 
volume as the intact synthase (Figure 3.10). 
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Figure 3.10: SDS-PAGE analysis of ammonium sulphate fractions in the purification of 
6-MSAS-DHm and gel filtration trace of 6-MSAS-DHm (eluted with NaH2PO4 100 mM, 
EDTA 1 mM, DTT 2 mM, glycerol 20%, pH 7.1). 
 
3.2.1.3 In vivo activity 
If the dehydratase has been successfully mutated, then no production of 6-MSA 
should occur in vivo. 50 ml of culture supernatant was acidifed with 1 M HCl and 
extracted twice with ethyl acetate. The solvent was evaporated and the resulting oil 
was redissolved in 1 ml of methanol and analysed by LC-MS. By comparison with a 
standard and a culture expressing unmutated 6-MSAS, it was clear to see that the 
DHm culture did not produce 6-MSA (Figure 3.11). This confirms that the mutation in 
the DH domain has the same effect as that observed for ATX in A. terreus. 
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Figure 3.11: LC-MS traces showing culture supernatant extracts from holo 6-MSAS-
DHm and holo 6-MSAS compared with a synthetic 6-MSA standard. The peak 
corresponding to 6-MSA is present in the holo 6-MSAS culture but is absent from the 
6-MSAS-DHm culture. Conditions: Synergi 4u Polar-RP 150 x 2.00 mm column 
(Phenomenex), water/methanol + 0.1% TFA gradient; 0-5 minutes, 0% organic, 5-30 
minutes 0-100% organic, 30-38 minutes 100% organic, 38-40 minutes 100%-0% 
organic. 
 
3.2.1.4 In vitro activity 
The ammonium sulphate pellet containing 6-MSAS-DHm was incubated overnight 
with 3 mM acetyl-CoA and 3 mM malonyl-CoA in the absence of NADPH. The assay 
mixture was then extracted with ethyl acetate, dried under nitrogen and redissolved 
in methanol before analysis on the LTQ-Orbitrap. A mass search for TAL (55) showed 
a strong peak at 12.0 minutes which had an exact mass of 127.0394 units (Figure 
3.12). This showed that 6-MSAS-DHm was capable of producing the shunt product 
triacetic acid lactone, and therefore that the mutation in the DH domain did not 
affect the ability of the KS, AT and ACP to interact with each other. 
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Figure 3.12: A HRMS mass search of an extract of a reaction containing 6-MSAS-
DHm, acetyl-CoA, malonyl-CoA and NADPH showed the presence of TAL (55), as 
expected. 
 
3.2.2 Off-loading experiments using 6-MSAS-DHm 
3.2.2.1 Starter unit off-loading: Acetyl 
6-MSAS-DHm was incubated with acetyl-CoA and non-hydrolysable analogue 30 
overnight to see if the starter unit can be off-loaded from the mutated synthase. The 
assay mixture was extracted with ethyl acetate, dried and redissolved in methanol 
before analysis on the LTQ Orbitrap (Figure 3.13). 
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Figure 3.13: HRMS trace of an extract of a reaction containing 6-MSAS-DHm, acetyl-
CoA and 30 as an offloading agent shows the presence of offloaded diketide (35). 
 
Diketide 35 with an exact mass of 186.1126 units was seen at a retention time of 
11.0 minutes. This corresponds with the off-loaded diketide seen when holo 6-MSAS 
was incubated with acetyl-CoA and non-hydrolysable analogue (section 2.2.5). 
 
3.2.2.2 Competitive assays 
For the unmutated synthase, increased malonyl-CoA concentration led to a 
reduction in the amount of intermediates off-loaded, as the non-hydrolysable 
analogue did not compete effectively with malonyl-CoA, and so the reaction with 
malonyl-CoA to form 6-MSA was preferred (section 2.2.7). With the dehydratase 
mutant unable to remove intermediates from the enzyme, it might be expected that 
the opposite effect would be observed, i.e. that off-loaded intermediates would 
increase with malonyl-CoA concentration since a greater amount would be formed 
on the enzyme. It could also be possible that longer chain intermediates would be 
isolated at higher malonyl-CoA concentrations since 6-MSAS-DHm could 
preferentially react with malonyl-CoA until the enzyme is unable to act any longer 
due to the mutation in the DH/TH domain. This stalled intermediate might then be a 
better candidate for off-loading.  
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6-MSAS-DHm was incubated with acetyl or acetoacetyl-CoA as a starter unit 
alongside varying concentrations of malonyl-CoA, and non-hydrolysable analogue 30 
(Figure 3.14). 
  
For the acetyl starter unit a significant amount of off-loaded diketide was seen at 
11.9 minutes for all three malonyl-CoA concentrations used (4.7 mM, 8.6 mM and 
11.9 mM). A mass search for triketide showed a peak at 12.8 minutes which 
corresponded to the correct mass, however this retention time is incorrect for the 
unreduced triketide which is expected at around 13.7 minutes. No reduced triketide 
could be seen in any assay. Assays using 3 mM malonyl-CoA also showed a peak 
corresponding to unreduced triketide at 13.7 minutes in samples both with and 
without NADPH.  
0
20
40
60
80
100
12.29
NL: 4.32E5
m/z= 186.1116-186.1134 
0
20
40
60
80
100
12.95 NL: 3.60E5
m/z= 228.1219-228.1241 
Time (min)
0
20
40
60
80
100
0
20
40
60
80
100
0 11.93 12.89
NL: 4.48E5
m/z= 186.1116-186.1134 
NL: 1.56E5
m/z= 228.1219-228.1241 
0
20
40
60
80
100
0
20
40
60
80
100
11.79 12.80
NL: 9.00E5
m/z= 186.1116-186.1134 
NL: 1.52E5
m/z= 228.1219-228.1241 
Diketide Triketide
4.7 mM
8.6 mM
11.9 mM
Mal-CoA conc
50
100
0
50
100 11.9411.62
13.65
m/z= 186.1116-186.1134 m/z= 228.1219-228.1241
0 10 20
Time (min)
0 10 20
Time (min)
3 mM
0 5 10 15 20 25 30 35
0 5 10 15 20 25 30 35
0 5 10 15 20 25 30 35 0 5 10 15 20 25 30 35
0 5 10 15 20 25 30 35
0 5 10 15 20 25 30 35
Time (min)
 
Figure 3.14: HRMS traces of extracts from competitive assays using 6-MSAS-DHm 
with acetyl-CoA as a starter unit, malonyl-CoA as an extender unit and 30 as an 
offloading agent showed offloaded diketide and triketide products. 
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For the acetoacetyl starter unit, no diketide was observed as would be expected. 
This also means that the decarboxylation of malonyl-CoA to acetyl-CoA which can 
prime the synthase and leads to off-loading of diketide was not a problem in this 
experiment. Again, when a mass search for triketide was performed a peak was seen 
at 12.8 minutes. No reduced triketide was present in the assay mixture. 
 
The lack of off-loaded triketide intermediates is surprising given that these were 
readily off-loaded from the unmutated synthase and given that the diketide was off-
loaded when acetyl-CoA was used as a starter unit. 
 
Since the stalled tetraketide has been shown to be attached to the ACP, it could be 
that this is not able to be off-loaded by the non-hydrolysable analogue. Since the 
method of off-loading is dependent on mimicking the action of malonyl-ACP, it 
implies that all the intermediates seen are off-loaded from the KS domain, rather 
than the ACP. It is possible that triketide intermediates are not seen since the 
analogue does not compete well with malonyl-CoA (section 2.2.7), but are instead 
rapidly extended to tetraketides attached to the ACP which cannot be off-loaded. 
This would also reduce the total amount of intermediates detectable, since an 
enzyme which still has tetraketide attached is unable to function further. The loading 
of acetyl-CoA on to the KS does not involve the ACP and so may occur while the 
tetraketide chain is stalled on the ACP. This could explain the ease of diketide off-
loading. It is also probable that a proportion of triketides (which would form 
tetraketide intermediates) are removed as TAL (55). Mass searches for TAL in initial 
off-loading assays found peaks at 11.7-11.8 minutes which corresponds to retention 
time seen when 6-MSAS-DHm acts in the absence of NADPH.  
 
If the work of Moriguchi et al. is correct then it might be hoped that a pentaketide 
(56) could be off-loaded, however this would require the 6-MSAS KS to accept an 
unnaturally large intermediate (Figure 3.15). A mass search yielded no evidence of 
this pentaketide in any assay. 
Chapter 3: The dehydratase/thioester hydrolase domain in 6-MSAS 
88 
 
Figure 3.15: Potential pentaketide (56) which could be off-loaded from the KS 
domain. 
 
Since the growing polyketide chain remains stuck on the enzyme in the dehydratase 
mutant, it was suggested that allowing the reaction between acetyl-CoA and 
malonyl-CoA on the enzyme before adding off-loading agent might result in the 
detection of longer chain intermediates rather than a high proportion of off-loaded 
starter unit as seen for holo 6-MSAS. 
 
6-MSAS-DHm was incubated with acetyl-CoA or acetoacetyl-CoA, malonyl-CoA and 
NADPH for 1 hour before addition of the non-hydrolysable analogue.The assay using 
an acetyl starter unit gave a strong diketide peak with a small potential peak for 
unreduced triketide at 13.80 minutes. No reduced triketide, tetraketide or 
pentaketide was seen. The assay using an acetoacetyl starter unit also gave a strong 
diketide peak. This must be from decarboxylation of malonyl-CoA and priming of the 
enzyme with acetyl-CoA which is then off-loaded. No triketide or reduced triketide 
could be seen, nor any tetraketide or pentaketide. 
 
These results suggest that the preferred enzyme reaction of 6-MSAS-DHm is to 
extend the starter unit with malonyl-CoA to the enzyme-bound tetraketide which 
cannot be processed further, or to remove the enzyme-bound triketide before the 
reduction step to form triacetic acid lactone. Alternatively, if the DH domain is a 
dehydratase and the mechanism of biosynthesis is not the same as in ATX, it could 
be that the reduced triketide is stalled on the ACP. 
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3.3 Future work 
The formation of enzyme-bound 6-MSA by 6-MSAS-DHm could be confirmed by 
alkaline hydrolysis using 14C-labelled acetyl-CoA or malonyl-CoA. Whether the 
enzyme-bound product can be released using intact 6-MSAS or the heterologously 
expressed DH domain could also be investigated. These would confirm that 6-MSAS 
carries out biosynthesis in the same way as ATX. 
 
3.3.1 Starter unit assay: acetoacetyl 
A repeat of the acetoacetyl starter unit assay used on the unmutated synthase 
(section 2.2.6) would be beneficial. This would establish whether off-loaded 
triketides could be seen when there is no competition from malonyl-CoA. Assays 
with and without NADPH could assess whether the KR domain is still capable of 
acting on non-enzyme bound substrates. 
 
Comparison of the reduced triketide minus water peaks for 6-MSAS and 6-MSAS-
DHm could give insight into whether the peak at 14.50 minutes seen in other assays 
(section 2.2.6) is in fact a product of the DH domain acting on the off-loaded 
intermediate. If the DH does act then the peak should be absent from assays using 6-
MSAS-DHm in place of 6-MSAS. 
 
3.3.2 Testing DH activity with synthetic substrates 
In order to test the activity of the DH domain on non-enzyme bound substrates, a 
non-hydrolysable reduced triketide mimic could be synthesised. Protected reduced 
triketide acid (57, synthesised in section 4.2.2) could be coupled to N-(2-
aminoethyl)acetamide (58) using a coupling reagent such as EDC. The dithiane group 
could then be removed using methyl iodide and calcium carbonate to give non-
hydrolysable analogue 60 (Figure 3.16). 
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Figure 3.16: Proposed synthesis of non-hydrolysable reduced triketide analogue (60). 
 
60 could be incubated with both 6-MSAS and 6-MSAS-DHm to see if dehydration can 
occur in solution and if the products can be detected by the LTQ-Orbitrap. 
 
If dehydrated intermediates are observed then this is evidence that the DH domain 
in 6-MSAS may be capable of performing both dehydration and thioester hydrolysis, 
while lack of dehydration would cement the role of the DH domain as a thioester 
hydrolase (Figure 3.17). 
 
 
Figure 3.17: Proposed experiment to test the activity of the DH domain using a non-
hydrolysable reduced triketide analogue that could form the dehydrated non-
hydrolysable reduced triketide analogue 61. 
 
If the dehydrated triketide is observed, then the stereospecificty of the DH domain 
could be probed by using enantiomerically resolved acids as starting materials 
(section 4.2.2). 
 
The same series of experiments could be performed using the commercially available 
substrate methyl 3,5-diketohexanoate which has previously been shown to be a 
substrate for the KR domain.55 This would require the KR activity with the substrate 
to be confirmed before it was possible to assay the DH. 
Chapter 3: The dehydratase/thioester hydrolase domain in 6-MSAS 
91 
 
The non-hydrolysable analogue strategy could also be employed in vivo, as has been 
successful for the lasalocid producer Streptomyces lasaliensis (Dr Manuela Tosin, 
personal communication). Bacterial cultures expressing either 6-MSAS or 6-MSAS-
DHm could be supplemented with protected carba(dethia)malonyl-N-
acetylcysteamine and grown in the normal way. The culture medium could then be 
extracted with organic solvent, as could the cell lysate, to retrieve off-loaded 
intermediates. This approach could lead to more off-loaded intermediates as there 
would be a greater variety of conditions present in the cell. However, any 
modifications of the off-loaded intermediates would be difficult to assign to any 
domain of 6-MSAS due to other enzymes present. 
 
3.4 Chapter summary 
The dehydratase domain of 6-MSAS was inactivated by mutation of the catalytic 
histidine to alanine. This abolished production of 6-MSA in culture medium but the 
6-MSAS-DHm mutant was still able to produce TAL when incubated with acetyl-CoA 
and malonyl-CoA. 
 
Incubation of 6-MSAS-DHm with acetyl-CoA, malonyl-CoA, NADPH and non-
hydrolysable analogue carba(dethia)malonyl-NAC led to the off-loading of only 
diketide intermediates. Using acetoacetyl-CoA did not give any observable triketide 
intermediates. Incubating the enzyme with substrates before adding the off-loading 
agent led to off-loading of diketide intermediates for both acetyl and acetoacetyl 
starter units.  
 
The lack of higher intermediates observed suggests that the off-loading agent does 
not compete effectively with malonyl-CoA and thus only enzyme-bound tetraketide 
is available for off-loading. As this would be attached to the ACP, it is unlikely that 
the off-loading mechanism would be as successful as for KS-bound intermediates. 
Work by Y. Sun et al. has suggested that chain transfer is possible between an intact 
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PKS module and a discrete holo ACP.104 If the holo ACP for 6-MSAS could be 
heterologously expressed and added in to the reaction mixture, this could enable the 
enzyme-stalled intermediates to be transferred to the discrete ACP. This small 
protein could then be monitored by mass spectrometry and the mass of the 
intermediates attached to it could be determined.  
 
There is still a considerable amount of work to do to assay whether the DH domain in 
6-MSAS performs both a dehydration and a hydrolysis reaction in 6-MSA 
biosynthesis, or whether it is only a thioester hydrolase. This chapter provides a 
framework for these experiments. 
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4.1 Introduction 
4.1.1 Ketoreductase domains 
In polyketide synthases the ketoreductase domain transforms the ketone formed by 
the ketosynthase into a hydroxyl group by addition of a hydride from the reduced 
form of nicotinamide dinucleotide phosphate (NADPH, 62). The ketoreductase (KR) is 
the first step in the reductive loop in fatty acid biosynthesis and is responsible for 
much of the structural diversity seen in polyketides.  
 
Extensive studies on the first ketoreductase domain (KR1) in the 6-
deoxyerythronolide B synthase (DEBS) Type I modular system have been carried out 
to determine how selective this KR is for stereocentres in the substrate as well as the 
inherent stereochemistry of reduction. As DEBS utilises methylmalonyl-CoA as an 
extender unit, there is an additional stereocentre present at C-2 from the methyl 
group. It was found that KR1 determined the stereochemistry at C-3 by exclusively 
reducing the ketone to the (3R)-hydroxy group. Additionally the KR set the 
stereochemistry at C-2 by exclusively recruiting the (2S)-methyl precursor.105 
Surprisingly, experiments with KR5 and KR6 from DEBS showed loss of stereocontrol 
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when the domains were presented with unnatural substrates which were much 
smaller.106 This went against previous results which had shown that DEBS modules 
engineered to contain a KR from a different module gave products with the natural 
stereochemistry of the imported KR.107 Further experiments on excised KR domains 
also reported loss of stereocontrol when KR domains which act on long chain 
substrates were presented with short chains, suggesting a fine energetic balance 
between modes of substrate presentation in the KR active site.108 
 
Incubation of DEBS 1 TE and DEBS 3 with chirally deuterated NADPH showed that 
KRs 1, 2, 5 and 6 all used the pro-S hydride to perform ketoreduction.109 As KR1 
generates an (R)-hydroxyl, while KRs 2, 5 and 6 all produce an (S)-hydroxyl, this rules 
out the KR setting the stereochemistry of its product by using different hydrides 
from NADPH to form the R and S isomers. 
 
Alignment of KR domains from 17 modular PKSs led to identification of motifs 
indicative of whether a KR domain formed the R or S hydroxyl, also known as A-type 
or B-type (Figure 4.1). The A-type was found to have a conserved tryptophan residue 
at position 142 in the aligned KR sequences, while the B-type lacked this tryptophan, 
but had a leucine-aspartate-aspartate (LDD) from residues 93-95. D95 was invariant, 
while D94 was replaced by glutamate in two cases. Leucine-93 was less strictly 
conserved. B-type KRs also typically had a proline at residue 144 and asparagine at 
residue 148. The identification of these ‘Caffrey motifs’ allows the prediction of KR 
stereochemistry in cases where the reduction product is further processed to 
remove the hydroxyl.110 
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Figure 4.1: Reduction of ketone by A and B type ketoreductases leads to opposing 
stereochemistry at C3. 
 
A putative catalytic triad consisting of tyrosine, serine and lysine was identified from 
homology to the short chain dehydrogenase/reductase superfamily. Mutation of 
each of these three residues abolished activity in the KR6 domain of DEBS. In the 
proposed mechanism, the ketone is coordinated by hydrogen bonding to tyrosine 
and serine while hydride attack occurs. A proton is then donated from the tyrosine 
residue to form the hydroxyl group. This mechanism could allow the formation of 
opposite stereochemistries of hydroxyl group by opposite orientation of the 
substrate in the active site (Figure 4.2).97 
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Figure 4.2: Proposed mechanism of reduction in A and B type ketoreductase domains 
using a hydride from NADPH (62). 
 
A KR domain from the actinorhodin Type II PKS was crystallised in the presence of 
NADPH and NADP+ and confirmed the tyrosine and serine active site residues. The 
structure also established an extensive proton relay network of water molecules. No 
conserved Caffrey motifs were found in the sequence, however this is generally true 
of all aromatic polyketide KRs and may be due to the fact that aromatic polyketide 
synthases have a different binding motif to modular ones.111  
 
The erythromycin KR1 (B-type) was crystallised by Keatinge-Clay and Stroud and 
revealed an active site groove. If substrates entered from opposite ends of this 
groove then it would explain the opposing stereoselectivities of A and B type KRs.112 
Comparison with the more ordered structure of the first KR of the tylosin PKS, which 
is also B-type, led to development of fingerprints for A-type, B-type and non-
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functional C-type ketoreductase domains. The conserved tryptophan in A-type KRs 
makes space for the phosphopantetheine arm to enter the active site from the one 
side. In B-type KRs the LDD motif seals the lid helix and LDD loop together, 
positioning the phosphopantetheine arm to enter the KR active site from the 
opposite side to the A-type (Figure 4.3).113 
BA
 
Figure 4.3: A: Superposition of EryKR1 (B type, green) and TylKR1 (A type, blue). B: 
Alignment of the catalytic regions of EryKR1 (green) and TylKR1 (blue). 2 is the 
position occupied by tryptophan in an A-type KR. (Reprinted from Chemistry & 
Biology, 113, Keatinge-Clay, A; A tylosin ketoreductase reveals how chirality is 
determined in polyketides, 898-908, Copyright (2007), with permission from 
Elsevier.)113 
 
4.1.2 Ketoreduction in 6-MSAS 
In 6-MSA biosynthesis, ketoreduction occurs only once in the three cycles of 
condensation carried out by 6-MSAS. In the absence of NADPH (62), the shunt 
product triacetic acid lactone (TAL, 55) is formed from acetyl-CoA and two units of 
malonyl-CoA (Figure 4.4).54 Incubation of 6-MSAS with acetylenic inhibitors led to 
reduction of 6-MSA production but did not interfere with NADPH oxidation. 
Acetylenic inhibitors react irreversibly with the active site histidine present in 
dehydratase domains, implying that reduction, then dehydration occurs on an 
intermediate.55 Mutation of the NADPH binding site in heterologously expressed 6-
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MSAS produced TAL in the culture medium, with concomitant loss of 6-MSA 
production.85 These pieces of evidence strongly suggest that reduction occurs on a C-
6 intermediate rather than on the completed 8 carbon polyketone chain (Figure 4.4). 
 
Figure 4.4: Ketoreduction occurs on the C6 intermediate in 6-MSA biosynthesis. In 
the absence of NADPH, TAL (55) is formed. 
 
As ketoreduction occurs on a C6 intermediate followed by elimination of the 
resulting hydroxyl, the stereochemistry of the reduced triketide produced is cryptic. 
In order to investigate this, the enantiomerically resolved reduced triketides 63 and 
64 were synthesised as NAC thioesters by Cheung et al. (Figure 4.5).87 It was hoped 
that the intermediate with the correct stereochemistry would be selected and 
loaded on to 6-MSAS, where it would be elaborated into 6-MSA. Unfortunately, on 
incubation with purified 6-MSAS neither intermediate was able to form 6-MSA at a 
rate greater than that observed with malonyl-CoA alone. Both intermediates did 
serve as inhibitors for the enzyme. 
 
 
Figure 4.5: Enantiomerically resolved reduced triketide NAC esters 63 and 64 
synthesised by Cheung et al.87 
 
The failure of this work could be due to the presence of intermediates as NAC 
thioesters when the natural substrate for the AT domain is a CoA thioester. 
Alternatively, the AT domain could be unable to identify and load the triketide on to 
the KS domain.  
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Recent work on the bacterial 6-methylsalicylic acid synthase ChlB1, from the 
chlorothricin pathway in Streptomyces antibioticus, has found that mutation of the 
NADPH binding site from GxGxxG via a single or triple mutation of glycine residues 
abolished 6-MSA production, but did not give rise to production of TAL. Ding et al. 
postulate that in the bacterial MSAS, NADPH binding induces a conformational 
change which is essential for activity. Instead, mutation of the active site tyrosine to 
phenylalanine was carried out in order to eliminate the reductive ability of the KR. 
Intriguingly, this led to the formation of orsellinic acid (2), albeit at a significantly 
reduced level, which suggests that the ketosynthase is not specific for the reduced 
triketide intermediate in bacterial MSAS (Figure 4.6).114 
 
 
Figure 4.6: Mutation of the ketoreductase domain in MSAS ChlB1 resulted in the 
formation of orsellinic acid (2) rather than 6-MSA (1). 
 
4.1.3 Aim 
The aim of this section is to synthesise the diastereomerically resolved reduced 
triketide-CoAs 65 and 66. These will be loaded on to apo 6-MSAS using a 
phosphopantetheinyltransferase. This can then be incubated with 13C-labelled 
malonyl-CoA and the 6-MSA produced analysed by LC-MS (Figure 4.7). 6-MSA 
produced from the triketide will only incorporate one unit of labelled malonate, 
while any 6-MSA formed from decarboxylation of labelled malonate to form acetate 
which can prime the synthase will be labelled at every carbon. 
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Figure 4.7: Synthesised reduced triketides 65 and 66 can be loaded on to 6-MSAS. 
The correct OH stereochemistry should be elaborated into 6-MSA (1). 
 
4.2 Results and discussion 
4.2.1 Caffrey motif analysis. 
Analysis of the protein sequence of 6-MSAS reveals that it contains two 
phenylalanine-serine-serine (FSS) motifs, which contain the active site serine in 
ketoreductase domains. The first covers residues 1256 to 1258, and the second, 
residues 1567 to 1569. The glycine-rich region proposed for the NADPH binding site 
is 1198GTPGVSG for the first potential KR domain and 1418GGLGVLG for the second.  
 
Both 6-MSAS KR sequences were aligned with the KR1 and KR2 domains from DEBS 
using ClustalW.115 DEBS KR1 is a B-type reductase while KR2 is an A-type. This 
showed that the first KR domain lacked the catalytic tyrosine close to the FSS motif, 
while the second KR domain contains tyrosine-1572 which could fulfil this role 
(Figure 4.8). This second domain is the one which is identified as the KR in the 
annotation of the sequence, from homology with FAS.57  
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DEBS_KR1        GTVLVTGGTGGVGGQIARWLARRGAPHLLLVSRSGPDADGAGELVAE-------------  
DEBS_KR2        GTILVTGGTAGLGAEVARWLAGRGAEHLALVSRRGPDTEGVGDLTAE-------------  
C-terminal      ------GGLGVLGLEVADFLVEKGARRLLLISRRALPPRRTWDQVSEDLQPTIA------  
N-terminal      GTPGVSGSMESLVHQIAWPPATPAEEPLSIETVILVSPDATTRALYAASLPTRVNSFQFS  
                      *.   :  ::*   .  .   * : :     .  .                    
 
DEBS_KR1        ------------LEALGARTTVAACDVTDRESVRELLGG-IGDDV-PLSAVFHAAATLDD  
DEBS_KR2        ------------LTRLGARVSVHACDVSSREPVRELVHGLIEQGD-VVRGVVHAAGLPQQ  
C-terminal      --------KIRLLESRGASVHVLPLDITKPDAVEQLTTALDRLSLPSVQGVVHAAGVLDN  
N-terminal      STQEFFSNASSLPLEKGTVVTYIPGEVASLAEVPAASESFTWNLLELIKFTVNGSLPIKV  
                                *: .   . :::.   *     .        :  ..:.:   .  
 
DEBS_KR1        GTVDTLTGER-------------IERASRAKVLGARNLHELTRELDLTAFVLFSSFASAF  
DEBS_KR2        VAINDMDEAA-------------FDEVVAAKAGGAVHLDELCSDAEL--FLLFSSGAGVW  
C-terminal      ELVMQTTRDA-------------FNRVLAPKIAGALALHEVFPPKSVDFFVMFSSCGNLV  
N-terminal      FTLTANIGEGQTPTALAQSPLYGLARVIASEHPDLGTLIDVEEPVIPLSTMRYIQGADII  
                  :                    : ..  .:  .   * ::         : : . ..   
 
DEBS_KR1        ----GAPGLGGYA--PGNAYLDGLAQQRRSDGLPATAVAWGTWAG---------------  
DEBS_KR2        ----GSARQGAYA--AGNAFLDAFARHRRGRGLPATSVAWGLWAA---------------  
C-terminal      ----GFTGQASYG--SGNAFLDTLATHRARLGDAAVSFQWTSWRGLGMGASTDFINAELE  
N-terminal      RINDGIARTSRFRSLPRNKLLPASEGPRLLPRPEGTYLITGGLGVLGLEVADFLVEKGAR  
 
Figure 4.8: Alignment of the N-terminal and C-terminal potential KR domains in 6-
MSAS with KR1 (B-type) and KR2 (A-type) from DEBS. Glycine-rich regions, the FSS 
motif, the catalytic tyrosine, the B-type LDD/LDN motif (KR1 and C-terminal KR from 
6-MSAS) and the A-type tryptophan (KR2) are marked. 
 
The C-terminal domain features an LDN motif between residues 1515 and 1517, 
which is similar to the LDD B-type Caffrey motif. This aligns with the LDD motif in the 
DEBS KR1 domain and suggests that the 6-MSAS KR is a B-type and will thus produce 
a product with an (R)-hydroxyl group (Figure 4.9). There is no tryptophan residue in 
proximity to the FSS motif and none which aligns with the tryptophan in DEBS KR2, 
which suggests that it is not an A-type KR. 
 
The assignment of the KR as B-type is in opposition to the assignment of the KR from 
the MSAS ChlB1, which was assigned as an A-type from sequence analysis as it lacked 
both the His residue in the active site and the LDD motif.114 
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Figure 4.9: Predicted stereochemistry of reduced triketide intermediate in 6-MSAS 
with a B-type KR domain. 
 
4.2.2 Synthesis 
Initially it was decided to synthesise the dithiane-protected reduced triketide acid 
(57) using the same method as Cheung et al. using (S)-camphanoyl chloride (75) to 
derivatise the hydroxyl group and enabling separation of the resulting diastereomers 
(Figure 4.10).87 This could then be deprotected to form a reduced triketide which 
could then be couple to coenzyme A. It was decided to perform the deprotection 
before coupling to CoA as the reactivity of methyl iodide, used in deprotection of the 
dithiane, with coenzyme A was unknown and side reactions could occur. 
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Figure 4.10: Synthesis of the resolved diastereomers 76 and 77. 
 
Methyl acetoacetate (67) was reacted with with 1,3-propanedithiol (68) and boron 
trifluoride dietherate at room temperature for 1 hour to form the protected species 
(69) in 99% yield. The methyl ester was removed by reaction with sodium hydroxide 
at 90 °C for 1 hour. The acid (70) was coupled with Meldrum’s acid (71) using DCC 
and DMAP in dry DCM to form the cyclic adduct (72). 72 was opened up using dry 
methanol in toluene to give the ketoester (73). Reaction with sodium borohydride 
reduced the ketone to a racemic alcohol (74) which was then coupled to (S)-
camphanic chloride (75) using triethylamine and DMAP in dichloroethane. The 
diastereomers formed (76 and 77) were separated by column chromatography on 
silica gel using a gradient of petroleum ether 40-60 and ethyl acetate (100:1 to 5:1) 
(Figure 4.10). 
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Deprotection of the camphanic and methyl esters by the acid and base hydrolysis 
method given in the paper of Cheung et al. did not lead to isolation of any product. 
Instead a simple base hydrolysis was used to cleave both esters simultaneously and 
the product (57) could be obtained by preparative TLC in low yield. 
 
Figure 4.11: Cleavage of esters to form 57 and deprotection of dithiane, which could 
potentially form the pyrone 79 . 
 
Attempts to deprotect 57 using methyl iodide and calcium carbonate did not yield 
the deprotected reduced triketide. This could be due to the formation of pyrone 79 
(Figure 4.11). After several attempts it was decided that an alternative strategy 
might be more successful. 
 
In the synthesis of non-hydrolysable malonyl-CoA analogues, Tosin et al. utilised the 
enzymes which form the pathway to coenzyme A in E. coli to elaborate synthetic 
pantetheine compounds to the corresponding CoA.81 These enzymes had been 
shown to have broad substrate specificity for pantothenate derivatives.116  
It was postulated that the reduced triketide-CoA (80) could be formed by the action 
of pantothenate kinase (PK), phosphopantetheine adenyltransferase (PT) and de-
phosphocoenzyme A kinase (DK) on the reduced triketide-pantetheine (81).  This 
could be formed by deprotection of the dithiane group after coupling of the 
previously synthesised acid (57) with pantetheine (83) (Figure 4.12). 
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Figure 4.12: Retrosynthetic analysis of racemic reduced triketide CoA (80) to 
protected racemic reduced triketide 57 and pantetheine (83). 
 
To test this synthetic route previously synthesised racemic ester (74) was converted 
to the racemic acid (57) using 1 M sodium hydroxide at room temperature and 
purified by column chromatography. D-Pantetheine (83) was obtained by reduction 
of D-pantethine (84) with sodium borohydride. Coupling of acid 57 to pantetheine 
was carried out using HATU as coupling reagent in the presence of DIPEA to give the 
thioester (82) in 18% yield after purification by preparative HPLC. The dithiane 
protecting group was removed using methyl iodide and calcium carbonate and the 
product purified again using preparative HPLC to give ketone (81) in 85% yield 
(Figure 4.13). 
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Scheme 4.13: Synthesis of reduced triketide-pantetheine 81. 
 
E. coli stocks containing plasmids coding for the hexa-histidine- tagged enzymes PK, 
PT and DK were kindly donated by Dr Manuela Tosin. All three enzymes were 
expressed in liquid culture with induction by IPTG and purified by nickel affinity 
chromatography. 
 
The pantetheine compound (81) was incubated overnight with PK, PT and DK in the 
presence of ATP. After precipitation of the proteins with chloroform, the aqueous 
layer was analysed using LC-MS but no CoA derivative was detected. This could be 
due to an old sample of pantetheine-triketide being used.  
 
4.2.3 Apo 6-MSAS expression and purification 
The 6-MSAS plasmid pKOS007-109 previously constructed in section 2.2.1 was used 
in this study. This plasmid was transformed into E. coli BL21 (DE3) for expression. It 
was found that the conditions used to obtain the holo synthase, namely induction 
with IPTG at an OD600 of 1 then incubation at 30 °C for 24 hours, did not give any high 
molecular weight bands in any fraction observed in purification. Lower incubation 
temperatures after induction were tried, along with the addition of EDTA (5 mM final 
concentration) to the cell lysis buffer to combat the activity of metalloproteinases. 
Induction at both 16 °C and 20 °C gave strong bands of the correct molecular weight 
on SDS-PAGE, but the 16 °C 22-40 % ammonium sulphate fraction contained fewer 
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additional bands. 16 °C was then used as the induction temperature for all future 
experiments. 
 
Apo 6-MSAS was purified by ammonium sulphate precipitation as for the holo 
synthase in section 2.2.1 (Figure 4.14). The 22-40 % pellet was then used directly for 
assays or further purified by FPLC. 
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Figure 4.14: SDS-PAGE showing the expression of apo 6-MSAS (approx. 190 kDa) in 
the cell lysate, and the presence of 6-MSAS in fractions from ammonium sulphate 
purification and FPLC purification and a gel filtration trace of apo 6-MSAS. 
 
Gel filtration of apo 6-MSAS on Sephadex 200 using the buffer system of Richardson 
et al.85 gave a single peak at elution volume 157 ml. This was collected and 
concentrated to give approximately 1 mg of 6-MSAS from 110 mg of ammonium 
sulphate pellet. Scaling up, this gives an approximate yield of 10 mg of apo 6-MSAS 
per litre of culture. 
 
4.2.4 Activity of apo 6-MSAS 
Apo 6-MSAS was assayed for activity by looking for 6-MSA production in the culture 
medium and by in vitro fluorimetry assay of the purified protein. 
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50 ml of harvested culture medium was acidified to pH 1 using hydrochloric acid and 
extracted using ethyl acetate. The ethyl acetate extracts were evaporated and the 
residue dissolved in methanol for LC-MS analysis. 6-MSA production was determined 
with regard to an authentic 6-MSA standard of known concentration. 
 
Surprisingly, production of approximately 2 mg /litre of 6-MSA was observed, 
compared to 17-25 mg/l for the holo synthase. This is unexpected as E. coli 
phosphopantetheinyltransferases do not generally act upon heterologously 
expressed PKSs. This suggests that a very small amount of 6-MSAS is converted to 
the active holo form in vivo. Production of 6-MSA during heterologous expression of 
the 6-MSAS homologue ATX was also observed for the apo enzyme.89  
 
Flurorimetry assays which directly measure the production of 6-MSA were carried 
out under the same conditions used by Spencer and Jordan for the native synthase56. 
No production of 6-MSA could be seen for either the ammonium sulphate pellet or 
the FPLC-purified protein over the control run which did not contain malonyl-CoA. 
This is as expected for an apo synthase, which lacks the phosphopantetheine arm 
which tethers the growing polyketide to the enzyme, but contradicts the in vivo 
result. 
 
4.2.5 Addition of a phosphopantetheine arm to apo 6-MSAS  
In order to attach the synthesised triketide-CoA on to 6-MSAS for elaboration into 6-
MSA, it is necessary to use a phosphopantetheinyltransferase (PPTase). This will 
transfer the phosphopantetheine section of CoA on to the active site serine in the 
ACP domain. The PPTase Sfp from B. subtilis has been extensively used to transfer 
acyl-CoAs on to ACP and PCP domains.117 
 
Apo 6-MSAS was incubated with Sfp (donated by Dr Yuhui Sun) and CoASH under 
standard conditions used within our group (pH 6.5, 1 hour at 37 °C). 6-MSA 
production was assayed using fluorimetry and no additional activity could be seen 
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over the control which contained no PPTase. This was unexpected as Sfp has been 
used extensively to phosphopantetheinylate ACPs in vitro and has also been 
coexpressed with 6-MSAS in vivo to yield active holo synthase.59 Additionally, recent 
work by Lee et al. has shown that a fluorescent CoA derivative is transferred on to 
heterologously expressed apo 6-MSAS using Sfp, although no activity studies have 
been performed using this method.118 
 
4.2.5.1 MtaA 
It was decided to use MtaA84, the PPTase from S. auriantica which had been 
successfully coexpressed with 6-MSAS in E. coli to give active synthase (see section 
2.2.1). MtaA was cloned into the pET28a (+) vector by Dr Fanglu Huang and the 
resultant plasmid was transformed into E. coli BL21 Codon Plus RP. His6-tagged MtaA 
was expressed in LB medium under IPTG induction before purification by nickel 
affinity chromatography. Essentially pure His-MtaA was obtained in the 200 mM 
imidazole elute in a yield of 27 mg/litre of culture. Purified His-MtaA was analysed by 
LC-MS. The spectrum revealed a single peak of retention time 14.7 minutes, which 
was deconvoluted to give a protein of mass 33 777 Da. This is in good agreement 
with the predicted mass for MtaA + His6 tag with loss of N-terminal methionine then 
N-terminal gluconylation119 of 33782 Da (Figure 4.15). 
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Figure 4.15: SDS-PAGE analysis of His-MtaA purification fractions and LCMS trace of 
His-MtaA that deconvolutes to a mass of 33 777 Da. 
 
In order to check that the N-terminal His-tag did not interfere with activity, the 
PPTase activity of purified His-MtaA was assayed by mass spectrometry.  
 
The discrete ACPs ChlD2 (from the chlorothricin gene cluster of Streptomyces 
antibioticus) and Con2* (from the concanamycin gene cluster of Streptomyces 
neyagawaensis) were donated by Dr Yuhui Sun (Department of Biochemistry). They 
are readily phosphopantetheinylated by Sfp and the reaction can be monitored by 
LC-MS. They have previously been successfully phosphopantetheinylated using Sfp 
and glyceryl-CoA.120 The required ACP was incubated with MtaA at room 
temperature for one hour in conditions used for its reaction with Sfp (10 mM MgCl2, 
200 mM sodium phosphate, pH 7.5), and the conditions used by Lee et al. (10 mM 
MgCl2, 75 mM Tris-HCl, pH 8.8). The assay mixture was then analysed by LC-MS. 
 
In the phosphate buffer, Con2* showed a loss of a peak at 18.3 mins, that 
deconvoluted to a mass of 12,102 Da, and a gain of a peak at 17.2 mins, which 
deconvoluted to a mass of 12,442 Da. This gain of 340 mass units is due to 
attachment of the phosphopantetheine arm. Under the conditions used by Lee et al., 
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the apo ACP eluted at 25.8 mins, while the holo ACP had a retention time of 17.4 
mins. Again, a gain of 340 mass units was observed after deconvolution (Figure 4.16).  
 
ChlD2 in phosphate buffer showed a no change in retention time of ACP peaks to the 
control experiment lacking MtaA, but deconvolution showed that the MtaA 
experiment gave a mass of 10,471 Da, while the control experiment gave a mass of 
10,131 Da. This difference of 340 Da indicates that a phosphopantetheine arm has 
been added. At pH 8.8, ChlD2 exhibited a small change in retention time between 
the putative apo form (Rt = 19.5mins) and the putative holo form (Rt = 19.0 mins). 
Deconvolution showed a mass gain of 341 Da, from 10,130 Da to 10,471 Da, which 
again indicates attachment of the phosphopantetheine arm (Figure 4.16). 
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Figure 4.16: LC-MS traces for ChlD2 and Con2* before and after incubation with His-
MtaA (6 g), MgCl2 (5 mM) and CoASH (0.55 mM) in phosphate buffer (100 mM 
sodium phosphate, pH 7.5). 
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Both Con2* and ChlD2 were completely converted from the apo form to the holo 
form as determined by mass spectrometry, proving that His-MtaA was active in vitro. 
 
To ascertain whether the His-tag would interfere with the in vivo activity of MtaA the 
plasmid encoding for His6-tagged MtaA and kanamycin resistance (pET28a(+)-MtaA), 
and the plasmid encoding for 6-MSAS and carbenicillin resistance (pKOS007-109) 
were cotransformed into E. coli BL21 and coexpressed in LB medium with IPTG 
induction. 
 
Holo 6-MSAS was harvested and purified from a 1 litre culture as in section 2.2.1. The 
activity was assayed by fluorimetry and showed similar specific activity to the holo 6-
MSAS that had been co-expressed with non-His-tagged MtaA.  
 
Purified His-MtaA was used to phosphopantetheinylate apo 6-MSAS in vitro. MtaA 
was incubated with apo 6-MSAS (as the ammonium sulphate pellet), MgCl2 and 
CoASH under conditions that had been used within the group for 
phosphopantetheinylation of an ACP using Sfp, and the conditions of Lee et al. The 
reaction mixture was used directly in the fluorimetry assay to ascertain if activity had 
been conferred. In both cases, no activity was seen over the control samples which 
lacked MtaA. 
 
In order to ascertain whether high concentrations of ammonium sulphate inhibited 
the reaction with 6-MSAS, apo 6-MSAS was desalted using a PD-10 column, 
concentrated and then incubated with MtaA and CoASH as before. No activity could 
be seen when the enzyme was assayed by fluorimetry. 
 
As MtaA has been shown to be active in the conditions used for 
phosphopantetheinylating 6-MSAS, but no active 6-MSAS was found from its 
incubation with intact apo 6-MSAS, this leads to two possibilities. Either MtaA is 
incapable of phosphopantetheinylating 6-MSAS in vitro, or MtaA does transfer the 
phosphopantetheine arm to 6-MSAS but the enzyme is misfolded or unfolds during 
phosphopantetheinylation and is thus still inactive. 
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4.2.5.2 SePptII 
To rule out the possibility that MtaA was unable to phosphopantetheinylate 6-MSAS 
in vitro due to its inability to activate an intact megasynthase, it was decided to 
express and test a PPTase which is known to perform this role in vitro. SePptII from S. 
erythraea transfers the phosphopantetheine arms onto the ACPs present in the DEBS 
megasynthases. It had previously been identified and expressed by Weissman et al. 
and used to phosphopantetheinylate the ACP-TE didomain and DEBS 3 from the 
DEBS assembly line in vitro.121 
 
pKJW152, which encodes for SePptII with an N-terminal His tag from pET28b(+), was 
obtained from Shilo Dickens (Department of Biochemistry) and transformed into E. 
coli BL21 Codon Plus RP.  
 
Expression of SePptII was carried out according to literature procedure121 and SePptII 
was purified by nickel affinity chromatography. The protein eluted was of 
approximately 60% purity as estimated by SDS-PAGE gel (Figure 4.17). 
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Figure 4.17: SDS-PAGE of SePptII (approx. 27 kDa) purification fractions. 
 
SePptII was assayed for its ability to transfer a phosphopantetheine arm from CoASH 
to the discrete ACPs Con2* and ChlD2. After incubation at room temperature for 2 
hours, the assay mixture was analysed by LC-MS. It was found that SePptII was able 
to phosphopantetheinylate Con2* but no holo ChlD2 was observed under the same 
conditions. 
 
To examine whether SePptII could phosphopantetheinylate 6-MSAS in vivo, pKJW152 
was cotransformed into E. coli BL21 (DE3) with pKOS007-109 which codes for the 6-
MSAS gene. 6-MSAS was purified by ammonium sulphate precipitation as previously 
described and activity was assayed by fluorimetry. On incubation with acetyl-CoA, 
malonyl-CoA and NADPH, 6-MSA production was observed at a specific activity 
which was comparable to that of 6-MSAS coexpressed with MtaA. 
 
Incubation of apo 6-MSAS with SePptII and CoASH at both pH7.5 and pH 8.8 did not 
lead to any activity as seen by fluorimetry. 
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4.2.4.3 Co-sonication 
As attempted phosphopantetheinylation of apo 6-MSAS with three different PPTases 
had been unsuccessful, it invited the possibility that apo 6-MSAS could be denaturing 
during purification. In order to assess whether the instability of the apo synthase was 
due to an inherent misfolding of the protein during its production or an artefact of 
purification, co-sonication of apo 6-MSAS and MtaA was performed. If purification 
were the cause of the instability, it would be expected that the MtaA would be able 
to phosphopantetheinylate the 6-MSAS and produce active holo synthase. 
 
Apo 6-MSAS and MtaA were expressed, as previously described, in separate cultures. 
After resuspension of the cell pellets, the two cultures were combined before 
sonication. Purification of 6-MSAS was then carried out as before. The ammonium 
sulphate pellet was assayed for activity using fluorimetry. Under these conditions, no 
production of 6-MSAS could be detected, which suggests that the protein is 
misfolded in vivo rather than becoming inactive during the purification steps. As 
successful phosphopantetheinylation was observed by Lee et al.  with heterologous 
expression of 6-MSAS in S. cerevisiae,118 this might be an improved system for 
obtaining the apo synthase. 
 
4.2.6 Limited proteolysis 
Since in vitro phosphopantetheinylation of apo 6-MSAS was unsuccessful, it was 
decided to investigate the structural differences between the holo and the apo forms 
using limited proteolysis to see if this showed any significant difference between the 
two. 
 
4.2.6.1 Hydroxylamine 
Hydroxylamine cleaves peptide bonds between asparagine and glycine residues by 
cyclisation of the asparaginyl residue with a backbone amide of the neighbouring 
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glycine residue.122 Cleavage of 6-MSAS by hydroxylamine is predicted to give six 
cutting sites, yielding eight fragments. 
 
Both holo and apo FPLC-purified 6-MSAS were incubated with 1.8 M hydroxylamine 
at 37 °C for four hours, with samples taken at intervals and analysed by SDS-PAGE 
(Figure 4.18). Although both synthases show a reduction in the amount of intact 
enzyme over time, there are no new bands appearing with lower molecular weight. 
This may be due to a lack of reaction with the hydroxylamine. Normally cleavage is 
carried out under denaturing conditions (6 M guanidinium chloride) but this would 
not allow the structural differences between the holo and apo synthases to be 
probed. It may also be that 6-MSAS unfolds under the conditions at which the 
reaction occurs, so that the two synthases are structurally the same and no 
differences in the structure of the ACP can be observed. 
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Figure 4.18: SDS-PAGE analysis of 6-MSAS incubated with hydroxylamine over 4 
hours. 
 
4.2.6.2 Trypsin 
Trypsin was previously used to investigate the structural organisation of 6-MSAS 
isolated from P. patulum, although the experimental details were not available for 
this study.52 In limited proteolysis studies on DEBS megasynthases it was found that 
cleavage occurred in the linker regions between domains.123 
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Sequence analysis of 6-MSAS predicted 146 cleavage sites. Incubation of holo and 
apo 6-MSAS with trypsin (100:1 wt/wt) showed a significant difference between the 
two protein forms. The holo enzyme formed a band at around 150 kDa slowly over 
45 minutes as the 190 kDa band disappeared. Surprisingly, the apo enzyme formed a 
band at the same molecular weight within 1 minute of addition of trypsin, with 
concomitant loss of the 190 kDa band. The 150 kDa band in both cases was resistant 
to further proteolysis over the 60 minute timescale of the reaction (Figure 4.19). 
 
Decreasing the concentration of trypsin to 250:1 and 500:1 did not slow the 
observed rate of cleavage of the apo enzyme. In both cases there was essentially full 
formation of the 150 kDa band within one minute. Increasing the concentration of 
trypsin to 50:1 did not lead to increased cleavage of the 150 kDa band, which 
remained resistant to further proteolysis. 
 
Analysis of the 100:1 mixture by SDS-PAGE on an 18% acrylamide gel revealed a 
band of 10 kDa was formed by digestion of both apo (after 1 minute) and holo 
synthase (after 5 minutes). 
 
 
 
 
 
 
 
Chapter 4: Stereochemistry of ketoreduction in 6-MSAS 
118 
5
 m
in
s
N
o
 tryp
s
in
1
 m
in
1
5
 m
in
s
3
0
 m
in
s
T
L
C
K
 c
trl
5
 m
in
s
N
o
 tryp
s
in
1
 m
in
1
5
 m
in
s
T
L
C
K
 c
trl
3
0
 m
in
s
apo holo
250
250
130130
38
95
72
55
38
95
72
55
A B
N
o
 tryp
s
in
1
 m
in
N
o
 tryp
s
in
1
 m
in
N
o
 tryp
s
in
5
 m
in
s
apo holoapo + MtaA
10
38
26
17
55
10
38
26
17
55
 
N
o
 try
p
s
in
1
 m
in
5
 m
in
s
5
 m
in
s
N
o
 try
p
s
in
1
 m
in
1
5
 m
in
s
apo holo
3
0
 m
in
s
3
0
 m
in
s
1
5
 m
in
s
250
130
38
95
72
55
250
130
38
95
72
55
N
o
 try
p
s
in
1
 m
in
5
 m
in
s
apo + MtaA
3
0
 m
in
s
1
5
 m
in
s
250
130
38
95
72
55
250
130
38
95
72
55
C
 
Figure 4.19: A: 6-MSAS/trypsin (100:1 wt/wt) digestion over 30 minutes. The lane 
labelled TLCK ctrl contains 6-MSAS/trypsin with TLCK added immediately. B: 6-
MSAS/trypsin (100:1 wt/wt) after 1 minute of reaction (apo and apo + Sfp) or 5 
minutes of reaction (holo) analysed on an 18% gel. C: Digest of holo, apo and 
apo+MtaA 6-MSAS with trypsin (50:1 wt/wt) over 30 minutes. All reactions 
performed in NaH2PO4 100 mM, EDTA 1 mM, DTT 2 mM, glycerol 50%, pH 7.1 and 
aliquots at each time point were quenched with TLCK (1 mM, final concentration). 
 
To investigate the phosphopantetheinylation of apo 6-MSAS, apo synthase was 
incubated as before with MtaA for 1 hour and the mixture digested with trypsin 
(100:1) over 1 hour. SDS-PAGE analysis at time points revealed that the mixture 
acted in the same way as the apo synthase, with a fragment cleaved within 1 minute. 
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This suggests that phosphopantetheinylation does not take place in the reaction 
mixture.  
 
Both the 150 kDa fragment and the 10 kDa fragment were submitted for N-terminal 
sequencing. The 150 kDa fragment corresponded to the N-terminus of 6-MSAS, 
although missing the first 12 amino acids after cleavage adjacent to lysine-13, for 
apo, apo+MtaA and holo 6-MSAS. As the missing N-terminal sequence cannot 
account for the large change in apparent mass of the band, there must also be 
cleavage at the C-terminus of a more substantial nature. 
 
The 10 kDa band did not give any distinct sequence information for any of the three 
bands submitted and it was suggested that it was in fact a mixture of sequences 
rather than the product of a single cleavage. 
 
In the apo+MtaA mixture, a strong band at 40 kDa was seen. N-terminal sequencing 
revealed this to be from the cleavage of His-MtaA in the N-terminal His-tag 
(predicted mass 31 852 Da). 
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Figure 4.20: Partial peptide map of 6-MSAS from P. patulum after trypsin digestion. 
Dashed peptides are formed transiently within 60 s (a, b and c). After 2 minutes, 
further fragments are observed (d and e). After 5 minutes only one major fragment 
remains (f). Figure redrawn from Shoolingin-Jordan and Campuzano, in 
Comprehensive Natural Products, 345-365.52 
 
The reported limited proteolysis results for 6-MSAS from P. patulum are shown in 
figure 4.20. These show rapid cleavage of C-terminal fragments including the ACP, 
before further digestion of the central domains.  
The results broadly concur with those observed for 6-MSAS expressed in E. coli, 
which rapidly loses C-terminal fragments. The mixed fragments proposed for the 10 
kDa band could be from the 10, 9 and 14 kDa bands. The 6-MSAS expressed in E. coli 
is not, however, digested further in the large central fragment, which is unexpected 
given the results from the native enzyme. As experimental conditions for the limited 
proteolysis of the P. patulum enzyme were unavailable, it is unknown whether this is 
due to different trypsin concentrations or reaction conditions.  
 
The difference between apo and holo 6-MSAS is striking. The apo enzyme loses the 
C-terminal fragment(s) within 1 minute, while the holo enzyme is stable for up to 45 
minutes under the same conditions. This implies a greater degree of conformational 
flexibility at the C-terminus of the apo enzyme, suggesting that the ACP is either 
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unfolded or very flexible. This could be why the phosphopantetheinylation is 
unsuccessful as the PPTases used might not be able to recognise the ACP domain. 
 
4.2.7 ACP expression 
As MtaA and Sfp were unable to phosphopantetheinylate apo 6-MSAS in vitro, it was 
decided to simplify the problem by cloning out the ACP from 6-MSAS. This ACP could 
be assayed for phosphopantetheinylation in vitro using LC-MS. 
 
The cloned ACP could also be used with either a truncated 6-MSAS which was 
missing its ACP or apo 6-MSAS to reform active enzyme, and so circumvent the 
problem of phosphopantetheinylation of the megasynthase in vitro. 
 
4.2.7.1 N-terminal His-tagged ACP 
To clone out the ACP, PCR was carried out on pKOS007-109 using primers designed 
by Dr Fanglu Huang. The PCR product was purified by preparative agarose gel 
electrophoresis and digested with NdeI and EcoRI. The digested DNA was purified 
again by preparative agarose gel electrophoresis. This product was ligated with 
pET28a(+) which had previously been digested with NdeI and EcoRI, using T4 ligase 
and incubated overnight. The ligation mixture was transformed into NovaBlue 
competent cells and plated out onto LB/Kanamycin plates. Colonies were screened 
for the ACP insert using colony PCR. Of the 12 colonies screened, all showed a band 
at 300 bp which corresponded to a successful ligation (Figure 4.21). 
 
The identity of the plasmid was confirmed by sequencing and the plasmid was 
transformed into E. coli BL21 (DE3). The His6-tagged ACP was expressed in LB 
medium with IPTG induction and the cell lysate was purified by nickel affinity 
chromatography.  
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Initially, no apo ACP could be seen on an SDS-PAGE gel, so co-expression with MtaA 
was attempted in case the apo ACP was misfolded and proteolysed in vivo. E. coli 
BL21 was transformed with both pET-28a(+) containing the ACP and pSU-MtaA 
containing untagged MtaA. Conditions were repeated for the expression of the intact 
synthase: ATCC-765 medium + 10% glycerol followed by sonication with lysozyme, 
benzamidine and PMSF. 
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Figure 4.21: A: Colony PCR of ACP tranformants shows the presence of the plasmid 
containing the ACP. B: SDS-PAGE of nickel affinity chromatography fractions from 
purification of holo N-His-ACP (predicted mass 11 kDa). 
 
On analysis by SDS-PAGE gel, it was found that neither holo nor apo N-His-ACP 
bound significantly to the His-bind column, instead being mainly found in the 
flowthrough. 
 
4.2.7.2 C-terminal His-tagged ACP 
The same forward primer as for the N-terminal ACP was used, but a new reverse 
primer was designed which incorporated an EcoRI site and changed the stop codon 
to a glycine residue, to enable the C-terminal tag to be incorporated. PCR was carried 
out on pKOS-109 as before and the PCR product was found to be of the correct size. 
The purified insert was digested with NdeI and EcoRI and ligated into pET-20b which 
had been digested with NdeI and EcoRI. The plasmid was transformed into NovaBlue 
competent cells and colonies were picked and screened by colony PCR. 
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pET20b(+)-ACP was transformed into E. coli BL21 and expressed in LB medium under 
IPTG induction. Purification was carried out by nickel affinity chromatography. 
Analysis of purification fractions by SDS-PAGE gel revealed that, like the ACP bearing 
the N-terminal His-tag, most of the ACP was found in the column flowthrough 
(Figure 4.22). 
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Figure 4.22: SDS-PAGE analysis of nickel affinity chromatography fractions for apo C-
His-ACP (predicted mass 11 kDa). 
 
4.2.7.3 N-terminal and C-terminal His-tagged ACP 
Since no single His-tag successfully bound to the nickel affinity column, it was 
decided to express the 6-MSAS ACP domain with both the N- terminal and C-terminal 
His6-tags. This is a similar approach to that taken with the ACP domain from the 
fungal PKS nosolorinic acid synthase.124 
 
The plasmid coding for the doubly tagged ACP can be constructed from pET20b(+)-
ACP and pET28a(+) (Figure 4.23). Digestion of pET28a(+) with BglII and NdeI gave a 
150 base pair fragment which codes for the T7 promoter and N-terminal His-tag. 
Digestion of pET20b(+)-ACP with BglII and NdeI excised the T7 promoter. The T7 and 
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His-tag containing fragment from pET28a(+)-ACP was then ligated with the digested 
pET20b(+)-ACP to give pHKP1 containing the 6-MSAS ACP flanked by N-terminal and 
C-terminal His-tags. The ligation mixture was transformed into NovaBlue cells and 
transformants screened by sequencing.  
 
 
Figure 4.23: Formation of pHKP1 from pET20b(+)-ACP and pET28a(+) by digestion 
with BglII and NdeI, followed by ligation. 
 
pHKP1 was transformed into E. coli BL21 and expressed in liquid culture with IPTG 
induction. The cell lysate was purified by nickel affinity chromatography and the 
fractions analysed by SDS-PAGE. A greater amount of ACP was seen in the 200 mM 
imidazole column eluate than ACP expressed with a single His-tag, however a 
substantial amount was still present in the flowthrough and wash steps (Figure 4.24). 
The 200 mM eluate also contained a large amount of non-specifically bound 
proteins. 
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Figure 4.24: A: pET28a(+) and pET20b(+)-ACP digested with BglII and NdeI. B: SDS-
PAGE of doubly His-tagged ACP (predicted mass 13 kDa). 
 
The 200 mM elute could be purified by FPLC to remove proteins of larger molecular 
weight and the resulting fractions analysed by LC-MS to confirm the presence of 
doubly-tagged ACP. 
 
4.3 Future work 
The experiment of Lee et al. using a fluorescent-CoA analogue could be repeated on 
apo 6-MSAS expressed in E. coli. This would provide a direct measure of whether the 
phosphopantetheinylation reaction takes place in vitro. If it does not, then 
expression in an alternative expression organism, such as S. cerevisiae could be 
considered. 
 
Alternative tags such as the glutathione-S-transferase (GST) tag or the maltose 
binding protein (MBP) tag could be used to express the ACP, with the tag being 
cleaved before any assay of ACP activity. The purified ACP could be incubated with a 
phosphopantetheinyltransferase and CoASH. The assay mixture could be easily 
analysed by LC-MS, and the ability of PPTases to act on the heterologously expressed 
ACP domain investigated. If the reaction with CoASH is successful, then the reduced 
triketide CoA (80) could be loaded on to the ACP and the product triketide-ACP 
observed by LC-MS. 
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Holo ACP could react in trans with apo 6-MSAS. Varying concentrations of holo ACP 
could be used in the standard fluorimetry assay for 6-MSA production to see if the 
separate ACP domain was able to successfully replace the inactive one linked to the 
enzyme. 
 
It is possible that the link of the cis ACP to the rest of the megasynthase makes 
reaction in trans difficult. One way of getting around this would be to express a 
truncated version of 6-MSAS which lacks the terminal ACP (procedure designed by Dr 
Fanglu Huang).  
 
pKOS007-109, which codes for the 6-MSAS gene could be digested with AflII which 
cuts in the linker region between the KR and ACP domains. The sticky end produced 
could be filled in to produce a blunt end which can be ligated in to an EcoRV site. The 
plasmid would then be digested again with NdeI to produce a DNA fragment 
containing the 6-MSAS gene lacking the ACP. This could then be ligated in to pET20b 
or pET29a which had been digested with NdeI and EcoRV (Figure 4.25). The plasmid 
could then be transformed in to NovaBlue for verification of the gene sequence and 
BL21 (DE3) for protein expression. 
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Figure 4.25: Proposed method for generating truncated 6-MSAS lacking the ACP 
domain. 
 
The truncated 6-MSAS would be assayed with varying concentrations of holo ACP, 
malonyl CoA, acetyl CoA and NADPH to optimise the reaction conditions. One 
advantage of using the discrete ACP rather than the intact apo synthase would be 
that it would remove the single turnover nature of the proposed labelling 
experiment. The amount of triketide reacted would be dependent only on the 
concentration of loaded ACP, which could be many times the concentration of 
synthase. 
 
4.4 Chapter Summary 
 
Steps have been made toward the synthesis of the resolved reduced triketide CoAs 
65 and 66. The synthetic diastereomeric intermediates 76 and 77 have been resolved 
by column chromatography. The racemic mixture of these intermediates has been 
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coupled with pantetheine and elaborated to the triketide-coenzyme A by the action 
of three enzymes. 
 
Apo 6-MSAS was heterologously expressed in E. coli and purified in a two step 
procedure. Attempts to phosphopantetheinylate the apo synthase using three 
different PPTases were unsuccessful, although all three enzymes were shown to be 
active in vitro. Co-sonication of the apo culture with a PPTase culture did not yield 
active synthase, implying that the ACP was misfolded in vivo. 
 
Limited proteolysis studies on apo and holo 6-MSAS with hydroxylamine and 
thrombin found no difference between the two protein forms. Studies with trypsin 
however showed that the apo enzyme contained a C-terminal fragment which was 
rapidly cleaved, while the holo enzyme was cleaved at a much slower rate, although 
N-terminal sequencing was unable to identify the fragment in question. 
 
The ACP from 6-MSAS was heterologously expressed in E. coli with N-terminal, C-
terminal and N- and C-terminal His6-tags. It was found that purification by nickel 
affinity chromatography was difficult as the ACP did not bind well to the column. 
Attempts to determine the stereochemistry of ketoreduction in 6-MSAS are ongoing, 
and may benefit from the use of the discrete 6-MSAS ACP with either the apo 
synthase or a truncated version. 
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5.1 Chemicals 
Ethyl 6-methylsalicylate was purchased from TCI Europe. All other chemicals were 
purchased from Sigma-Aldrich and were of analytical grade.  HPLC-grade organic 
solvents were from Fisher Scientific, while HPLC water was from Rathburn. Dry 
solvents were from in-house stills. All water was deionised using a Milli-Q Gradient 
A10 Ultrapure water system. 
5.2 Enzymes 
Pfu DNA polymerase, DreamTaq polymerase, T4 DNA ligase, all restrictions enzymes, 
BSA, all associated buffers and dNTPs were purchased from Fermentas. 
Chymotrypsin, trypsin and lysozyme were purchased from Sigma-Aldrich.  
5.3 Biological reagents  
NADPH, dithiothreitol (DTT), isopropyl-β-D-thiogalactopyranoside (IPTG), kanamycin 
and carbenicillin were purchased from Melford. Agarose and Bradford reagent were 
purchased from Sigma-Aldrich.  Luria-Bertani (LB) medium was purchased from 
Fisher Scientific. 30% acrylamide/bisacrylamide mix was purchased from Severn 
Biotech Ltd. DNA and protein molecular weight markers were purchased from 
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Fermentas. Chemically competent cells were donated by Dr Fanglu Huang and El-
Habib Sahraoui. pET28a(+) and pET20b(+) were obtained from Novagen. pKOS012-
65a and pKOS007-95 containing the 6-MSAS gene and appropriate vector were 
donated by Kosan Biosciences Ltd. pSU-MtaA was kindly donated by Dr Yanyan Li. 
pET28a(+)-MtaA, encoding MtaA with an N-terminal His6 tag was kindly donated by 
Dr Fanglu Huang. pKJW152 containing the gene for SePptII with an N-terminal His6-
tag was obtained from Shilo Dickens, Department of Biochemistry, University of 
Cambridge. Cells containing the plasmids coding for the CoA biosynthetic enzymes 
PK, PT and DK were kindly donated by Dr Manuela Tosin. GeneJET PCR purification 
kits, GeneJET Gel Extraction kits and GeneJET Plasmid Preparation kits were 
purchased from Fermentas. 
5.4 Bacterial strains 
Escherichia coli Novablue (Novagen) was used for general cloning and Escherichia coli 
BL21(DE3) was used for protein expression. 
5.5 Apparatus 
PCR was carried out using an Eppendorf Mastercycler Gradient thermocycler with 
0.5 ml PCR tubes. Agarose gels were run in a Mini-Sub Gel GT gel electrophoresis 
tank attached to a Model BRL 250EX power supply (Gibco). SDS-polyacrylamide gels 
were cast using an 80 mm by 70 mm 4 gel caster from Hoefer.  SDS-PAGE was carried 
out using an EPS Model 301 (Amersham Pharmacia Biotech). Gels were visualised 
with a White/UV Transilluminator (UVP) and photographs taken with a GelCam 
(Polaroid). Sterile work was carried out in a BioMAT2 laminar flow hood (Thermo 
Electron Corporation). Buffers and media were sterilised in a KaVoKlave 2100 
autoclave from Prestige Medical. pH was measured using a Philips PW9410 pH meter 
attached to a  Mettler Toledo pH electrode.  LB-agar plates were incubated in a 
Raven incubator oven (LTE Scientific) and liquid cultures in a Multitron II incubator 
shaker (Infors). Cells were lysed using a Vibra-Cell sonicator. Centrifugation was 
carried out in an Avanti J-26 XPI (Beckman Coulter) or a 5804R benchtop centrifuge 
(Eppendorf).  Microcentrifugation was performed in a Biofuge Pico centrifuge 
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(Heraeus). Samples were lyophilised using a Drywinner MicroModulyo (Jencons-Plus) 
lyophiliser attached to a RV8 pump (Edwards).  TLC analysis was performed on glass 
sheets precoated with silica gel 60 and plates were visualised using UV and a 
potassium permanganate dip. Flash column chromatography was carried out using 
silica gel 60 (0.040-0.630 mm, Merck). UV/Vis spectroscopy was carried out using a 
Cary 100 Bio UV-Visible Spectrophotometer (Varian). Fluorimetric assays were 
performed using a Cary Eclipse fluorimeter (Varian). The iBlot Dry Blotting system 
from Invitrogen was used to transfer protein from acrylamide gels to PVDF 
membrane. 
5.6 Computational analysis and Bioinformatics 
DNA sequencing data was viewed using FinchTV v1.4.0 developed by Geospiza, Inc. 
Restriction sites within DNA sequences were determined using NEBcutter v2.0 
(http://tools.neb.com/NEBcutter2/).125 Proteolytic sites in proteins were found using 
Peptide Cutter (http://expasy.org/tools/peptidecutter/). Sequence alignment was 
performed using ClustalW115 accessed at EBI 
(http://www.ebi.ac.uk/Tools/clustalw2/index.html). Protein sequences were 
accessed from UniProt Protein Knowledge Base (http://www.uniprot.org/)126 and 
BLAST searches were also performed using this site. Other protein tools were used at 
the ExPASy proteomics server (http://expasy.org/tools/#proteome). Domain 
searches within a PKS sequence were carried out using the PKS/NRPS analysis at 
http://nrps.igs.umaryland.edu/nrps/.127 
5.7 Analytical techniques 
5.7.1 LC-MS 
LC-MS analysis was performed using a Hewlett-Packard HPLC 1100 series coupled to 
a Finnigan MAT LCQ ion trap mass spectrometer fitted with an ESI source using 
XcaliburTM Version 1.1. 
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MS of synthetic samples was carried out on a Luna 5u C18 250 x 2.00 mm column 
(Phenomenex) or a Synergi 4u Polar-RP 150 x 2.00 mm column (Phenomenex). Both 
columns were run at 0.3 ml/min in either water/acetonitrile + 0.1% TFA or 
water/methanol + 0.1% TFA gradient; 0-5 minutes, 0% organic, 5-30 minutes 0-100% 
organic, 30-38 minutes 100% organic, 38-40 minutes 100%-0% organic. 
 
MS of protein samples was carried out on a Jupiter 5u C4 250 x 2.00 mm column 
(Phenomenex) run at 0.2 ml/min in water/acetonitrile + 0.1% TFA. The gradient was 
0-3 minutes, 5-40% MeCN; 3-30 minutes, 40-95% MeCN; 30-37 minutes, 95% MeCN; 
37-40 minutes, 95-5% MeCN. 
5.7.2 HPLC 
Semi-preparative HPLC was carried out on an Agilent 1100 HPLC fitted with a Synergi 
4u Polar-RP 250 x 10.00 mm column (Phenomenex) using either a water/acetonitrile 
+ 0.1% TFA or water/methanol + 0.1% TFA gradient from 0% organic solvent to 100% 
over 40 minutes at 2.5 ml/min. UV traces were observed at 210 nm, 254 nm and 280 
nm. 
 
Preparative HPLC was carried out on an Agilent 1200 HPLC fitted with a Luna C18 10u 
250 x 21.20 mm column (Phenomenex) using a water/acetonitrile + 0.1% formic acid 
or water/methanol + 0.1% formic acid gradient from 0% organic solvent to 100% 
over 40 minutes at 20 ml/min. UV traces were observed at 210 nm, 254 nm and 280 
nm. 
5.7.3 LTQ Orbitrap 
HPLC-HR-ESI-MS analyses of off-loading assays were performed on a Thermo 
Electron LTQ-Orbitrap. Samples were injected onto a Dionex Acclaim C18 PepMap 
100 column (150 mm x 1.0 mm, 3 Dm), eluting with a linear gradient of 0% to 100% B 
in 28 min with a flow rate of 50 l/min (A: 98% H2O, 2% MeCN, 0.1% formic acid, B: 
90% MeCN, 10% H2O, 0.1% formic acid). The mass spectrometer was run in positive 
Chapter 5: Materials and Methods 
133 
ionization mode, scanning from m/z 100 to 1800, with the FTMS analyser resolution 
set at 60K; the collision energy was set to 30-35% for mass fragmentation. 
 
5.8 Synthetic Chemistry 
5.8.1 Synthesis of 6-MSA (1) standard128 
Ethyl 6-methysalicylate (100 mg, 0.55 mmol) was refluxed in 1M NaOH (5 ml) for 2 
hours. The solution was cooled and 10% sulphuric acid was added to precipitate a 
white solid. The mixture was filtered and the solid freeze dried. 6-Methylsalicylic acid 
was obtained as a white solid (41.4 mg, 50%). LCMS: Rt =  26.0 mins, [M+H
+] = 
152.94. 1H NMR (400 MHz, CDCl3): = 10.94 (s, 1H, COOH), 7.27 (t, 1H, J = 8 Hz), 6.80 
(d, 1H, J = 8 Hz), 6.70 (d, 1H, J = 8 Hz), 2.56 (s, 3H). Rf = 0.50 (3:1 ethyl acetate: 
methanol, spot blue under UV). 
5.8.2 Synthesis of non-hydrolysable analogue 3086 
5.8.2.1 Synthesis of 4-acetamidobutanoic acid (32) 
-Aminobutyric acid (0.5 g, 4.85 mmol) and triethylamine (1.35 ml, 9.70 mmol) were 
suspended in dry methanol (30 ml) and cooled to 0 °C. Acetyl chloride (0.379 ml, 
5.36 mmol) was added dropwise and the mixture stirred at 0 °C for 1 hour, then at 
room temperature overnight. The resulting colourless solution was evaporated 
under reduced pressure to leave crude 32 as a white solid (704 mg). 
5.8.2.2 Synthesis of N-(4-(2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-yl)-4-
oxobutyl)acetamide (33) 
32 (704 mg, 4.85 mmol), Meldrum’s acid (770 mg, 5.34 mmol) and DMAP (1.50 g, 
7.28 mmol) were stirred in dry THF (100 ml) and cooled to 0 °C. EDC (1.02 g, 5.34 
mmol) was added and the mixture stirred overnight at room temperature. The 
yellow solution was evaporated under reduced pressure and the resulting oil was 
redissolved in DCM. The organic layer was washed with 1 M aq. HCl, dried with 
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magnesium sulphate and evaporated under reduced pressure to give crude 33 as a 
yellow oil (925 mg). 
 
 
 
5.8.2.3 Synthesis of methyl 6-acetamido-3-oxohexanoate (34) 
 
 
Figure 5.1: Numbering of 34 for NMR assignment. 
 
33 (925 mg, 3.41 mmol) was dissolved in dry methanol (0.65 ml) and dry toluene (20 
ml) and heated under reflux for 3 hours. The solvents were removed under reduced 
pressure to give 34 as a yellow oil. 
 
Crude 34 (18 mg) was purified by preparative HPLC using a methanol/water + 0.1% 
formic acid gradient (0% methanol to 100% methanol over 40 minutes) to give 34 as 
a yellow oil (4.2 mg, 23%). Rt = 12.4 mins. LCMS: Rt = 15.1 mins, [M+H
+] = 201.89. 1H 
NMR (400 MHz, CDCl3):  = 5.66 (br s, 1H, NH), 3.73 (s, 3H, H-9), 3.46 (s, 2H, H-7), 
3.25 (q, 2H, J = 6 Hz, H-3), 2.61 (t, 2H, J = 6 Hz, H-5), 1.95 (s, 3H, H-1), 1.81 (qn, 2H, J = 
7 Hz, H-4). 13C (100MHz, CDCl3): = 202.6 (C-6), 170.3 (C-2), 167.7 (C-8), 52.4 (C-9), 
48.9 (C-7), 40.3 (C-3), 38.8 (C-5), 23.3, 23.2 (C-4, C-1). 
5.8.2.4 Formation of 6-acetamido-3-oxohexanoic acid (30) 
34 was dissolved in 6-MSAS assay buffer (e.g. 10 l) to a final concentration of 60 
mM. An equal volume of pig liver esterase solution (e.g. 10 l, ammonium sulphate 
suspension, 150 units/mg protein) was added and the mixture was incubated at 37 
°C for 2 hours. Chloroform (e.g. 20 l) was added and the mixture was vortexed and 
spun at 13,000 rpm for 5 minutes. The crude aqueous layer was used directly in 
assays. 
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5.8.3 Synthesis of reduced triketide 
5.8.3.1 Synthesis of methyl 2-(2-methyl-1,3-dithian-2-yl)acetate (69)129 
Methyl acetoacetate (0.43 ml, 4 mmol) was stirred in dry DCM (15 ml). 1,3-
Propanedithiol (0.60 ml, 6 mmol) and boron trifluoride dietherate (1.01 ml, 8 mmol) 
were added and the mixture stirred at room temperature for 1 hour. The mixture 
was diluted with DCM (20 ml) and 1 M NaOH (30 ml). The organic layer was washed 
with brine and dried (MgSO4). The solvent was removed under reduced pressure and 
the residue was freeze dried to give 69 as a white solid (1.29 g, 99%). 1H NMR (400 
MHz, CDCl3): = 3.68 (s, 3H, -OCH3), 3.03 (s, 2H, CH2), 2.97-3.06 (m, 2H, CH2), 2.69-
2.76 (m, 2H, CH2), 2.03-2.12 (m, 1H, CH), 1.80-1.91 (m, 1H, CH), 1.75 (s, 3H, CH3) 
5.8.3.2 Synthesis of 2-(2-methyl-1,3-dithian-2-yl)acetic acid (70)87 
69 (0.5 g, 2.42 mmol) was dissolved in 1.0M aq. NaOH (10 ml) and stirred at 90 °C for 
30 minutes. The mixture was allowed to cool, acidified to pH 1 using 1 M HCl and 
extracted with ethyl acetate. The solvent was removed under reduced pressure and 
the product lyophilised. 70 was obtained as a white solid (0.45 g, 97%). 1H NMR (400 
MHz, CDCl3): = 3.09 (s, 2H, CH2), 2.98-3.07 (m, 2H, CH2), 2.71-2.79 (m, 2H, CH2), 
2.05-2.14 (m, 1H, CH), 1.80-1.91 (m, 1H, CH), 1.77 (s, 3H, CH3). 
5.8.3.3 Synthesis of 5-(1-hydroxy-2-(2-methyl-1,3-dithian-2-yl)ethylidene)-2,2-
dimethyl-1,3-dioxane-4,6-dione (72)87 
70 (0.289 g, 1.50 mmol), DMAP (0.275 g, 2.25 mmol) and Meldrum’s acid (0.237 g, 
1.65 mmol) were dissolved in dry DCM (10 ml) at 0 °C. DCC (0.34 g, 1.65 mmol) in dry 
DCM (5 ml) was added dropwise over 1 hour. The mixture was allowed to warm to 
room temperature overnight with stirring. The mixture was filtered, and the filtrate 
washed with NaHSO4 (10 ml), brine (10 ml) and water (10 ml). The organic layer was 
dried (MgSO4), the solvent removed under reduced pressure and freeze dried to give 
72 as a white powder (0.337 g, 71%). 1H NMR (400 MHz, CDCl3): = 3.99 (s, 2H, CH2), 
3.07-3.16 (m, 2H, CH2), 2.64-2.71 (m, 2H, CH2), 2.06-2.14 (m, 1H, CH), 1.78-1.86 (m, 
1H, CH), 1.76 (s, 6H, 2xCH3), 1.74 (s, 3H, CH3). 
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5.8.3.4 Synthesis of methyl 4-(2-methyl-1,3-dithian-2-yl)-3-oxobutanoate (73)87 
72 (0.337 g, 1.06 mmol) was dissolved in dry toluene (10 ml) with dry methanol 
(0.213 ml) and heated under reflux for 3 hours. The solvents were removed under 
reduced pressure to give 73 as a white solid (0.292 g, 99%). 1H NMR (400 MHz, 
CDCl3): [keto] = 3.74 (s, 3H, CH3), 3.60 (s, 2H, CH2), 3.22 (s, 2H, CH2), 2.88-2.99 (m, 
2H, CH2), 2.78-2.85 (m, 2H, CH2), 1.98-2.10 (m, 1H, CH), 1.85-1.96 (m, 1H, CH), 1.73 
(s, 3H, CH3). [enol] = 12.00 (s, 1H, OH), 5.08 (s, 1H, CH), 3.73 (s, 3H, CH3), 3.60 (s, 
2H, CH2), 3.22 (s, 2H, CH2), 2.88-2.99 (m, 2H, CH2), 2.78-2.85 (m, 2H, CH2), 1.98-2.10 
(m, 1H, CH), 1.85-1.96 (m, 1H, CH), 1.73 (s, 3H, CH3). 
5.8.3.5 Synthesis of methyl 3-hydroxy-4-(2-methyl-1,3-dithian-2-yl)butanoate (74)87 
 
Figure 5.2: Numbering of 74 for NMR assignment. 
 
73 (270 mg, 1.09 mmol) was dissolved in dry methanol (5 ml) and cooled to 0 °C. 
Sodium borohydride (123 mg, 3.26 mmol) was added portionwise over 15 minutes 
and the mixture stirred at room temperature for 1 hour. Saturated aq. citric acid (5 
ml) was added and the mixture extracted twice with ether (2x 20 ml). The organic 
layer was washed with water, dried with magnesium sulphate and evaporated under 
reduced pressure to give crude 74 as a colourless oil (279 mg, 102%).1H NMR (400 
MHz, CDCl3): 
1H NMR (400 MHz, CDCl3):  4.38 (1H, m, H-4), 3.70 (3H, s, H-7), 3.64 
(1H, d, J = 2 Hz, OH), 2.89-3.03 (2H, m, H-8/H-10), 2.72-2.82 (2H, m, H-8/H-10), 2.56 
(1H, dd, J = 8, 16 Hz, H-5), 2.46 (1H, dd, J = 5, 16 Hz, H-5), 2.37 (1H, dd, J = 9, 15 Hz, H-
3), 1.99-2.08 (1H, m, H-9), 1.95 (1H, dd, J = 2, 15 Hz, H-3), 1.92-1.81 (1H, m, H-9), 
1.66 (3H, s, H-1). 13C (100 MHz, CDCl3):  172.2 (C-6), 65.8 (C-4), 51.8 (C-7), 47.5 (C-2), 
46.7 (C-3), 42.0 (C-5), 28.4 (C-1), 26.8 (C-8/C-10), 26.6 (C-8/C-10), 24.6 (C-9) 
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5.8.3.6 Synthesis of (1R,4R)-4-methoxy-1-(2-methyl-1,3-dithian-2-yl)-4-oxobutan-2-
yl 4,7,7-trimethyl-3-oxo-2-oxabicyclo[2.2.1]heptane-1-carboxylate (76 and 77)87 
To a solution of 73 (253 mg, 0.34 mmol), triethylamine (0.14 ml, 1.01 mmol) and 
DMAP (41.5 mg, 0.34 mmol) in dichloroethane (10 ml) was added (S)-camphanoyl 
chloride (219 mg, 1.01 mmol) in dichloroethane (2 ml) and the mixture was heated 
under reflux for 24 hours. The mixture was cooled and the organic layer washed with 
water (20 ml), saturated aq. sodium bicarbonate (20 ml), saturated aq. citric acid (20 
ml) and brine (20 ml). The organic layer was dried with magnesium sulphate and 
evaporated under reduced pressure. Crude 78 was obtained as a brown oil and 
purified by column chromatography on silica gel using a gradient from 50:1 
(Petroleum ether 40-60: ethyl acetate) to 2:1. 
 
The (R,S) diastereomer (77) was isolated as a white solid (15 mg , 10%). Rf = 0.33 (2:1 
petroleum  ether 40-60: ethyl acetate. 1H NMR (400 MHz, CDCl3): = 5.48 (m, 1H), 
3.63 (s, 3H), 2.86 (m, 2H), 2.68 (m, 4H), 2.33 (m, 3H), 1.95-1.80 (m, 4H), 1.61 (m, 1H), 
1.57 (s, 3H), 1.03 (s, 3H), 1.01 (s, 3H), 0.90 (s, 3H). 
 
The (S,S) diastereomer (76) was isolated as a white solid (6 mg, 4%). Rf = 0.41 (2:1 
petroleum  ether 40-60: ethyl acetate.  1H NMR (400 MHz, CDCl3): = 5.49 (m, 1H), 
3.61 (s, 3H), 2.91 (m, 2H), 2.67 (m, 4H), 2.52-2.23 (m, 3H), 1.92-1.76 (m, 4H), 1.61 (s, 
1H), 1.56 (s, 3H), 1.04 (s, 3H), 1.00 (s, 3H), 0.88 (s, 3H). 
5.8.3.7 Removal of esters to form 3-hydroxy-4-(2-methyl-1,3-dithian-2-yl)butanoic 
acid (57) 
78 (20 mg, 0.05 mmol) was stirred in 1M NaOH (20 ml) overnight. The pH was 
adjusted to 1 with HCl and the solution extracted with ethyl acetate. The organic 
layer was dried with magnesium sulphate and evaporated under reduced pressure to 
give crude 57 as a yellow oil (14.2 mg). 57 was purified by preparative TLC run in 
ethyl acetate. A very small amount was recovered with Rf = 0.46. LC-MS (C18, 
MeCN/H2O + 0.1% TFA) found 236.96 [M+H]
+ at 16.2 minutes. 
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5.8.3.8 Deprotection of 3-hydroxy-4-(2-methyl-1,3-dithian-2-yl)butanoic acid (79)87 
57 (15 mg, 0.05 mmol), methyl iodide (0.1 ml) and calcium carbonate (10 mg) were 
stirred in acetonitrile/water (9:1, 1 ml) at 50 °C. The reaction was monitored by TLC 
every 30 minutes and additional portions of methyl iodide and calcium carbonate 
added until no further changes in number of spots or Rf were observed. The mixture 
was evaporated under reduced pressure, suspended in DCM and filtered. The filtrate 
was evaporated under reduced pressure. A brown oil was produced which showed 
the loss of the dithiane signals in NMR, but no structure could be assigned. 
5.8.3.9 Synthesis of 3-hydroxy-4-(2-methyl-1,3-dithian-2-yl)butanoic acid (57) 
 
Figure 5.3: Numbering of 57 for NMR assignment. 
 
74 (141 mg, 0.56 mmol) was stirred in 1 M NaOH (25 ml) overnight. The solution was 
acidified to pH1 using hydrochloric acid and extracted with diethyl ether. The organic 
layer was dried with magnesium sulphate and evaporated under reduced pressure. 
The residue was purified by column chromatography on silica gel using ethyl 
acetate/methanol (3:1) to give 57 as a colourless oil (130 mg, 0.51 mmol, 93 %).1H 
NMR (400 MHz, CDCl3): = 4.40 (m, 1H, H-4), 2.98 (m, 2H, H-7/H-8), 2.78 (m, 2H, H-
7/H-8), 2.57 (m, 2H, H-5), 2.45 (dd, 1H, J = 9, 15 Hz, H-3), 2.05 (m, 1H, H-9), 1.94 (dd, 
1H, J = 1.4, 15 Hz, H-3), 1.88 (m, 1H, H-9), 1.67 (s, 3H, H-1). 13C (100 MHz, CDCl3): = 
175.9 (C-6), 65.7 (C-4), 47.2 (C-2), 46.4 (C-3), 41.8 (C-5), 28.4 (C-1), 26.8 (C-8/C-10), 
26.6 (C-8/C-10), 24.5 (C-9). Rf: 0.53 (3:1 ethyl acetate/methanol). 
5.8.3.10 Synthesis of D-pantetheine (83)130 
D-pantethine (226 mg, 0.41 mmol) was dissolved in dry isopropanol (5 ml) and 
degassed with argon for 40 minutes. Sodium borohydride (108 mg, 2.86 mmol) was 
added and the mixture heated under reflux for 18 hours. The mixture was allowed to 
cool then methanol (7.5 ml) and glacial acetic acid (2.5 ml) were added and the 
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solution stirred for 30 minutes. The solvents were removed under reduced pressure. 
Crude 83 was purified by column chromatography on silica gel using ethyl 
acetate/methanol (3:1). D-pantetheine (83) was obtained as a colourless oil (70 mg, 
31%).1H NMR (400 MHz, D2O):  = 3.92 (s, 1H), 3.47 (m, 2H), 3.44 (s, 1H), 3.35 (s, 1H), 
3.31 (m, 2H), 2.60 (t, 2H,  J = 7Hz), 2.46 (t, 2H, J= 7Hz), 0.86 (s, 3H), 0.83 (s, 3H). Rf: 
0.57 (3:1 ethyl acetate/methanol). 
5.8.3.11 Synthesis of S-(2-(3-((R)-2,4-dihydroxy-3,3-
dimethylbutanamido)propanamido)ethyl) 3-hydroxy-4-(2-methyl-1,3-dithian-2-
yl)butanethioate (82) 
 
Figure 5.4: Numbering of 82 for NMR assignment. 
 
57 (103 mg, 0.44 mmol) was placed in a flask which was flushed with argon and 
cooled to 0 °C. D-pantetheine (64 mg, 0.23 mmol) dissolved in dry THF (8 ml) was 
added and the flask flushed with argon again. DIPEA (0.043 ml, 0.25 mmol) and 
HATU (175 mg, 0.46 mmol) were added and the mixture stirred at 0 °C for three 
hours before being stirred at room temperature overnight. The mixture was 
evaporated under reduced pressure and the yellow oil was redissolved in ethyl 
acetate and water. The aqueous layer was extracted with ethyl acetate. The 
combined organic layers were dried with magnesium sulphate and evaporated under 
reduced pressure. 82 was obtained as a yellow oil (58.4 mg). Purification of 82 was 
carried out by preparative HPLC with a C18 column using an acetonitrile/water 
gradient (0% acetonitrile to 100% acetonitrile over 40 minutes) to give a colourless 
oil (7.5 mg, 0.015 mmol, 7 %). Rt = 14.5 mins. HRMS: 497.1810 found ([M+H]
+, calcd 
497.1808,  = 0.42 ppm).1H NMR (400 MHz, D2O):  4.29 (m, 1H, H-14), 3.89 (s, 1H, 
H-5), 3.37-3.47 (m, 1H + 2H, H-1, H-7), 3.24-3.34 (m, 1H + 2H, H-1, H10), 2.97 (td, 2H, 
J = 6.6, 1.9 Hz, H-11), 2.92-2.74 (m, 2H + 2H + 2H, H-13, H-18, H-20), 2.38 (t, 2H, J = 
6.6 Hz, H-8), 2.17 (dd, 1H, J = 15.2, 2.2 Hz, H-15), 1.99 (dd, 1H, J = 15.2, 8.2 Hz, H-15), 
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1.86-1.95 (m, 1H, H-19), 1.79-1.81 (m, 1H, H-19), 1.56 (s, 3H, H-17), 0.82 (s, 3H, H-
3/H-4), 0.79 (s, 3H, H-3/H-4). 13C NMR (100 MHz, D2O): 201.0 (C-12), 175.1 (C-9), 
174.0 (C-6), 75.8 (C-5), 68.4 (C-1), 66.2 (C-14), 51.7 (C-13), 47.4 (C-16), 46.4 (C-15), 
38.6 (C-10), 38.6 (C-2), 35.5 (C-7), 35.3 (C-8), 28.2 (C-11), 27.7 (C-17), 26.1 (C-18/C-
20), 25.9 (C-18/C-20), 24.3 (C-19), 20.5 (C-3/C-4), 19.1 (C-3/C-4). 
5.8.3.12 Synthesis of S-(2-(3-((R)-2,4-dihydroxy-3,3-
dimethylbutanamido)propanamido)ethyl) 3-hydroxy-5-oxohexanethioate (81) 
 
Figure 5.5: Numbering of 81 for NMR assignment. 
 
82 (3 mg, 0.006 mmol), methyl iodide (150 l) and calcium carbonate (15 mg) were 
stirred in MeCN/H2O (9:1, 15 ml) at 50 °C for 24 hours. The solvent was removed 
under reduced pressure and the solid (23.4 mg) redissolved in methanol for 
purification by semi-preparative HPLC using a MeCN/H2O + 0.1% formic acid gradient 
(0-100% MeCN over 40 minutes). 81 was obtained as a colourless oil (0.9 mg, 0.002 
mmol, 33%). Rt = 13.5 mins. HRMS: 407.1837 found ([M+H]
+, calcd 407.1846,  = -2.2  
ppm).  1H NMR (500 MHz, D2O): 4.47 (q, 1H, J = 6 Hz, H-14), 3.91 (s, 1H, H-5), 3.37-
3.47 (m, 2H+1H, H-1 + H-7), 3.28-3.34 (m, 2H+1H, H-1 + H-10), 2.99 (dt, 2H, J = 2, 6 
Hz, H-11), 2.78 (dd, 2H, J =  6, 2 Hz, H-13), 2.72 (d, 2H, J =  7 Hz, H-15), 2.40 (t, 2H, J =  
7 Hz, H-8), 2.16 (s, 3H, H-17), 0.84 (s, 3H, H-3/H-4), 0.81 (s, 3H, H-3/H-4). 13C NMR 
(125 MHz, D2O):   212.9(C-16), 200.7 (C-12), 175.0 (C-6), 174.0 (C-9), 75.7 (C-5), 68.3 
(C-1), 64.4 (C-14), 49.9 (C-13), 49.2 (C-15), 38.5 (C-2), 38.4 (C-10), 35.3 (C-8), 35.2(C-
7), 29.9 (C-17), 28.1 (C-11), 20.4 (C-3/C-4), 19.0 (C-3/C-4). 
5.8.3.13 Formation of 3-hydroxy-5-oxohexanoyl CoA (80)81 
81 (1 mg, 0.002 mmol) was dissolved in buffer (Tris-HCl (50 mM), KCl (20 mM), MgCl2 
(10 mM), pH 7.5) to a final volume of 1 ml. ATP (5 mg, 0.01 mmol) was added and 
the pH was adjusted to 7 with 4 M NaOH. Pantothenate kinase (800 g), 
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phosphopantetheine adenyltransferase (900 g) and dephosphocoenzyme A kinase 
(948 g) were added and the mixture was incubated at room temperature overnight. 
Chloroform (1 ml) was added and the mixture was centrifuged at 13,000 rpm for 5 
minutes. The crude aqueous layer was lyophilised and redissolved in water for 
analysis by LC-MS, but no peak for 3-hydroxy-5-oxohexanoyl CoA could be found. 
5.9 Molecular biology methods 
5.9.1 Polymerase Chain Reaction (PCR) 
5.9.1.1 Primers 
Name Sequence 
pMSAS_ACP-for* 
5’-CAGCGACGCG GTGCATATGT CTGGACCGGA 
GCTTAAGGCT-3’ 
pMSAS_ACP-rev* 5’-GCCGTTCTTA TGAATTCAAT CATTTGGCAA-3’ 
MSAS_ACP-rev-CHis 5’ –GCCGTTCTTA TGAATTCAAT CCTTTGGCAA-3’ 
pDH_H34A_1A* 5’-GGCATCTCCCCTAAGGAGGCCGAGCAGATG-3’ 
pDH_H34A_1B* 5’-CTCGGTACCATGGAGAGGAGCGCTGCCCGG-3’ 
pDH_H34A_2A* 5’-CAGCCACCCTCTCCATGGTACCGAG ATCGT-3’ 
pDH_H34A_2B* 5’-GATCTTGGGC GGATCCTGCG AGGTGAAGAC-3’ 
*Designed by Dr Fanglu Huang 
5.8.1.2 Plasmid PCR 
Plasmid DNA (1 l), 10x Pfu buffer (5 l), dNTP mix (2 mM each NTP, 5 l), forward 
and reverse primers (1 l each), Pfu DNA polymerase (1 l) and DMSO (1 l) were 
made up to 50 l with water. 
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The mixture was heated to 95 °C for 3 minutes initially. Then 25-30 cycles of the 
following conditions were carried out: 95 °C for 30 seconds, 58 °C for 30 seconds, 72 
°C for 2 minutes. The mixture was then held at 72 °C for 10 minutes before being 
cooled to 4 °C. 
5.9.1.3 Colony PCR 
A single colony was picked from an LB-agar plate and resuspended in water (30 l) 
using a sterilised toothpick. 10x Dream Taq buffer (5 l), dNTP mix (2 mM each NTP, 
5 l), forward and reverse primers (1 l each), Dream Taq polymerase (1 l) and 
DMSO (1 l) were added and the total volume made up to 50 l with water. 
The PCR reaction was carried out as for plasmid PCR. 
5.9.2 Digestion of DNA with restriction endonucleases 
Plasmid DNA (30 l), appropriate 10x buffer (5 l), BSA (2 l) and restriction 
endonucleases (1 l each) were made up to 50 l with water and incubated at 37 °C 
overnight.  Digested DNA was purified by preparative agarose gel electrophoresis. 
5.9.3 Ligation  
5.9.3.1 Two piece ligation 
Digested vector (e.g. x l) and insert (e.g. y l) were incubated with 10x reaction 
buffer (1.5 l) and T4 DNA ligase (1.5 l) in a total reaction volume of 15 l at 16°C 
overnight. The relative concentrations of vector and insert were established either 
by analysing the fluorescence of each on an agarose gel or by analysis using a 
nanodrop. The amounts of vector and insert (x and y) were adjusted to give a final 
concentration ratio of 2:1 (insert:vector). 7.5 l of the ligation mixture was 
transformed into E. coli NovaBlue cells as described in section 5.9.7. Colonies were 
screened for the presence of insert using colony PCR as previously described. 
Colonies containing the correct insert then had the plasmid extracted and sent for 
sequencing. All constructs in this study were sequenced by the staff of the 
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sequencing facility of the Department of Biochemistry, University of Cambridge. 
pET28a(+) and pET20b(+) constructs were sequenced using T7 and T7T primers.  
5.9.3.2 Three piece ligation 
pKOS007-109 that had been digested with Bsu36I and BamHI (e.g. x l), the left 
insert digested with Bsu36I and KpnI (e.g. y l) and the right insert digested with 
KpnI and BamHI (e.g. z l) were added to 10x reaction buffer (1.5 l) containing T4 
ligase (1.5 l) in a total volume of 15 l. The amounts x, y and z were calculated to 
give a final concentration ratio of (1:5:5 vector:left:right). The mixture was incubated 
overnight at 16 °C and 7.5 ml of ligation mixture was transformed into NovaBlue and 
plated onto LB/Cb plates. Colonies were screened by plasmid preparation and 
comparison of plasmid size to the original pKOS007-109 plasmid. Sequencing of 
plasmids was performed using the DHm-1A and DHm-2B primers. 
5.9.4 Plasmid preparation 
NovaBlue cells containing the required plasmid were grown in LB medium (10 ml) 
overnight at 37 °C, 220 rpm. The culture was centrifuged at 5000 rpm for 5 minutes. 
Plasmid was extracted from the cell pellet using the GeneJET Plasmid Purification kit 
(Fermentas) according to the manufacturer’s protocol. 
5.9.5 Agarose gel electrophoresis 
Agarose (electrophoresis-grade) was dissolved in TAE buffer to final concentration of 
0.7-1.5% as required with microwave heating. Ethidium bromide solution (2 l) was 
added and the agarose poured into a horizontal caster. DNA samples were mixed 
with 5:1 DNA loading dye before being loaded onto the gel. Gels were run at room 
temperature in TAE buffer at 100V for 25 minutes and then visualised on a UVI-Doc 
ultraviolet transilluminator. 
 
TAE buffer: 40 mM Tris-acetate, 1 mM EDTA. 
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5.9.6 DNA purification 
PCR products and digested DNA were purified on a preparative 1% agarose gel. The 
appropriate band was excised and the DNA extracted using a GeneJET Gel extraction 
kit (Fermentas) according to the manufacturer’s protocol. 
5.9.7 Transformation of plasmid 
E. coli NovaBlue or BL21(DE3) competent cells were thawed on ice, then 
recombinant plasmid was added (1 l). The mixture was incubated on ice for ten 
minutes, then heated to 42 °C for 35 seconds before being incubated on ice for 5 
minutes. SOC medium (80 l) was added and the culture was incubated at 37 °C, 220 
rpm for 1 hour. The culture was then spread onto an LB-agar plate containing an 
appropriate antibiotic (50 g/ml) and incubated overnight at 37 °C. 
 
SOC medium: Bacto-tryptone, 20 g; bacto-yeast extract, 5 g; NaCl, 0.5 g; KCl, 0.186 g; 
MgCl2, 0.952 g; glucose, 3.603 g; ddH2O to 1 litre, pH 7.0. 
LB-agar: LB granules 2.5 g/100 ml, agar 2 g/100 ml, ddH2O. 
5.9.8 Gene expression 
5.9.8.1 6-MSAS59 
A single colony from an LB-agar plate was inoculated into ATCC 765 media (10 ml) 
containing 100 g/ml carbenicillin (apo) or 100 g/ml carbenicillin and 50 g/ml 
kanamycin (holo). The culture was grown for 8 hours at 37 °C with shaking at 220 
rpm and then added to 1L of ATCC 765 medium containing 10% glycerol (v/v), 100 
g/ml carbenicillin (apo) or 100 g/ml carbenicillin and 50 g/ml kanamycin (holo) 
and grown at 37 °C, 220 rpm until an OD600 of 1 was reached. Protein expression was 
induced with IPTG (0.5 mM). Holo 6-MSAS was then incubated at 30 °C for 24 hours, 
while apo 6-MSAS cultures were incubated at 16 °C for 24 hours. 
 
Cells were harvested by centrifugation at 7000 rpm for 10 minutes at 4 °C, 
resuspended in resuspension buffer with the addition of benzamidine (20 mg), PMSF 
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(20 mg) and lysozyme (20 mg), and sonicated on ice for 24 minutes (2 seconds on, 10 
seconds off, 4 minutes total on, 80% amplitude). The cell lysate was cleared by 
centrifugation at 17,000 rpm and 4 °C for 30 minutes. 
 
ATCC 765 medium: potassium dihydrogen phosphate, 4.49 g; dipotassium hydrogen 
phosphate, 11.67 g; ammonium sulphate, 1.98 g; iron (II) sulphate heptahydrate, 0.5 
mg; magnesium sulphate, 0.25 g; glycerol, 20.25 ml; casamino acids, 11.0 g; dd H2O, 
1 litre. 
5.9.8.2 Other proteins 
A single colony from an LB-agar plate was inoculated into LB medium (10 ml) 
containing an appropriate antibiotic (50-100 g/ml). The culture was grown 
overnight at 37 °C, 220 rpm and then added to 1L of LB medium containing the 
appropriate antibiotic (50-100 g/ml). The culture was grown at 37 °C, 220 rpm until 
an OD600 of 0.5-0.9 was reached and protein expression was induced using IPTG (0.2 
mM-0.5 mM). The culture was then incubated overnight at 16°C with shaking at 220 
rpm. Cells were harvested by centrifugation at 7000 rpm for 10 minutes at 4 °C and 
resuspended in binding buffer, before being sonicated on ice (2 seconds on, 10 
seconds off, 4 minutes total on, 80% amplitude).  The cell lysate was cleared by 
centrifugation at 17,000 rpm and 4 °C for 30 minutes. 
 
Luria-Bertani medium: LB granules, 25 g; distilled water, 1 litre. 
5.9.9 Protein purification  
5.9.9.1 Ammonium sulphate precipitation of 6-MSAS 
Solid ammonium sulphate was added to cleared cell lysate at 4 °C to give a final 
concentration of 22%. The mixture was left to equilibrate at 4 °C for 30 minutes 
before centrifugation at 11000g and 4 °C for 15 minutes. The supernatant was 
decanted and solid ammonium sulphate added at 4 °C to give a final concentration 
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of 40%. The mixture was left to equilibrate at 4 °C for 1 hour and centrifuged at 
5000g and 4 °C for 30 minutes. The pellet was stored at -80 °C.  
5.9.9.2 FPLC of 6-MSAS 
Gel filtration was carried out on an ÄKTA Explorer FPLC system with a HiLoad 16/60 
Superdex 200 Prep Grade column. The mobile phase was that used by Richardson et 
al.85 6-MSAS ammonium sulphate pellet (100 mg/ml in assay buffer, 1 ml) was 
injected on to the column. The fractions containing the desired peak were collected 
and concentrated in a PVP-treated spin concentrator with a 100 kDa cut-off 
(Amicon). The glycerol content of concentrated fractions was adjusted to 50% and 
the protein was stored at -20 °C. 
 
FPLC buffer: NaH2PO4 100 mM, EDTA 1 mM, DTT 2 mM, glycerol 20%, pH 7.1. 
5.9.9.3 Purification of His6-tagged proteins 
His-bind resin (2 ml) was washed with water (12 ml) and charged with 50 mM NiCl2 
(10 ml), before being washed with binding buffer (6 ml). Cleared cell lysate was 
passed through the column and the column washed with binding buffer (20 ml). 
Fractions were eluted with wash buffer (6 ml), elution buffer (6 ml) and 400 mM 
elution buffer (6 ml). The elution buffer fraction was concentrated in an Amicon spin 
concentrator of appropriate size and the buffer exchanged for storage buffer. 
Protein samples were stored at -20 °C. 
 
Binding buffer: 20 mM Tris.HCl, 0.5 M NaCl, 5 mM imidazole, 10% glycerol, pH 7.9. 
Wash buffer: 20 mM Tris.HCl, 0.5 M NaCl, 20 mM imidazole, 10% glycerol, pH 7.9. 
Elution buffer: 20 mM Tris.HCl, 0.5 M NaCl, 200 mM imidazole, 10% glycerol, pH 7.9. 
400 mM elution buffer: 20 mM Tris.HCl, 0.5 M NaCl, 400 mM imidazole, 10% 
glycerol, pH 7.9. 
Storage buffer: 50 mM HEPES, 200 mM NaCl, 50% glycerol, pH 7.6. 
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5.9.10 Sodium dodecylsulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
Premade 10% gels and 8-16% gradient Precise Protein gels were purchased from 
Thermo Scientific. 18% gels were prepared according to standard protocols with a 5 
% acrylamide stacking gel. Protein samples were mixed 1:1 with SDS loading buffer 
before loading on to the gel. Premade gels were run at 150 V, 400 mA for 45 minutes 
in Tris-HEPES buffer. 18% gels were run in Tris-glycine buffer, 250 V, 20 mA for 2 
hours. PageRulerPlus protein marker (Fermentas) was used for reference. After 
running, gels were stained with Coomassie Blue staining solution for 10 minutes and 
then in destaining solution overnight. Gels were visualised on a UVI-Doc ultraviolet 
transilluminator. 
 
Tris-HEPES buffer: Tris base, 12.1 g; HEPES, 23.8 g; SDS, 1.0 g; ddH2O 1 litre. 
Tris-glycine buffer: Tris 25 mM, glycine 250 mM, 0.1% SDS, pH 8.3. 
SDS loading buffer: Tris-HCl 50 mM, DTT 100 mM, 2 % SDS, 0.1% bromophenol blue, 
10% glycerol, pH 6.8. 
Staining solution: 2.5 g/L Coomassie Brilliant Blue in MeOH:H2O:acetic acid 
(4.5:4.5:1) 
 
Destaining solution: MeOH:H2O:acetic acid (4.5:4.5:1) 
5.9.11 Protein concentration 
Protein concentration was determined by the Bradford method.131 1-5 l of protein 
stock was mixed with Bradford reagent (900 l) in a final volume of 1 ml at room 
temperature. The mixture was allowed to stand for 5 minutes before the absorbance 
at 595 nm was determined. This was compared with a standard curve measured 
using known concentrations of BSA to calculate protein concentration. 
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5.9.12 Limited proteolysis 
5.9.12.1 Digestion of 6-MSAS with hydroxylamine 
FPLC-purified 6-MSAS (600 g) and hydroxylamine (34 l, 1.8 M final concentration) 
in a final volume of 300 l were incubated at 37 °C. A sample of 50 g was taken 
every 30 minutes and quenched with 1 drop of 10% HCl before freezing. Samples 
were analysed using SDS-PAGE. 
5.9.12.2 Digestion of 6-MSAS with trypsin  
FPLC-purified 6-MSAS (100 g) and trypsin (x g, where desired ratio is 100:x wt/wt 
6-MSAS:trypsin) were incubated at room temperature. Samples were taken at timed 
intervals and the reaction was stopped by addition of TLCK (1 mM final 
concentration). Samples were analysed using SDS-PAGE. 
5.9.12.3 N-terminal sequencing 
SDS-PAGE gels containing the bands of interest were blotted onto PVDF membrane 
using the iBlot dry blotting system. The PVDF membrane was placed on top of the 
nitrocellulose membrane in the supplied cartridges and the rest of the blotting 
apparatus was assembled according to the manufacturer’s instructions. The blot was 
stained using Coomassie Blue staining solution and destained with destaining 
solution until bands were visible, before being allowed to air dry. N-terminal 
sequencing was carried out by the Protein and Nucleic Acid Chemistry Facility 
(Department of Biochemistry). 
5.10 Enzyme assays 
5.10.1 Production of 6-MSA in culture 
Culture supernatant (50 ml) was acidified to pH 1 with 1M HCl and extracted three 
times with ethyl acetate. The combined organic extracts were dried with magnesium 
sulphate and evaporated under reduced pressure. The residue was dissolved in 
methanol (1 ml) and 15 l of this was injected onto the LC-MS. The 6-MSA peak was 
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identified by comparison with authentic 6-MSA (10 l of 1 mg/ml) run in the same 
session. The amount of 6-MSA was calculated based on a comparison of the peak 
area between the extract and the standard in the UV traces at 254 nm and 280 nm. 
5.10.2 Activity of 6-MSAS in vitro 56  
6-MSAS, either as the ammonium sulphate pellet (40 mg/ml, 50 l), or FPLC-purified 
(3 mg/ml, 25 l) was incubated with DTT (10 mM final concentration) at room 
temperature for 15 minutes. 6-MSAS was then added to a mixture of acetyl-CoA (0.1 
mol), NADPH (0.1 mol) and bovine serum albumin (0.5 mg) in assay buffer with a 
final volume of 0.5 ml. Malonyl-CoA (0.1 mol) was added to start the reaction. 
Production of 6-MSA was monitored using a Cary fluorimeter (Varian) with ex = 310 
nm and em = 390 nm at 25 °C for 30 minutes. Activity of 6-MSAS was calculated 
using a standard curve of 6-MSA concentrations. 
 
6-MSAS assay buffer: 100 mM Tris sulphate, 1 mM EDTA, 15% glycerol, pH 7.6. 
5.10.3 Phosphopantetheinylation of 6-MSAS 
Apo 6-MSAS (50 l, 40 mg/ml pellet), PPTase (1 l, 6 mg/ml), CoASH (1 l, 30 mM 
stock) and DTT (10 mM final concentration) were incubated at room temperature or 
37 °C for 1 hour in Sfp, CoA or phosphate buffer with addition of MgCl2 (5 mM final 
concentration) with a final volume of 55 l.  
Sfp buffer: 50 mM HEPES, 1 mM MgCl2, pH 6.5. 
CoA buffer:118 75 mM Tris.HCl, 10 mM MgCl2, 25 mM DTT, pH 8.8 
Phosphate buffer: 100 mM sodium phosphate, pH 7.5. 
5.10.4 Phosphopantetheinylation of Con2* and ChlD2 
Apo ACP (1.25 l, 10 mg/ml stock), PPTase (0.7 l, 3 mg/ml stock) and CoASH (1 l, 
30 mM stock) were made up to a final volume of 25 l with either CoA buffer or 
phosphate buffer with addition of MgCl2 (10 mM final concentration). The mixture 
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was incubated for 2 hours at room temperature before injection of 15 l for analysis 
by LC-MS. 
5.10.5 Off-loading of intermediates from 6-MSAS 
5.10.5.1 Starter unit 
A typical assay contained FPLC-purified 6-MSAS (100 g, treated with DTT), 30 (15 
mM), acetyl-CoA or acetoacetyl-CoA (3 mM), with NADPH (10 mM) if required, made 
up to a final volume of 100 l with 6-MSAS assay buffer. Assays were incubated at 
room temperature overnight. The aqueous layer was extracted twice with ethyl 
acetate (150 l) and the organic extracts were dried under N2. The residue was 
dissolved in methanol (20 l) and 10 l was analysed by HRMS. 
5.10.5.2 Competitive assays 
A typical assay contained FPLC-purified 6-MSAS (100 g, treated with DTT), 30 (15 
mM), acetyl-CoA or acetoacetyl-CoA (3 mM), NADPH (10 mM) and malonyl-CoA (1-
13 mM) made up to a final volume of 100 l with 6-MSAS assay buffer. Assays were 
incubated at room temperature overnight. The aqueous layer was extracted twice 
with ethyl acetate (150 l) and the organic extracts were dried under N2. The residue 
was dissolved in methanol (20 l) and 10 l was analysed using the LTQ Orbitrap. 
5.10.5.3 Delayed off-loading from 6-MSAS-DHm  
The assay mixture containing FPLC-purified 6-MSAS-DHm (100 g, treated with DTT), 
acetyl-CoA or acetoacetyl-CoA (3 mM), malonyl-CoA (5 mM) and NADPH (10 mM) 
made up to a final volume of 100 l with 6-MSAS assay buffer was incubated at room 
temperature for 1 hour. Non-hydrolysable analogue 30 was added to a final 
concentration of 15 mM and the reaction mixture was incubated overnight. The 
aqueous layer was extracted twice with ethyl acetate (150 l) and organic extracts 
were dried under N2. The residue was dissolved in methanol (20 l) and analysed 
directly using the LTQ Orbitrap. 
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A1 Alternative syntheses of reduced triketide intermediates  
A1.1 Introduction 
The biosynthesis of 6-MSA is proposed to proceed via an enzyme-bound reduced 
triketide.52 The hydroxyl group at C-4 is produced by reduction of a ketone by the 
ketoreductase domain found in 6-MSAS. The hydride group is provided by NADPH. 
 
To probe the stereochemistry of this reduction, it was proposed to synthesise the 
enantiomerically resolved reduced triketides 65 and 66 , after Cheung et al. 87 These 
could be provided to the 6-MSAS enzyme as CoA thioesters, which could potentially 
be loaded on to the apo enzyme by a phosphopantetheinyltransferase enzyme, such 
as Sfp. The reduced triketide that had the correct hydroxyl configuration could be 
elaborated to 6-MSA by dehydration, condensation with a unit of malonyl CoA, 
cyclisation and aromatisation, followed by release of the product. The reduced 
triketide that has the incorrect stereochemistry should not be a substrate for the 
dehydratase domain and so no production of 6-MSA should be observed from 
incorporation of the reduced triketide (Figure A1). 
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Figure A1: Resolved reduced triketides 65 and 66 could be loaded on to 6-MSAS 
using Sfp. The triketide with the correct hydroxyl stereochemistry should be 
extended to form 6-MSA (1). 
 
As malonyl-CoA can decarboxylate to form acetyl-CoA, which can prime 6-MSAS, it 
would be expected that there would be a significant background rate of formation of 
6-MSA. In order to differentiate 6-MSA formed through the background reaction 
from that formed through reaction with the enantiomerically resolved reduced 
triketides, it was necessary to include an isotopic label in the reduced triketide. This 
would allow 6-MSA formed from the triketides to be easily distinguished in a mass 
spectrum. 
 
A1.2 Synthesis of singly-D labelled reduced triketide 
The simplest method of incorporating a label into the reduced triketide CoA that 
would be retained in 6-MSA is to replace the sodium borohydride used in the 
reduction of the central ketone in 73 with sodium borodeuteride. This would add a 
single deuterium label at C-4 and cause the mass of the 6-MSA produced to increase 
by 1 unit. 
 
Figure A2: Synthesis of protected singly-deuterated reduced triketide 84 from 
protected triketide 73. 
 
Protected triketide 73 was dissolved in methanol and cooled to 0 °C. Sodium 
borodeuteride was added portionwise over 15 minutes and the solution was stirred 
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at room temperature for 1 hour. Citric acid was added, the mixture was extracted 
with diethyl ether and the organic layer washed with water. The organic layer was 
dried with magnesium sulphate and removed under reduced pressure to give 84 as a 
yellow oil in 68% yield (Figure A2). 
 
84 was easily prepared and could potentially be deprotected and coupled with 
CoASH to form the desired reduced triketide-CoA (section 4.2.2). However the +1 
mass shift in the 6-MSA produced would coincide with the +1 peak observed for the 
incorporation of 13C into 6-MSA, which should account for a peak height of 1.1% of 
that for unlabelled 6-MSA. As the loading of the reduced triketide on to 6-MSAS was 
a single turnover event, while the background reaction forming 6-MSA from acetyl- 
and malonyl-CoA would turn over many times, the unlabelled 6-MSA peak would be 
much larger than the labelled 6-MSA peak. This meant that the 13C [M+1] peak would 
be a significant contributor to any peak at seen at m/z = 154 and so the 
incorporation of the labelled reduced triketide would be very difficult to detect 
unambiguously. 
A1.3 Synthesis of multiply D-labelled reduced triketide 
To avoid the problem of overlapping peaks, it was decided that it would be best to 
label the reduced triketide with deuterium at multiple sites. The position with the 
best potential retention of deuterium label throughout the synthesis is the methyl 
group at C-1. This is the least acidic site throughout the synthesis, as it is adjacent to 
a dithiane, and allows the label to be installed in the very first step. 
 
Methyl acetoacetate, the starting point for the synthesis of the reduced triketide-
CoA (see section 4.2.2), can be deuterated using freshly prepared deuterated sodium 
methoxide in deuterated methanol (Figure A3).132 The first protons to be replaced 
would be the two between the ketone and ester groups as this position is the most 
acidic. The next most acidic position is the methyl group adjacent to the ketone and 
these protons would then be replaced to produce the fully labelled acetoacetate 
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moiety. It is also possible that the methyl ester would be replaced by a deuterated 
methyl ester.  
 
 
Figure A3: Deuterium labelling of methyl acetoacetate at multiple sites, followed by 
dithiane protection of the ketone to produce 86. 
 
Attempts to purify the deuterated product by Kugelrohr distillation produced very 
little labelled methyl acetoacetate. The distillation product obtained was protected 
with 1,3-propanedithiol to install the dithiane at the C-2.129 This should prevent the 
exchange of the deuterium atoms attached to C-1 and also provide an internal 
standard for comparison of the extent of labelling at positions C-1 and C-3 by NMR. 
 
It was found that a shorter reaction time produced a slightly higher yield of methyl 
acetoacetate, but that the labelling extent was reduced (Table A1). An overnight 
reaction had little advantage over a 5 hour reaction time. 
 
Table A1: The extent of deuterium labelling at different positions in 86 for different 
deuteration reaction times, as determined by 1H NMR. 
 
 Extent of deuteration at position 
Time Yield (%) -CH3 -CH2- -OCH3 
3 hours 20.5 67 50 83 
5 hours 17.7 83 50 100 
Overnight 17 83 50 100 
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The low yields of the labelled methyl acetoacetate meant that it would be 
challenging to carry a useful amount of labelled material through the rest of the 
synthesis to form labelled reduced triketide-CoA. Instead, it was decided to use 
unlabelled reduced triketide-CoA and labelled malonyl-CoA for this experiment (see 
section 4.2.2). This would produce a peak for 6-MSA from the reduced triketide at 
m/z = 155 [M+H]+ while the background reaction would produce fully deuterated 6-
MSA at m/z = 160 [M+H]+. 
  
A1.4 Alternative synthetic route using chymotrypsin 
As the cleavage of the camphanic ester in the original synthesis was proving difficult 
(see section 4.2.2), an alternative synthetic route was sought. 
 
Diethyl 3-hydroxyglutarate that has been protected at the central hydroxyl group 
with an acetate group (87) is a substrate for the enzyme chymotrypsin.133 This 
cleaves one of the ethyl esters to preferentially form the (R)-hydroxy chiral 
compound 88. The presence of the acetate group increases the enantioselectivity of 
the reaction. 
 
The carboxylic acid formed could be reacted with Meldrum’s acid to form the cyclic 
adduct 89. Heating 89 under reflux in water should result in the opening of the cyclic 
adduct and the decarboxylation of the -ketoacid formed to give the protected 
reduced triketide 90 (Figure A4). This could be reacted with sodium hydroxide to 
remove the ester protecting groups before coupling with CoASH to form the (R)-
reduced triketide CoA. 
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Figure A4: Proposed synthesis of the (R)-reduced triketide 91 from the product of the 
a-chymotrypsin reaction via coupling to Meldrum’s acid and ring 
opening/decarboxylation. 
 
The (S)-hydroxyl could be formed by the action of pig liver esterase (PLE) on diethyl 
3-hydroxyglutarate in moderate ee.134 However, the addition of the acetyl protecting 
group does not increase the enantioselectivity of the reaction. Instead, the specificity 
of the PLE is switched from the (S)-hydroxyl to the (R)-hydroxyl.135 The formation of 
the (S)-reduced triketide CoA presents a more significant synthetic challenge, as the 
separation of the (S)- and (R)-enantiomers of the ester cleavage reaction would be 
difficult. Alternatively, the (S)-reduced triketide could be formed from the (R)-
product. The acid moiety would have to be protected, for example with a 2-alkyl-1,3-
oxazoline while the esters were removed and a methyl group installed on the newly 
revealed acid. This could be done using a Weinreb amide and methyl magnesium 
iodide. The original carboxylic acid moiety could then be deprotected and coupled to 
CoASH (Figure A5).  
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Figure A5: Proposed synthesis of the (S)-reduced triketide from the (R)-ester 
cleavage product. 
 
Diethyl 3-hydroxymethylglutarate (96) was protected with acetic anhydride in 
pyridine to give the acetylated species 87 in 92% yield. The acetylated species was 
dissolved in 1 M KH2PO4 and the pH was adjusted to 7.8 with 1 M NaOH. 
Chymotrypsin was suspended in distilled water and added to the buffered solution. 
The pH was adjusted back to 7.8 using 1 M NaOH and kept constant throughout the 
reaction by further addition of NaOH. After 2 hours, the reaction was acidified with 1 
M HCl and extracted with ether. The organic layer was treated with ammonia water 
and the mixture was separated. The aqueous layer was acidified with 1 M HCl and 
extracted with ether. The organic layer was dried with magnesium sulphate and the 
solvent was removed under reduced pressure to give the acid 88 (Figure A6). 
 
 
Figure A6: Protection of diethyl 3-hydroxyglutarate with acetic anhydride in pyridine, 
followed by ester cleavage using chymotrypsin leads to the chiral molecule 88. 
 
To determine the enantiomeric excess (ee) of 88, the acid was derivatised by 
coupling with (R)-(+)-2-phenylethylamine.136 This enabled the stereochemistry of the 
protected hydroxyl group to be measured by the difference in chemical shift of the 
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2-phenylethylamine methyl group and comparing them to the literature values for 
these compounds.  
 
Acid 97 was coupled with (R)-(+)-2-phenylethylamine using oxalyl chloride to give 98 
as a crude white solid (Figure A7). Comparison of the signals in the methyl region of 
the NMR spectrum of 98 with the literature values gave the (R)-(R) isomer at d = 1.97 
and (S)-(R) isomer at  = 1.95.135 The ratio of the peak integrals gives an ee of 77% for 
the (R)-(R) isomer. The yield was not determined, but the crude product contained 
mainly starting material.  
 
 
Figure A7: Coupling of the chymotrypsin reaction product 97 with (R)-
phenylethylamine for the determination of the ee by NMR. 
 
The chymotrypsin reaction was challenging since the pH had to be carefully 
controlled throughout the reaction, as a wider pH range would result in a reduced 
ee.136 The yield was also rather low at 29%, compared with 95% reported in the 
literature.135 
 
A1.5 Coupling to Meldrum’s acid 
The crude product from the chymotrypsin reaction was coupled with Meldrum’s acid 
using DCC and DMAP in DCM, conditions that were used for a similar reaction in 
section 4.2.2. Under these conditions, no product was seen. Using THF as a solvent 
or EDC as a coupling reagent also did not result in any product, although in all cases 
the reaction turned blue, then brown. 
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It was decided that the protecting group might be causing problems with the 
coupling reaction, and so a different protecting group for the hydroxyl was 
investigated. 
 
A1.6 Change of protecting group 
It has been shown that a variety of protecting groups are tolerated by chymotrypsin 
in the cleavage reaction.137 A methoxymethyl (MOM) ether protecting group due to 
its ease of installation and cleaveage, as well as the fact that the NMR data for the 
MOM-protected 3-hydroxyglutarate compound was reported in the literature, which 
would allow calculation of the ee. 
 
Diethyl 3-hydroxyglutarate was protected using MOM chloride and DIPEA in DCM to 
give 99 in nearly quantitative yield.138 Chymotrypsin-catalysed cleavage of the ethyl 
ester was carried under the same conditions that were used for the acetyl-protected 
version. The cleavage product was obtained in a yield of approximately 10%. No ee 
was determined since the viability of the route would depend on whether the 
coupling to Meldrum’s acid was successful. 
 
 
Figure A8: Protection of the hydroxyl group in diethyl 3-hydroxyglutarate (96) with 
MOM-Cl, followed by ester cleavage with chymotrypsin. 
 
100 was coupled with Meldrum’s acid using DCC and DMAP, or EDC and DMAP, in 
DCM. In both cases, no product could be seen. 
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A1.7 Reasons for discontinuing work 
The difficulty in obtaining a good yield from the enzymatic ester cleavage, the fact 
that only one stereoisomer of the reduced triketide should be formed and the 
subsequent synthesis required to obtain both forms of the reduced triketide, and the 
difficulty of the coupling reaction with Meldrum’s acid all contributed to this 
synthetic route being abandoned. Instead, it was decided to pursue the original 
synthesis but to couple the protected reduced triketide with a pantetheine 
derivative rather than CoA. This should allow elaboration to the CoA form without 
any of the associated problems with CoA reactivity (section 4.2.2). 
 
A2 Synthetic approaches to 5-amidinyl teicoplanin 
A2.1 Introduction 
Teicoplanin is a glycopeptide antibiotic, which ares used as a “drugs of last resort” in 
the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections. It is 
marketed under the name Targocid, and has been shown to be effective in the 
treatment of pseudomembranous colitis and Clostridium difficile-associated 
diarrhoea.139  
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Figure A9: The structure of the glycopeptide antibiotic, teicoplanin 101. The fatty 
acid side chain can vary, giving rise to different forms. 
 
Teicoplanin (101) is made up of a heptapeptide core, which  follows the consistent 
stereochemical motif for glycopeptides of D-D-L-D-D-L-L. Not only does the chain 
contain 4 amino acids with the unnatural D configuration, it also incorporates the 
non-proteinogenic amino acids 4-D-hydroxyphenylglycine (hpg) at positions 1, 4, and 
5, (S)-3,5-dihydroxyphenylglycine (Dhpg) at postions 3 and 7 and -hydroxy-m-
chlorotyrosine at postion 6.  The structure of teicoplanin is identical to that of 
vancomycin at the C terminus, but the 3 amino acids at the N terminus are different 
(Figure A9). 
 
The amino acids are cross-linked by ether formation between the aromatic rings on 
residues 1 and 3, 2 and 4, 4 and 6, and by a C-C bond formation between rings at 
residues 5 and 7. The aglycon is then coupled to three sugars – two N-acetyl 
glucosamine molecules and a mannose. A fatty acyl chain is coupled to the N of the 
glucosamine attached to amino acid 4. 
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A2.1.1 Biosynthesis of Teicoplanin 
The teicoplanin gene cluster in A. teichomyceticus was sequenced previously within 
the group140 and by Sosio et al. 141 It spans about 89 kb and contains 49 putative 
open reading frames (ORFs), most of which have been assigned via homology to 
characterised proteins (Figure A10). 
 
 
Figure A10: The gene cluster encoding all the enzymes required for teicoplanin 
biosynthesis. (Reprinted from Chemistry & Biology, 11, Li, T. L.; Huang, F. L.; Haydock, 
S. F.; Mironenko, T.; Leadlay, P. F.; Spencer, J. B., Biosynthetic gene cluster of the 
glycopeptide antibiotic teicoplanin: Characterization of two glycosyltransferases and 
the key acyltransferase, 107-119, Copyright (2004), with permission from Elsevier.)140 
 
A2.1.1.1 Amino acids 
Teicoplanin includes the non-proteinogenic amino acids D-hydroxyphenylglycine, L-
dihydroxyphenylglycine and -hydroxytyrosine. 
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D-hydroxyphenylglycine (107) is synthesised from tyrosine by four enzyme catalysed 
steps. Initially chorismate is produced by the shikimate primary metabolic pathway 
and is then converted into prephenate (102) by Orf14*. The prephenate undergoes 
decarboxylation by Orf 24* to form 4-hydroxyphenylpyruvate (103) which acts as a 
substrate for Orf28* to form (S)-4-hydroxymandelic acid (104). This is then oxidised 
by Orf29* and transaminated by Orf23*, using tyrosine (106) as the amine donor to 
produce HPG (107). The deaminated tyrosine can then be used directly as a 
substrate for Orf28* (Figure A11). 
 
Figure A11: Biosynthesis of D-hydroxyphenylglycine (107) from tyrosine, via (S)-4-
hydroxymandelic acid (104). 
 
Despite their structural similarity, L-dihydroxyphenylglycine (DHPG, 109) is 
biosynthesised by a very different pathway. Feeding experiments with acetate 
showed that DHPG was formed by a polyketide synthase. Experiments in the 
glycopeptide chloroeremomycin have elucidated a 4 enzyme pathway to DHPG.142 A 
Type III PKS forms the cyclised tetraketide (108) from four malonyl-CoA units, 
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followed by dehydration and aromatisation by two enzymes and the addition of 
oxygen by a mono-oxygenase. The product is then transaminated by HpgT to form 
DHPG (109) (Figure A12). 
 
Figure A12: The unnatural amino acid L-dihydroxyphenylglycine (109) is 
biosynthesised by a Type III PKS, DpgA, encoded in the biosynthetic gene cluster for 
teicoplanin. 
 
The biosynthesis of -hydroxytyrosine remains cryptic. Feeding studies in the 
glycopeptide vancomycin indicated that -hydroxylation occurred before the 
assembly of the heptapeptide chain and a 3 gene operon was identified for this 
process.141 There are no homologues of these genes in the teicoplanin gene cluster 
and so it is probable that an alternative mechanism for the biosynthesis is present. 
Gene inactivation studies in the glycopeptide A40926 suggest that Obv28 (Orf12* in 
the teic cluster) is the -hydroxylase.143 
 
A2.1.1.2 Non-ribosomal peptide synthetases 
Non-ribosomal peptide synthetases (NRPSs) are molecular assembly lines that are 
analogous to polyketide synthases. NRPSs catalyse the stepwise condensation of 
both proteinogenic and specially biosynthesised amino acids.  
 
The adenylation (A) domain (analogous to the acyltransferase domain in PKSs) 
selects and activates the amino acid. The thiolation (T) domain or peptidyl carrier 
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protein (PCP, analogous to the ACP in PKSs) is the site of binding for the 4’-
phosphopantetheine cofactor and the attachment of the substrate. The 
condensation (C) domain (analogous to the ketosynthase domain in PKSs) catalyses 
the formation of the peptide bond between the growing peptide chain attached to 
the PCP and the activated amino acid attached to the adenylation domain. An 
additional epimerisation (E) domain is also present in modules that require the 
incorporation of D- rather than L-amino acids. The first module in the teicoplanin 
NRPS contains no E domain, despite the amino acid having a D configuration in the 
final product (Figure A13). This is consistent with other glycopeptide NRPS systems. 
 
In the teicoplanin gene cluster, the genes teicA-D encode for four subunits of the 
NRPS. The NRPS has seven modules in total (one per amino acid incorporated) 
distributed 2:1:3:1 between the subunits. Each module catalyses a single 
condensation between an amino acid and the growing peptide chain. A thioesterase 
domain at the end of the final module cleaves the completed heptapeptide chain 
from the megasynthase. 
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Figure A13: The biosynthesis of the heptapeptide core of teicoplanin by the NRPS 
proteins TeiA-D. 
 
A2.1.1.3 Post NRPS tailoring 
Teicoplanin has two chlorinated amino acids at positions 2 and 6, m-chlorotyrosine 
and m-chloro- -hydroxytyrosine, respectively. Feeding experiments have suggested 
that chlorination occurs after the incorporation of the amino acid into the peptide 
chain.144 The chlorination of both residues is proposed to be carried out by a single 
halogenase, Orf8*.140 
 
Gene knockout work in the balhimycin cluster has suggested that the oxidative 
coupling to form the ring systems is carried out by three oxygenases, OxyA, OxyB and 
OxyC.145 
 
Work on the balhimycin cluster knocking out the Dpg gene for formation of DHPG 
led to the isolation of a cyclised hexapeptide, implying that the C-O-D ring closure 
catalysed by OxyB took place while the peptide chain was still bound to the NRPS.146 
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Additional work has also suggested that OxyB may be able to act on both the hexa- 
and heptapeptide chains.147  
 
By homology, is proposed that the cross-linking in teicoplanin is carried out by Orfs 
5*, 6*, 7* and 9*.141 
 
The teicplanin aglycon is decorated with three sugar moieties, a mannose and two N-
acyl-glucosamine residues.  
 
N-acetyl-glucosamine is transferred onto the amino acids at postions 4 and 6 
glycosyltransferases Orf1 and Orf 10*. The substrate for both enzymes is UDP-(N-
acetyl)-glucosamine.140 
 
It is proposed that the mannose is attached by Orf 3*, a putative glycosyltransferase 
that shows sequence motifs that are characteristic of mannosyl-transferases.140 
The N-acetyl-glucosamine at amino acid 4 must be deacetylated before the fatty acyl 
chain can be attached. Work within the group has shown that Orf2*, originally 
characterised as a nucleotidyltransferase is in fact a deacetylase.148 The acyl chain is 
then attached to the free amine by Orf11*.140 
 
A2.1.1.4 Mode of action 
The bacterial cell wall consists of peptidoglycan, a rigid polymer made up of 
alternating N-acetyl-glucosamine and N-acteylmuramic acid units. The polymer is 
cross-linked via short peptide chains. The precursor disaccharide-pentapeptide 
monomers are synthesised inside the cell and translocated across the cell membrane 
as a C55 lipid carrier complex. The polymer is then cross-linked outside the cell by 
transglycosylases and transpeptidases.149 
 
Glycopeptides act by disrupting the cross-linking of the peptidoglycan chains that 
form the cell wall in Gram-positive bacteria. This lack of cross-linking means that the 
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chains no longer have the tensile strength to withstand the osmotic pressure within 
the cell and the cell lyses.  
 
Glycopeptides bind to the D-Ala-D-Ala terminus of the extracellular peptidoglycan 
pentapeptide (N-acetyl-muramyl-L-Ala-D-Glu-Lys-D-Ala-D-Ala) via hydrogen bonds 
and disrupt both transpeptidase activity (responsible for cross linking the chains) and 
transglycosylase activity (preventing growth of the peptidoglycan chain).150 This 
mode of action explains the glycopeptides’ specificity for Gram-positive bacteria. 
Such large molecules would be unable to pass through the outer lipopolysaccharide 
membrane that protects the peptidoglycan layer.151 
 
Most glycopeptides form a head-to-tail, back-to-back dimer in vivo.152 There are two 
hypotheses as to why this would be favourable. The first is that the dimer enables 
the binding of the second glycopeptides to D-Ala-D-Ala to be effectively an 
intramolecular binding event, and so greatly decreases the entropic cost of binding. 
The second is that the formation of a dimer allows the amide bonds to become more 
polarised, thus enhancing the binding to D-Ala-D-Ala.153,154 
 
The exception is teicoplanin which, unusually, binds as a monomer. It is believed that 
the lipid chain enables teicoplanin to anchor itself in the lipid bilayer, postioning 
itself correctly for binding to peptidoglycan and so making any binding to D-Ala-D-Ala 
effectively intramolecular again.152 
 
A2.1.1.5 Antibiotic resistance 
With the rise of bacterial strains resistant to traditional antibiotics such as penicillins, 
macrolides and cephalosporins, vancomycin became a drug of last resort for 
treatment of infections with multiply resistant bacteria. Vancomycin-resistance was 
observed in enterococci (VRE) in 1986 and it was demonstrated in a laboratory 
environment that this resistance could be transferred to S. aureus.155 In Japan in 
1996 the first S. aureus strains showing intermediate resistance (VISA) (MIC ≈ 8 
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ug/ml) was discovered.156 The mechanism of resistance in VISA is different to that in 
enterococci, with strains characterised by thickened cell walls instead of a 
transposable DNA element.157 Vancomycin-resistant S. aureus (VRSA) have been 
reported since 2002 carrying the transposon responsible for resistance in 
enterococci.158 
 
There are seven different phenotypes (vanA-G) currently thought to be responsible 
for vancomycin resistance in enterococci, with the most prevalent clinically being 
vanA and vanB. These disrupt the binding of the antibiotic to the peptidoglycan cell 
wall by replacing D-Ala-D-Ala with D-Ala-D-Lac (Figure A14). This simple change 
results in a loss of approximately 4 kcal/mol of binding energy and results in a 
thousand-fold decrease in binding affinity.151 
 
 
Figure A14: Schematic of the binding of glycopeptides to D-Ala-D-Ala (left) and D-Ala-
D-Lac (right). The binding occurs via 5 hydrogen bonds. The substitution of the NH 
for O leads to the exchange of a hydrogen bond for an electrostatic repulsion 
(double headed arrow). 
 
Teicoplanin is still active against strains that exhibit low level vanB resistance but the 
vanZ gene in the vanA cassette confers teicoplanin resistance.159 
 
A synthetic teicoplanin analogue synthesised by Crowley and Boger, where the 
carbonyl from residue 4 was replaced with a methylene group. The analogue 
exhibited a 40-fold increase in affinity for D-Ala-D-Lac over the aglycon, but showed 
a 35-fold reduction in binding to D-Ala-D-Ala. Although the reduced binding would 
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hinder the activity of the antibiotic against non-resistant S. aureus, the analogue 
exhibited antimicrobial activity against a vanA-resistant organism (MIC of 31 
g/ml).160 
 
A2.1.1.6 5-amidinyl teicoplanin 
The aim of this project is to produce a teicoplanin analogue that can bind to D-Ala-D-
Lac whilst retaining binding to D-Ala-D-Ala, by a chemoenzymatic method. It is 
proposed to disrupt the NRPS assembly line to halt the biosynthesis of the 
heptapeptide core. A novel peptide could be synthesised chemically then loaded 
onto the NRPS where it will be extended, cyclised and tailored into a novel 
teicoplanin analogue. 
 
It is proposed to introduce an amidine linkage between residues 4 and 5 of the 
teicoplanin heptapeptide core (Figure A15). This has both hydrogen bond donor and 
hydrogen bond acceptor characteristics and so should bind to D-Ala-D-Lac while still 
binding to D-Ala-D-Ala. 
 
Figure A15: Proposed structure of 5-amidinyl teicoplanin 110, with the amidine 
linkage between residues 4 and 5. 
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Work by Robinson et al. has shown that is possible to attach a synthetically 
constructed peptide chain to the NRPS using Sfp and that it will continue to be 
enzymatically elaborated into the finished glycopeptide.161 
 
If the appropriate peptidyl carrier protein (PCP) were knocked out on the NRPS it 
could be possible to feed a chemically synthesised peptide chain incorporating the 
amidine linkage. This could be incorporated into the assembly line and extended into 
the altered teicoplanin. The knockout of the PCP would remove the potential for 
background formation of wild-type teicoplanin. It would be most efficient to 
synthesise only the minimum chain length that is required for the amidine to be 
installed between amino acids 4 and 5 (Figure A16). 
 
Figure A16: The proposed chemoenzymatic synthesis of 5-amidinylteicoplanin. The 
teicoplanin assembly line would be disrupted at the thiolation domain in module 5. A 
pentapeptide incorporating the amidine linkage could be fed as an SNAC derivative 
and extended to the altered teicoplanin. 
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A2.2 Retrosynthetic analysis 
The SNAC or pantetheine derivatives could be formed from the pentapeptide chain 
that contains an amidine linkage. Disconnecting the pentapeptide (111) along the 
bonds indicated leads to two dipeptide fragments and the commercially available 
(S)-dihydroxyphenylglycine (Dhpg, 109). As Dhpg is only available in small quantities 
it would be best to reduce the number of coupling steps by synthesising the 1-2 
(113) and 4-5 (112) building blocks separately, rather than building up the peptide 
chain in a sequential manner (Figure A17). 
 
Figure A17: Disconnection of the pentapeptide to two dipeptide units and the 
commercially available dihydroxyphenylglycine. 
 
The 1-2 building block could be disconnected into commercially available D-
hydroxyphenylglycine (107) and m-chloro-D-tyrosine (114) formed from 
commercially available D-tyrosine (115) and sulfuryl chloride (Figure A18). 
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Figure A18: Disconnection of amino acids 1 and 2 to D-hydroxyphenylglycine and m-
chlorotyrosine. 
 
It was envisaged that the amidine could be disconnected into D-
hydroxyphenylglycine (107) and a nitrile (116). The nitrile could be formed by the 
oxidation of D-hydroxyphenylglycinol (117) in the presence of ammonia (Figure A19). 
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Figure A20: Disconnection of the amidine linking amino acids 4 and 5 into a nitrile 
and an amine. 
A2.3 Synthesis of 1-2 dipeptide 
A2.3.1 Chlorination 
The chlorination of D-Tyrosine (115) was performed in ether. The reaction 
proceeded either with 50% conversion to the mono-chlorinated derivative (by 1H 
NMR) using 3 equivalents of sulfuryl chloride or with complete conversion to the di-
chlorinated amino acid (by 1H NMR) using 10 equivalents. It was not possible to 
separate the chlorinated and unchlorinated tyrosines by TLC, and it was decided that 
the separation would be best performed on the coupled product. 
A2.3.2 Coupling of amino acids 
Boc-protected hpg was coupled to the mixture of m-chloro-D-tyrosine (114) and D-
tyrosine (115) using DCC, HOBt and DMAP. The resulting mixture of compounds was 
purified by column chromatography and the fractions analysed by LC-MS. One 
fraction was found to contain the correct compound in a 12% yield. For repeating the 
experiment it was suggested that using EDC as a coupling reagent would give better 
results. The synthesis was not been repeated due to issues with protecting groups. 
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A2.3.3 Protecting groups 
The synthesis of the 1-2 dipeptide (113) was hindered by lack of appropriate 
protecting groups. The N of hpg was easily protected as both an Fmoc- and Boc- 
derivative. The carboxylic acid of D-tyrosine proved more difficult to protect, with 
repeated attempts to install a tBu ester failing. A methyl ester was successfully 
installed using thionyl chloride and methanol, but the conditions for removal of this 
group could result in racemisation of the peptide chain. A benzyl ester protecting 
group was successfully installed and this strategy could be carried forward using N-
Boc protection. 
 
A2.4 Amidine trial synthesis 
On examination of the literature it became apparent that although the formation of 
terminal amidines was well documented, the formation of substituted amidines was 
underreported.  
 
The synthesis of terminal amidines using a mild method under neutral conditions 
was reported by Lange et al.,162 using N-acetylcysteine as a catalyst (Figure A21). 
 
 
Figure A21: A mild method for the synthesis of amidines using N-acetyl cysteine as a 
catalyst.162 
 
It was proposed that replacing ammonia with a substituted amine should lead to the 
production of the substituted amidine. 
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A2.4.1 Trial reactions 
The formation of substituted amidines was tried using 3-
(trifluoromethyl)benzonitrile (118), which had been used successfully in the Lange 
paper (Figure A22). The nitrile was stirred with triethylamine, isopropylamine or 
benzylamine and N-acetylcysteine for four days in dry methanol at 50˚C (33˚C for 
isopropylamine). The product was then analysed via 13C NMR and LC-MS. 
 
 
Figure A22: Trial synthesis of amidines using N-acetyl cysteine as a catalyst and iso-
propylamine and benzylamine as amine donors. 
 
The 13C NMR showed the loss of the carbon signal at 117 ppm assigned to the nitrile 
carbon, and the introduction of a signal at 138 ppm that was assigned to the carbon 
bearing the amidine group. No starting material signals were visible in the product 
NMR. 
 
It was decided to trial the amidine-forming ability of the amino group of hpg with the 
successfully used 3-(trifluoromethyl)benzonitrile. This would suggest conditions that 
could be used to form the final amidine product with the nitrile from hpg. D-
hydroxyphenylglycine methyl ester was stirred at 50°C with N-acetylcysteine and 
triethylamine in methanol. The solution turned bright yellow and an orange oil was 
extracted. Unfortunately no amidine was detected by either 13C NMR or direct 
injection mass spectrometry. This could be due to the reduced nucleophilicity of the 
amino acid amine, in which case a longer reaction time may lead to product 
formation. 
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A2.4.2 Amidine stability 
In order to assist with the choice of protecting groups for the overall synthesis, the 
stability of the amidine group was investigated. 119 was stirred overnight in water at 
37°C, for 24 hours in TFA and overnight in piperidine and the results analysed by 13C 
NMR.  
 
There was no difference in the 13C NMR for the amidine (119) before and after 
treatment with water, TFA and piperidine. In particular there was no reformation of 
the nitrile group by acid cleavage of the amidine or substitution of the benzylamine 
by piperidine. This enables both Boc and Fmoc protecting groups to be used. The 
water incubation was used to assess the stability of the amidine in conditions that 
would be used in future enzymic steps and ensuring that the pentapeptide analogue 
would be sufficiently stable to be loaded on to the NRPS. 
 
A2.4.3 Nitrile formation 
The oxidation of a primary alcohol to a nitrile would be a simple route to providing 
the correct stereochemistry for the nitrile. 
 
Protected hpg was reduced using lithium aluminium hydride to produce the alcohol 
(120). Both Boc- and Fmoc-protected amino acids were reduced successfully, 
although Fmoc protection was less stable under the reduction conditions. 
 
Both Boc-D-hydroxyphenylglycinol and Fmoc-D-hydroxyphenylglycinol were stirred 
with iodine in ammonia water at 60°C for 24 hours (Figure A23).163 In both cases no 
product was isolated by NMR. It would be worth repeating the experiment with a 
protecting group on the phenolic OH in case this interfered with nitrile formation. 
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Figure A23: Attempted synthesis of D-hydroxyphenylglycine-nitrile (122) from D-
hydroxyphenylglycine. 
A2.4.4 Synthesis of nitrile 
Due to the difficulty in synthesising the enantiomerically resolved nitrile, it was 
decided to proceed with the racemic nitrile, which could be formed via the Strecker 
synthesis from 4-hydroxybenzaldehyde (123). 
 
The hydroxyl group was protected with a MOM-ether using MOM-Cl and DIPEA in 
dichloromethane, to give 124 in a 99% yield. The protected aldehyde 124 was 
reacted with potassium cyanide, ammonium chloride and ammonia in methanol, to 
give protected nitrile 125 in 76% yield. 125 could be deprotected by stirring in 
methanol and 2 M HCl to give the crude nitrile 126. 
 
 
Figure A24: Synthesis of racemic nitrile 126 from 4-hydroxybenzaldehyde. 
A2.5 Feeding of nitrile 
Nitriles have been observed to be inhibitors of cysteine proteases due to the 
formation of a thioimidate. This implies that an activated thiol group, such as the one 
on the PCP could form a covalent bond with the nitrile. This might then undergo a 
condensation reaction with the growing peptide chain to form an amidine in vivo. 
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This could result in the formation of 5-amidinyl teicoplanin by the NRPS. As 
dihydroxyphenylglycine is incoporated at postions 1, 4, and 5 in the teicoplanin 
backbone, the formation of amidine linkages between amino acids 1 and 2, and 
positions 5 and 6 would also be possible, and separation of these compounds would 
be challenging. 
 
Crude deprotected nitrile 126 (15 mg total) was fed to cultures of the teiocoplanin-
producing strain A. orientalis at 36, 40, 44 and 48 hours. Growth was continued until 
110 hours, as for normal teicoplanin production. The cultures were spun down and 
the supernatant was filtered and analysed by LCMS. No peaks of the correct mass 
could be seen for amidinyl teicoplanin, while production of teicoplanin was observed 
in both control and fed cultures. A bioassay for teicoplanin production after 96 hours 
using activity against B. subtilis showed that approximately equal amounts of 
antibiotic was produced by both control and fed cultures. This implies that the nitrile 
did not inhibit the biosynthesis, and so probably did not form a covalent 
intermediate with active thiols present on the NRPS. 
A2.6 Reasons for discontinuing work 
The difficulties encountered in the synthesis of the amidine, along with the inherent 
challenges in synthesising the pentapeptide analogue, attaching it to the NRPS, 
elaborating it to 5-amidinyl teicoplanin and finally detection of the product, meant 
that this approach had an extremely limited chance of success. It was therefore 
decided to concentrate on the 6-MSA project.  
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